NCT Number	Status	Study Results	Interventions	Outcome Measures	Phases	URL
NCT01877187	Active, not recruiting	No Results Available	Drug: Lipiodol	Tumor response by Response Evaluation Criteria in Solid Tumors (RECIST)|6-month survival rate of patients with HCC and liver metastases treated with conventional TACE	Phase 2	https://ClinicalTrials.gov/show/NCT01877187
NCT02557503	Unknown status	No Results Available	Drug: Oxaliplatin and fluorouracil	Progression-free survival (PFS)|overall survival (OS)	Phase 4	https://ClinicalTrials.gov/show/NCT02557503
NCT02753881	Recruiting	No Results Available	Drug: whole liver lobe cTACE doxorubicin|Drug: superselective cTACE doxorubicin	Pharmacokinetics profile-- peak of plasma concentration|Pharmacokinetics profile-- time of maximum concentration|Pharmacokinetics profile-- area under the concentration time curve|Incidence of feasibility/technical success of the cTACE procedure.|Frequency of toxicities from cTACE procedure measured using NCI Common Toxicity Criteria v.4.0|Assessment of toxicities by time from cTACE procedure using NCI Common Toxicity Criteria v.4.0	Phase 1	https://ClinicalTrials.gov/show/NCT02753881
NCT01164202	Completed	No Results Available	Drug: sunitinib malate|Drug: Placebo|Procedure: transarterial chemoembolization	Occurrence of severe bleeding or liver failure|Overall survival|Toxicities|Disease-free survival	Phase 2|Phase 3	https://ClinicalTrials.gov/show/NCT01164202
NCT00128596	Completed	No Results Available	Drug: arsenic trioxide	Efficacy|Safety and tolerability	Phase 2	https://ClinicalTrials.gov/show/NCT00128596
NCT00949182	Completed	No Results Available	Drug: sorafenib tosylate, HACE : Doxorubicin Hydrochloride and Mitomycin C|Other: laboratory biomarker analysis	Safety and tolerability as assessed by NCI CTCAE v3.0|Number of hepatic arterial chemoembolization (HACE) treatments required to achieve objective complete response|Progression-free survival and time to radiologic progression as assessed by CT scan|Overall survival at 6, 12, and 24 months|AFP and VEGF serum levels as assessed at baseline, prior to each HACE treatment, and then every 3 months thereafter	Phase 2	https://ClinicalTrials.gov/show/NCT00949182
NCT02013830	Completed	Has Results	Drug: bevacizumab [Avastin]|Drug: capecitabine [Xeloda]	Percentage of Participants With Objective Response (OR)|Percentage of Participants With Disease Control|Time to Disease Progression - Percentage of Participants With an Event|Time to Disease Progression|Time to Disease Progression - Percentage of Participants Progression-free at 12 Months|Overall Survival - Percentage of Participants With an Event|Overall Survival|Overall Survival - Percentage of Participants Event Free at 12 Months	Phase 2	https://ClinicalTrials.gov/show/NCT02013830
NCT00867321	Completed	Has Results	Biological: bevacizumab|Drug: sorafenib tosylate	Maximum Tolerated Dose (Phase I)|Time to Progression (TTP) (Phase II)|Overall Survival|Tumor Response at 6 Months	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT00867321
NCT01324076	Unknown status	No Results Available	Drug: doxorubicin-eluting beads|Drug: sorafenib tosylate|Other: laboratory biomarker analysis|Other: pharmacogenomic studies|Other: pharmacological study|Procedure: quality-of-life assessment	Progression-free survival|Overall survival|Time to progression|Toxicity|Disease control (complete or partial response or stable disease)|Quality of life	Phase 3	https://ClinicalTrials.gov/show/NCT01324076
NCT03092895	Recruiting	No Results Available	Biological: SHR-1210|Drug: Apatinib|Drug: FOLFOX4	The safety and tolerability|Objective Response Rate (ORR)|Duration of Response (DoR)|Disease Control Rate (DCR)|Time to Progression (TTP)|Overall Survival	Phase 2	https://ClinicalTrials.gov/show/NCT03092895
NCT00605722	Completed	Has Results	Drug: bevacizumab (Avastin)|Drug: erlotinib (Tarceva)	Percentage of Participants With Progression-free Survival (PFS)|Overall Response Rate (ORR)|Disease Control Rate (DCR)|Time to Tumor Progression|Progression-free Survival (PFS)|Overall Survival (OS)|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)	Phase 2	https://ClinicalTrials.gov/show/NCT00605722
NCT00087282	Completed	No Results Available	Drug: alvocidib|Drug: irinotecan hydrochloride		Phase 2	https://ClinicalTrials.gov/show/NCT00087282
NCT00717756	Completed	Has Results	Drug: lenalidomide	Response Rate by Recist Criteria	Phase 2	https://ClinicalTrials.gov/show/NCT00717756
NCT00006006	Completed	No Results Available	Biological: recombinant interferon alfa|Drug: thalidomide		Phase 2	https://ClinicalTrials.gov/show/NCT00006006
NCT02069145	Completed	No Results Available	Drug: OMP-54F28 with Sorafenib	Safety and tolerability of OMP-54F28 in combination with sorafenib in patients with hepatocellular cancer|Pharmacokinetics (PK) of OMP-54F28 and sorafenib when administered in combination to patients with hepatocellular cancer	Phase 1	https://ClinicalTrials.gov/show/NCT02069145
NCT00077142	Completed	No Results Available	Drug: TAC-101	Maximum Tolerated Dose (MTD) of TAC-101	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT00077142
NCT02626312	Recruiting	No Results Available	Radiation: Radiation Therapy|Drug: Chemotherapy|Behavioral: Questionnaire	Maximum Dose Constraints (MDC) for Two Radiation Regimens|Local Disease Control Rate	Phase 1	https://ClinicalTrials.gov/show/NCT02626312
NCT02321202	Completed	No Results Available	Drug: Omega-3 Fatty Acid-Based Parenteral Nutrition|Drug: Structolipid	complications (blood test for liver and renal function, urine output, postoperative complications)|hospital stay (time of hospital stay after surgery)|mortality	Phase 4	https://ClinicalTrials.gov/show/NCT02321202
NCT00003912	Completed	No Results Available	Drug: carboplatin|Drug: cisplatin|Drug: doxorubicin hydrochloride|Procedure: conventional surgery	Tumor response|Complete resection rate|Overall survival|Event-free survival|Toxicity|Response rate|Resection rate	Phase 3	https://ClinicalTrials.gov/show/NCT00003912
NCT00003044	Unknown status	No Results Available	Drug: cisplatin-e therapeutic implant		Phase 2	https://ClinicalTrials.gov/show/NCT00003044
NCT02716012	Recruiting	No Results Available	Drug: MTL-CEBPA	Incidence of Grade 3 or 4 drug related adverse events and clinical lab abnormalities defined as Dose Limiting Toxicities (DLTs) using NCI CTCAE v 4.03|Recommended Phase 2 Dose (RP2D) of MTL-CEBPA defined as the most appropriate dose to maximise a favourable risk/benefit reward for the participant population|Total Active Pharmaceutical Ingredient (API) levels in plasma.|Preliminary evidence of liver function improvement	Phase 1	https://ClinicalTrials.gov/show/NCT02716012
NCT00191412	Completed	No Results Available	Drug: Pemetrexed	Antitumor activity as measured by Response Evaluation Criteria in Solid Tumors|Toxicity measured by CTCAE grading|Duration of response: First complete or partial response until progressive disease (PD) or death of any cause|Duration of stable disease: Enrollment to PD or death of any cause|Time to treatment failure: Enroll. to PD, death of any cause, early discontinuation of treatment for any reason other than adequate response or start of new therapy|Progression-free survival: Enroll. to PD or death of any cause|Overall survival: Enroll. to death of any cause	Phase 2	https://ClinicalTrials.gov/show/NCT00191412
NCT01182272	Unknown status	No Results Available	Drug: sorafenib tosylate|Other: laboratory biomarker analysis|Procedure: neoadjuvant therapy|Procedure: therapeutic conventional surgery	Antiangiogenic effects of sorafenib tosylate|Significant pathological changes|Pathologic findings in sorafenib tosylate pre-treated patients undergoing surgical resection for hepatocellular carcinoma|Number of R0 resections|Correlations between baseline patient characteristics, cancer biomarkers, and outcome variables and resected tumors|Plasma biomarkers at baseline, day 28, and the day before surgery|Safety profile of sorafenib tosylate|Tolerance of liver resection after sorafenib tosylate treatment	Phase 2	https://ClinicalTrials.gov/show/NCT01182272
NCT01075113	Active, not recruiting	No Results Available	Drug: sorafenib tosylate|Drug: vorinostat	Determine the appropriate Doses for the combination of sorafenib tosylate and vorinostat appropriate for phase II study in hepatocellular carcinoma (HCC).|Adverse events will be characterized in terms of nature, severity, attribution, onset and resolution according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0.|Anti-tumor effects of the combination of sorafenib tosylate and vorinostat	Phase 1	https://ClinicalTrials.gov/show/NCT01075113
NCT01005199	Completed	No Results Available	Drug: everolimus|Drug: sorafenib tosylate	Progression-free survival|Objective response|Disease stabilization (DS)|Duration of disease stabilization|Progression-free survival (PFS)|Time to progression (TTP)|Overall survival|Adverse events at baseline and during trial treatment|Serum alpha fetoprotein (AFP) level|Viral reactivation in patients with chronic hepatitis B or C virus infection|Correlation between vitamin B12 and overall survival	Phase 2	https://ClinicalTrials.gov/show/NCT01005199
NCT02292173	Recruiting	No Results Available	Drug: Trametinib|Drug: Sorafenib	Maximum Tolerated Dose (MTD)|Progression Free Survival (PFS)|Response Rate|Overall Survival (OS)	Phase 1	https://ClinicalTrials.gov/show/NCT02292173
NCT00881751	Completed	Has Results	Biological: bevacizumab|Drug: erlotinib hydrochloride|Drug: sorafenib tosylate	Overall Survival|Event-free Survival|Number of SAEs Experienced|Response Rate	Phase 2	https://ClinicalTrials.gov/show/NCT00881751
NCT03143270	Recruiting	No Results Available	Drug: Drug Eluting Bead Transarterial Chemoembolization|Drug: Nivolumab	Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	Early Phase 1	https://ClinicalTrials.gov/show/NCT03143270
NCT00875615	Completed	Has Results	Drug: Carboplatin|Drug: Cisplatin|Drug: Sorafenib	Number of Subjects Experiencing Adverse Events|Number of Patients Achieving Clinical Benefit	Phase 2	https://ClinicalTrials.gov/show/NCT00875615
NCT01011010	Completed	No Results Available	Drug: doxorubicin hydrochloride|Drug: mitomycin C|Drug: sorafenib tosylate|Other: laboratory biomarker analysis|Other: pharmacological study	Safety and toxicity as assessed by NCI CTCAE v3.0 criteria|Overall survival|Correlative studies	Phase 1	https://ClinicalTrials.gov/show/NCT01011010
NCT01075555	Completed	No Results Available	Drug: pravastatin sodium|Drug: sorafenib tosylate	Overall survival|Progression-free survival|Time to progression|Quality of life	Phase 3	https://ClinicalTrials.gov/show/NCT01075555
NCT00410956	Active, not recruiting	No Results Available	Biological: bevacizumab|Drug: dexamethasone|Drug: floxuridine|Genetic: protein expression analysis|Other: flow cytometry|Other: immunoenzyme technique|Other: immunohistochemistry staining method|Other: immunologic technique|Other: laboratory biomarker analysis|Procedure: dynamic contrast-enhanced magnetic resonance imaging	Antitumor efficacy (complete and partial response, stable and progressive disease)|Toxicity as measured by NCI Common Toxicity Criteria	Phase 2	https://ClinicalTrials.gov/show/NCT00410956
NCT00956930	Completed	No Results Available	Radiation: yttrium Y 90 glass microspheres|Drug: Doxorubicin	Time to progression in patients treated with TACE and Y90|Characterize the safety and toxicity profile of these regimens|Determine tumor response and the need for subsequent treatment in these patients|Characterize change in quality of life and performance status in these patients	Phase 2	https://ClinicalTrials.gov/show/NCT00956930
NCT00870558	Completed	No Results Available	Drug: ethiodized oil|Radiation: iodine I 131 ethiodized oil	Tumor recurrence at 2 years	Phase 3	https://ClinicalTrials.gov/show/NCT00870558
NCT00941967	Unknown status	No Results Available	Drug: gemcitabine hydrochloride|Drug: oxaliplatin|Drug: sorafenib tosylate	Tumor response according to RECIST criteria|Progression-free survival	Phase 2	https://ClinicalTrials.gov/show/NCT00941967
NCT00003424	Completed	No Results Available	Drug: tamoxifen citrate		Phase 3	https://ClinicalTrials.gov/show/NCT00003424
NCT00514228	Completed	No Results Available	Drug: sunitinib malate	Progression-free survival|Objective response|Disease stabilization (DS)|Duration of DS|Time to progression|Overall survival|Adverse events as assessed by NCI CTCAE v3.0|Serum alpha fetoprotein level	Phase 2	https://ClinicalTrials.gov/show/NCT00514228
NCT00483405	Completed	Has Results	Biological: cetuximab|Drug: capecitabine|Drug: oxaliplatin	Disease Response Rate|Number of Subjects Experiencing Adverse Events|Overall Survival|Time to Progression	Phase 2	https://ClinicalTrials.gov/show/NCT00483405
NCT00467194	Completed	No Results Available	Drug: Rapamycin|Drug: Bevacizumab	Dose-limiting toxicity|Maximum tolerated dose|Response rate (complete and partial response and stable disease)|Progression-free survival|Overall survival|Distribution of p70S6K activity in peripheral blood mononuclear cells|Correlation of p70S6K with tumor response|Expression of tumor tissue biomarkers (PTEN, 4EBP-1, CD31, p70S6K, and vascular endothelial growth factor)|Correlation of tumor biomarkers with response|Best overall response (complete and partial response; stable and progressive disease)|Change in DCE-CT scan assessment of angiogenesis	Phase 1	https://ClinicalTrials.gov/show/NCT00467194
NCT00004248	Completed	No Results Available	Biological: aldesleukin|Drug: doxorubicin hydrochloride		Phase 2	https://ClinicalTrials.gov/show/NCT00004248
NCT00054262	Completed	No Results Available	Drug: T900607		Phase 2	https://ClinicalTrials.gov/show/NCT00054262
NCT00257426	Completed	No Results Available	Drug: octreotide acetate	Median survival|number of subjects with toxicities	Phase 2	https://ClinicalTrials.gov/show/NCT00257426
NCT00335829	Completed	Has Results	Biological: bevacizumab|Drug: chemotherapy|Drug: embolization therapy|Procedure: hepatic artery infusion	Median Progression-free Survival|Time to Tumor Progression (TTP) of Targeted Lesions|TTP of Nontargeted Lesions Within the Liver|Overall TTP|TTP Rate at 6 Months and 1 Year|Overall Survival (OS)|Response Rate - Based on Response Evaluation Criteria in Solid Tumors (RECIST)|Response Rate - Based on Tumor Enhancement|Safety and Treatment Toxicity - Cycle 1 Pre-TACE|Safety and Treatment Toxicity - Cycle 1 Post-TACE|Safety and Treatment Toxicity - Cycles 2 and 3	Phase 2	https://ClinicalTrials.gov/show/NCT00335829
NCT00041275	Completed	No Results Available	Drug: megestrol acetate	Survival measured weekly|Quality of life as measured by EORTC quality of life instrument monthly	Phase 3	https://ClinicalTrials.gov/show/NCT00041275
NCT00030082	Completed	No Results Available	Drug: isolated perfusion|Drug: melphalan		Phase 1	https://ClinicalTrials.gov/show/NCT00030082
NCT00095992	Completed	No Results Available	Drug: ispinesib	Response|Toxicity|Pharmacokinetics at day 1 of course 1 (day 1 of course 2 if dose is adjusted)|Molecular correlates on archival tumor specimens and peripheral blood mononuclear cells (PBMCs)	Phase 2	https://ClinicalTrials.gov/show/NCT00095992
NCT00109954	Completed	No Results Available	Drug: cisplatin|Radiation: brachytherapy|Radiation: yttrium Y 90 glass microspheres	Progression-free survival as assessed by tumor progression in the treated lobe of the liver|Health-related quality of life at baseline and every 3 months|Toxicity as measured by NCI CTCAE version 3.0	Phase 3	https://ClinicalTrials.gov/show/NCT00109954
NCT00058487	Completed	No Results Available	Drug: epirubicin hydrochloride|Drug: thalidomide	Antitumor activity|Toxic effects	Phase 2	https://ClinicalTrials.gov/show/NCT00058487
NCT00825955	Completed	No Results Available	Drug: Brivanib|Other: Placebo|Procedure: Best Supportive Care	To compare overall survival of subjects with advanced HCC who have progressed on/after or are intolerant to Sorafenib and receive Brivanib plus best supportive care (BSC) to those receiving placebo plus BSC|To compare time to progression (TTP) (Investigator assessed using modified Response Evaluation Criteria In Solid Tumors (RECIST) for HCC criteria)|To compare the Independent Radiological Review Committee (IRRC) assessed objective response rate (ORR) and disease control rate (DCR) using modified RECIST for HCC criteria|To assess duration of response, duration of disease control and time to response|To assess safety profile of brivanib. Safety will be assessed by the number of adverse events (AEs), serious adverse events (SAEs), periodic data monitoring committee (DMC) review	Phase 3	https://ClinicalTrials.gov/show/NCT00825955
NCT00006010	Completed	No Results Available	Drug: docetaxel|Drug: gemcitabine hydrochloride	six-month overall survival|tumor response|time to progression	Phase 2	https://ClinicalTrials.gov/show/NCT00006010
NCT00004108	Completed	No Results Available	Drug: exatecan mesylate		Phase 2	https://ClinicalTrials.gov/show/NCT00004108
NCT00012324	Completed	No Results Available	Drug: doxorubicin hydrochloride|Drug: nolatrexed dihydrochloride	Overall survival|Time to progression|Time to treatment failure|Response rate (complete response, partial response, stable disease)|Survival probabilities at 3, 6, 9, and 12 months|Safety|Response to treatment in patients with and without prior therapy	Phase 3	https://ClinicalTrials.gov/show/NCT00012324
NCT00576199	Completed	Has Results	Drug: Bevacizumab|Procedure: Transarterial chemoembolisation (TACE)	Progression-free Survival|Percentage of Participants With an Objective Response|Time to Progression|Overall Survival|Percentage of Participants With a Best Overall Response of Complete Response, Partial Response, or Stable Disease|Tumor Necrosis	Phase 2	https://ClinicalTrials.gov/show/NCT00576199
NCT00471484	Unknown status	No Results Available	Biological: recombinant interferon alfa-2b|Drug: doxorubicin hydrochloride|Drug: fluorouracil|Drug: oxaliplatin|Other: diagnostic laboratory biomarker analysis|Other: immunoenzyme technique|Other: immunohistochemistry staining method|Procedure: adjuvant therapy|Procedure: biopsy|Procedure: neoadjuvant therapy|Procedure: therapeutic conventional surgery	Objective tumor response rate as measured by RECIST criteria|Serum VEGF levels|Tissue VEGF expression	Phase 2	https://ClinicalTrials.gov/show/NCT00471484
NCT00079027	Unknown status	No Results Available	Drug: doxorubicin hydrochloride|Procedure: hepatic artery embolization	Overall survival|Overall response|Quality of life as assessed by EORTC QOL QLQ-30 and EORTC QLQ HCC18 at baseline and 10 and 24 weeks|Time to progression as assessed by RECIST criteria|Toxicity|Health economics|Proteomic and immunological analysis	Phase 3	https://ClinicalTrials.gov/show/NCT00079027
NCT00276705	Unknown status	No Results Available	Drug: cisplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: thalidomide|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy	Event-free and overall survival following tumor resection|Efficacy and tolerability following course 2 and 4 of pre-operative chemotherapy	Phase 2	https://ClinicalTrials.gov/show/NCT00276705
NCT00047229	Completed	No Results Available	Biological: oblimersen sodium|Drug: doxorubicin hydrochloride	Rate of objective response (complete and partial)|Stable disease rate|Duration of response|Progression-free survival rate|Median survival rate|Overall survival rate|Safety and tolerability	Phase 2	https://ClinicalTrials.gov/show/NCT00047229
NCT03037437	Recruiting	No Results Available	Drug: Sorafenib (SOR)|Drug: Hydroxychloroquine (HCQ)	Time to tumor progression evaluated via tumor imaging	Phase 2	https://ClinicalTrials.gov/show/NCT03037437
NCT02181075	Completed	No Results Available	Drug: lyso-thermosensitive liposomal (LTSL) doxorubicin	To determine whether targeted release of doxorubicin from ThermoDox® ('drug') using mild hyperthermia generated noninvasively by focused ultrasound (FUS) is feasible in cancer patients|(Part I only) To determine optimal FUS exposure parameters for a range of participant Body Mass Indices (BMIs) and tumour locations within the liver|(Part II Only) To assess the safety of FUS-induced mild hyperthermia for drug delivery without real-time thermometry|To assess the local and systemic cytotoxic effects of ThermoDox® in this setting	Phase 1	https://ClinicalTrials.gov/show/NCT02181075
NCT00997022	Completed	No Results Available	Drug: Sorafenib	Maximum tolerated dose of daily sorafenib|Duration of disease free survival|Duration of progression free survival	Phase 1	https://ClinicalTrials.gov/show/NCT00997022
NCT02829359	Completed	No Results Available	Drug: Entecavir therapy	Rate of HBV reactivation|HBV reactivation on the recovery of liver function	Phase 2|Phase 3	https://ClinicalTrials.gov/show/NCT02829359
NCT01754987	Completed	No Results Available	Drug: Ascorbic Acid + Sorafenib|Drug: Sorafenib	Safety|Efficacy|Quality of Life|Survival	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT01754987
NCT03397654	Not yet recruiting	No Results Available	Drug: Pembrolizumab|Combination Product: Trans-arterial chemoembolization	Incidence of treatment-emergent adverse events (safety and tolerability)|Improvement of progression-free survival rate (PFSR; efficacy)	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT03397654
NCT01264705	Unknown status	No Results Available	Drug: bavituximab and sorafenib	Safety as measured by the number of participants with adverse events.|Time to Progression (phase II)as measured by abdominal magnetic resonance imaging.|Overall Survival.	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT01264705
NCT00706576	Completed	No Results Available	Drug: Infusion of opioid growth factor	Number of participants with opioid growth factor toxicity|Change in plasma opioid growth factor levels	Phase 1	https://ClinicalTrials.gov/show/NCT00706576
NCT00006198	Unknown status	No Results Available	Drug: thalidomide|Procedure: chemoembolization with doxorubicin/collagen		Phase 2	https://ClinicalTrials.gov/show/NCT00006198
NCT00813293	Active, not recruiting	No Results Available	Drug: Sorafenib|Procedure: radiofrequency ablation	To prospectively investigate if sorafenib increases the effectiveness of RFA.|To describe the safety and feasibility of sorafenib prior to RFA.|To explore the relationship between MRI and RFA effectiveness|To investigate tumor tissue for changes after sorafenib and to assess for RFA predictors	Phase 2	https://ClinicalTrials.gov/show/NCT00813293
NCT00374660	Unknown status	No Results Available	Drug: Irofulven + oxaliplatin	Confirmed response rate: Hepatocellular Cancer (HCC) Cohort: Response Evaluation Criteria in Solid Tumors (RECIST) criteria.|Hormone Refractory Prostate Cancer (HRPC) Cohort: Prostate-Specific Antigen Working Group Recommendations (PSAWGR) and RECIST criteria.|Efficacy: HRPC Cohort: confirmed response rate according to RECIST; progression-free survival (PFS) for progression according to RECIST; new bone lesions or skeletal events; PFS according to PSA progression; overall survival.|Efficacy: HCC cohort - PFS (RECIST); overall survival	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT00374660
NCT00057980	Completed	No Results Available	Drug: celecoxib|Drug: epirubicin hydrochloride	Maximum tolerated dose of epirubicin|Response rate|Survival at 6 months|Overall survival|Toxicity profile|Serum vascular endothelial growth factor levels in correlation to response|Cyclooxygenase-2 expression in tumor tissue and nonmalignant liver tissue in correlation to response	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT00057980
NCT01395030	Active, not recruiting	No Results Available	Diagnostic Test: Computed Tomography|Drug: 18F-fluoromethylcholine|Other: Laboratory Biomarker Analysis|Diagnostic Test: Positron Emission Tomography	Operating characteristics of kinetic and static PET measures of tumor FCH metabolism|Identification of cancer signaling pathways associated with choline metabolism|Clinical liver disease severity|Ability of corresponding gene expression signatures to predictively model HCC disease outcome	Phase 2	https://ClinicalTrials.gov/show/NCT01395030
NCT00652132	Completed	No Results Available	Drug: cisplatin|Drug: sodium thiosulfate	Rate of Brock grade ≥ 1 hearing loss|Response to preoperative chemotherapy|Complete resection|Complete remission|Event-free survival (EFS)|Overall survival (OS)|Toxicity as graded by CTCAE v 3.0|Long-term renal clearance|Feasibility of central audiology review	Phase 3	https://ClinicalTrials.gov/show/NCT00652132
NCT00006016	Completed	No Results Available	Drug: thalidomide|Drug: doxorubicin hydrochloride|Other: laboratory biomarker analysis	Survival	Phase 2	https://ClinicalTrials.gov/show/NCT00006016
NCT01236690	Unknown status	No Results Available	Drug: Cinobufacin injection	The evaluation of the patient's respondence for the therapy is carried out every phase, according to RECIST:CR,PR,SD and PD.	Phase 2	https://ClinicalTrials.gov/show/NCT01236690
NCT00365391	Completed	Has Results	Biological: bevacizumab|Drug: erlotinib hydrochloride	Number of Patients With Confirmed Tumor Response Defined to be Either a Complete Response (CR) or Partial Response (PR).|Survival Time|Time to Disease Progression|Duration of Response|Time to Treatment Failure	Phase 2	https://ClinicalTrials.gov/show/NCT00365391
NCT02862587	Recruiting	No Results Available	Drug: Chemotherapy|Biological: precision cells	Overall survival|Progress-free survival|Quality of life	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT02862587
NCT00052364	Completed	No Results Available	Drug: oxaliplatin|Other: laboratory biomarker analysis	Response rate evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST)|Time to progression|Duration of overall survival|Progression-free survival	Phase 2	https://ClinicalTrials.gov/show/NCT00052364
NCT00003907	Completed	Has Results	Drug: cisplatin|Drug: doxorubicin|Drug: mitomycin|Procedure: embolization	Time to Progression|Tumor Response|Overall Survival	Phase 2	https://ClinicalTrials.gov/show/NCT00003907
NCT01497444	Active, not recruiting	No Results Available	Drug: hypoxia-activated prodrug TH-302|Drug: sorafenib tosylate	Number of dose-limiting toxicity incidents as assessed by CTCAE version 4.0 (Phase I)|MTD of sorafenib tosylate and TH-302 (Phase I)|Overall response rate (Phase II)|Adverse events as assessed by NCI CTCAE version 4.0 (Phase II)|Overall response rate based on standard RECIST criteria (Phase II)|Duration of response based on modified (standard) RECIST criteria (Phase II)|PFS (Phase II)|OS (Phase II)|AFP response rate (Phase II)	Phase 1	https://ClinicalTrials.gov/show/NCT01497444
NCT00093444	Completed	No Results Available	Drug: lyso-thermosensitive liposomal doxorubicin|Procedure: radiofrequency ablation	Maximum tolerated dose of heat-activated doxorubicin HCL liposome|Pharmacokinetics and pharmacodynamics of heat-activated doxorubicin HCL liposome at 15, 30, 45, 60, 75, and 90 minutes; 2, 3, 4, 6, 24, and 46 hours; and 4 and 8 days following infusion|Effects of ablative therapy on tumor blood flow and tumor vascular density as measured by MRI at 28 days following study completion	Phase 1	https://ClinicalTrials.gov/show/NCT00093444
NCT00287976	Unknown status	No Results Available	Drug: irinotecan hydrochloride	Best overall response (complete response and partial response)|Early progression|Death|Disease progression or recurrence|Surgical resection (complete or incomplete)	Phase 2	https://ClinicalTrials.gov/show/NCT00287976
NCT01932385	Completed	No Results Available	Drug: Sorafenib|Other: Best Supportive Care	progression free survival and overall survival|response rate	Phase 2|Phase 3	https://ClinicalTrials.gov/show/NCT01932385
NCT00077389	Unknown status	No Results Available	Drug: carboplatin|Drug: cisplatin|Drug: doxorubicin hydrochloride|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy	Rate of complete remission after completion of study therapy|Complete resection rate|Response rate to preoperative chemotherapy|Rate of grade 2 cardiac and renal, grade 3 otological, and grade 4 nonhematological toxicity as assessed during and after completion of study therapy|Overall survival|Event-free survival	Phase 2	https://ClinicalTrials.gov/show/NCT00077389
NCT02649153	Recruiting	No Results Available	Drug: smoked plum|Drug: gum chewing	Time to first peristalsis	Phase 3	https://ClinicalTrials.gov/show/NCT02649153
NCT03164382	Recruiting	No Results Available	Drug: FOLFOX regimen|Drug: Sorafenib 200Mg Tab	Overall survival|Time to Progression|Time to Intrahepatic tumor Progression	Phase 3	https://ClinicalTrials.gov/show/NCT03164382
NCT00242502	Completed	Has Results	Drug: Bevacizumab (Avastin)|Drug: Erlotinib	Progression-free Survival (PFS) Rate	Phase 2	https://ClinicalTrials.gov/show/NCT00242502
NCT02471313	Completed	No Results Available	Drug: [18F] FMISO	Uptake of [18F]-MISO with cross-sectional imaging	Phase 2	https://ClinicalTrials.gov/show/NCT02471313
NCT00861783	Completed	No Results Available	Drug: irinotecan and ON 01910.Na|Drug: oxaliplatin and ON 01910.Na	maximum tolerated dose|pharmacokinetics|tumor measurement	Phase 1	https://ClinicalTrials.gov/show/NCT00861783
NCT03184493	Recruiting	No Results Available	Drug: Celebrex plus Metformin|Drug: Celebrex|Drug: Metformin	Number of participants with tumor recurrence	Phase 3	https://ClinicalTrials.gov/show/NCT03184493
NCT00282100	Unknown status	No Results Available	Drug: Iressa	To study the changes of selected genetic or protein markers through the treatment and find out whether some of them can be potential biomarkers for disease relapse.|To evaluate the effect of gefitinib as an adjuvant therapy on recurrence free survival in patients with resectable hepatocellular carcinoma; to evaluate the treatment toxities of genifitib.	Phase 2	https://ClinicalTrials.gov/show/NCT00282100
NCT02239900	Active, not recruiting	No Results Available	Drug: Ipilimumab|Radiation: Stereotactic Body Radiation Therapy (SBRT)	Maximum Tolerated Dose (MTD) of Ipilimumab and Stereotactic Body Radiation Therapy (SBRT)|Response Rate of Ipilimumab and Stereotactic Body Radiation Therapy (SBRT)	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT02239900
NCT02646137	Recruiting	No Results Available	Drug: Transarterial chemoembolization (TACE)|Procedure: Radiofrequency ablation combined with TACE|Procedure: Microwave ablation combined with TACE	Number of patients with successful ablation	Phase 3	https://ClinicalTrials.gov/show/NCT02646137
NCT03215355	Not yet recruiting	No Results Available	Drug: Primovist	Improved image quality after injection as determined by contrast-to-background calculation and expert observation.|Toxicity with "off label" dosing	Phase 4	https://ClinicalTrials.gov/show/NCT03215355
NCT01042041	Completed	No Results Available	Drug: sorafenib tosylate|Drug: doxorubicin hydrochloride|Drug: cisplatin|Drug: mitomycin C|Procedure: transarterial chemoembolization|Procedure: hepatic artery embolization	Dose adjustment, number and percentage of subjects with adverse events, laboratory changes, number and percentage of subjects with laboratory values that are outside the pre-determined ranges, cumulative toxicity, and TLT.|Time to Disease Progression	Phase 1	https://ClinicalTrials.gov/show/NCT01042041
NCT02029157	Completed	No Results Available	Drug: ARQ197|Drug: Placebo	Progression-free survival (PFS)|Overall survival	Phase 3	https://ClinicalTrials.gov/show/NCT02029157
NCT00247676	Completed	Has Results	Drug: Sunitinib (SU011248)	Best Overall Response|Objective Response (CR or PR)|Duration of Objective Response (CR or PR)|Clinical Benefit Response (CR, PR, or SD With Duration ≥12 Weeks)|Best Overall Response of PR or SD With Duration ≥12 Weeks|Progression-Free Survival (Overall ITT)|Progression-Free Survival (ITT Child Pugh Class A Subject Population)|Time to Tumor Progression (Overall ITT)|Time to Tumor Progression (ITT Child Pugh Class A Subject Population)|Overall Survival (Overall ITT)|Overall Survival (ITT Child Pugh Class A Subject Population)|1-Year Survival Probability|Trough Plasma Concentrations (Ctrough) of Sunitinib|Ctrough of SU-012662 (Metabolite of Sunitinib)|Ctrough of Total Drug (Sunitinib + SU-012662)|Dose-Corrected Ctrough of Sunitinib|Dose-Corrected Ctrough of SU-012662 (Metabolite of Sunitinib)|Dose-Corrected Ctrough of Total Drug (Sunitinib + SU-012662)|Circulating Endothelial Cells (CECs) and Circulating Endothelial Progenitor Cells (CEPs)|Tissue Tumor Markers Assessed by Tumor Biopsy|Plasma Concentration of Vascular Endothelial Growth Factor (VEGF)|Plasma Concentration of VEGF-C|Plasma Concentration of Soluble VEGF Receptor-2 (sVEGFR-2)|Plasma Concentration of Soluble VEGF Receptor-3 (sVEGFR-3)|Plasma Concentration of Soluble KIT (sKIT)	Phase 2	https://ClinicalTrials.gov/show/NCT00247676
NCT00001587	Completed	No Results Available	Procedure: Isolated hepatic portal and arterial perfusion|Drug: Melphalan		Phase 1	https://ClinicalTrials.gov/show/NCT00001587
NCT01900002	Active, not recruiting	No Results Available	Drug: Sorafenib|Radiation: Yttrium-90 Microspheres|Behavioral: Follow-Up Phone Calls	Toxicity of Sorafenib and Yttrium-90	Phase 2	https://ClinicalTrials.gov/show/NCT01900002
NCT00604409	Completed	No Results Available	Radiation: SIRT|Drug: capecitabine	To determine the safety, toxicity, and recommended phase II dose (RPTD) of capecitabine when administered concurrently with SIR-Spheres in patients with advanced cancer.|Efficacy	Phase 1	https://ClinicalTrials.gov/show/NCT00604409
NCT00003994	Completed	No Results Available	Procedure: therapeutic conventional surgery|Drug: cisplatin|Drug: vincristine sulfate|Drug: fluorouracil|Drug: amifostine trihydrate|Drug: carboplatin	Event-free survival (EFS) rates|Toxicity rates assessed using National Cancer Institute (NCI) Common Toxicity Criteria (CTC)	Phase 3	https://ClinicalTrials.gov/show/NCT00003994
NCT01180959	Active, not recruiting	No Results Available	Drug: Bevacizumab|Drug: Erlotinib	Number of Patients with Progression Free Survival (PFS) at 16 weeks	Phase 2	https://ClinicalTrials.gov/show/NCT01180959
NCT00250822	Completed	No Results Available	Drug: Gemcitabine and Oxaliplatin	Response Rate ( CR + PR rate); namely, to determine response rate to the Gemcitabine and Oxaliplatin combination administered to patients with hepatocellular cancer. Furthermore, patients who achieve a response leading to tumor respectability.	Phase 2	https://ClinicalTrials.gov/show/NCT00250822
NCT01356628	Active, not recruiting	Has Results	Drug: PD-0332991	Time to Disease Progression|Number of Adverse Events|Overall Survival (OS)|Response Rate (RR)	Phase 2	https://ClinicalTrials.gov/show/NCT01356628
NCT01730937	Recruiting	No Results Available	Drug: sorafenib tosylate|Radiation: stereotactic body radiation therapy	Overall survival (OS)|TTP|PFS|Grade 4 or 5 hepatic adverse events, grade 4 or 5 gastrointestinal AEs, grade 4 thrombocytopenia associated with any bleeding or grade 5 thrombocytopenia. All AEs must be definitely or probably related to protocol treatment and use CTCAE version 4.0|Health related quality of life assessments measured by the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep)|Quality adjusted survival defined as the weighted sum of different time in different health states added up to a total quality-adjusted survival time using EuroQol (EQ-5D)	Phase 3	https://ClinicalTrials.gov/show/NCT01730937
NCT00321594	Completed	Has Results	Drug: belinostat	Dose-limiting Toxicities (DLT) and Maximum Tolerated Dose (MTD) of Belinostat in Patients With Inoperable HCC (Phase I)|Tumor Response in Patients With Inoperable HCC Using Belinostat (Phase II)	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT00321594
NCT01545804	Completed	No Results Available	Drug: Lenalidomide	disease stabilization	Phase 2	https://ClinicalTrials.gov/show/NCT01545804
NCT00238394	Completed	No Results Available	Drug: cediranib maleate|Other: laboratory biomarker analysis	Survival after 6 months of treatment|Time to disease progression|Confirmed tumor response is defined to be a CR or PR noted as the objective status on 2 consecutive evaluations at least 4 weeks apart|Laboratory measures	Phase 2	https://ClinicalTrials.gov/show/NCT00238394
NCT00513461	Unknown status	No Results Available	Drug: S-adenosyl-L-methionine disulfate p-toluene-sulfonate|Other: placebo|Other: laboratory biomarker analysis|Other: immunoenzyme technique|Other: high performance liquid chromatography	Change in serum AFP levels|Treatment-related changes in additional serum markers for hepatocellular carcinoma|Change in markers of liver disease|Changes in markers of oxidative stress|Change in SAMe metabolites|Safety and tolerability of SAMe|Changes in quality of life	Phase 2	https://ClinicalTrials.gov/show/NCT00513461
NCT02174549	Recruiting	No Results Available	Drug: Tirapazamine|Procedure: Transarterial embolization (TAE)	determine the recommended phase 2 dose|Complete Response (CR) rate|Duration of response	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT02174549
NCT00370513	Completed	No Results Available	Drug: pazopanib	Adverse events (AEs) and changes in vital signs and laboratory values. A dose regimen where no more than 1 out of 6 subjects experience a dose-limiting toxicity (DLT) will define the maximum tolerated dose (MTD).|Various pharmacokinetic parametersAlpha-fetoprotein (AFP) measurements and scans	Phase 1	https://ClinicalTrials.gov/show/NCT00370513
NCT00728078	Unknown status	No Results Available	Drug: thalidomide	progress free survival|morbility|overall survival|recurrence rate	Phase 2|Phase 3	https://ClinicalTrials.gov/show/NCT00728078
NCT00845689	Unknown status	No Results Available	Drug: placebo|Drug: adenosine|Procedure: Liver resection		Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT00845689
NCT02702323	Not yet recruiting	No Results Available	Drug: Apatinib|Procedure: TACE	Progress Free Survival|overall survival|Objective response rate|The Quality of Life|Toxicity as measured by CTCAE V4.0	Phase 2|Phase 3	https://ClinicalTrials.gov/show/NCT02702323
NCT00553683	Unknown status	No Results Available	Drug: cyclophosphamide|Drug: poly ICLC|Procedure: hepatic artery embolization|Radiation: 3-dimensional conformal radiation therapy	Overall tolerability|Progression-free survival at 6, 12, and 24 months|Overall survival at 6, 12, and 24 months	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT00553683
NCT01033240	Completed	No Results Available	Drug: CS-1008|Drug: sorafenib	time to progression (TTP) for chemotherapy naive subjects with advanced hepatocellular carcinoma (HCC)|objective response rate (ORR) i.e. the proportion of subjects with the best response of complete response or partial response|overall survival (OS)	Phase 2	https://ClinicalTrials.gov/show/NCT01033240
NCT00507585	Completed	No Results Available	Drug: Fluorouracil|Drug: Avastin|Drug: Leucovorin|Drug: Oxaliplatin	To study the highest tolerable dose of oxaliplatin used in combination with 5-fluorouracil, leucovorin, and Avastin® (bevacizumab) for patients with advanced cancer that has spread to the liver.	Phase 1	https://ClinicalTrials.gov/show/NCT00507585
NCT01624285	Active, not recruiting	No Results Available	Drug: sorafenib tosylate|Other: placebo|Other: laboratory biomarker analysis	Recurrence-free survival, evaluated using the new international criteria proposed by the Modified Response Evaluation Criteria in Solid Tumors (mRECIST) Committee|Overall survival|Recurrence-free survival, evaluated using the new international criteria proposed by the mRECIST Committee|Adverse events assessed in terms of seriousness, severity, and relationship to the study material according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Impact of drug-drug interactions|Impact of biomarkers (AFP and PIVKA II)|Time to wound healing|Time to first HCV viral recurrence	Phase 2	https://ClinicalTrials.gov/show/NCT01624285
NCT00019786	Completed	No Results Available	Drug: isolated perfusion|Drug: melphalan|Procedure: conventional surgery	Response rate|Duration of response|Patterns of recurrence|Disease-free survival|Overall survival	Phase 2	https://ClinicalTrials.gov/show/NCT00019786
NCT00361309	Completed	No Results Available	Drug: SU011248	Progression free survival of hepatocellular carcinoma (HCC) patients treated with SU011248.|Number of adverse events in patients treated with SU011248 for advanced hepatocellular carcinoma|Objective Response Rate|Overall Survival	Phase 2	https://ClinicalTrials.gov/show/NCT00361309
NCT03352349	Recruiting	No Results Available	Drug: Terlipressinum	Change of Portal vein pressure|Incidence of hepatic dysfunction after hepatectomy|Incidence of acute renal dysfunction after hepatectomy|Adverse effect of Terlipressurinum	Phase 2	https://ClinicalTrials.gov/show/NCT03352349
NCT00604721	Completed	Has Results	Drug: selumetinib|Other: pharmacological study	Number of Participants With Radiographic Objective Response (OR)|Median Progression Free Survival (PFS)|Median Overall Survival (OS)	Phase 2	https://ClinicalTrials.gov/show/NCT00604721
NCT02509507	Recruiting	No Results Available	Drug: Talimogene Laherparepvec|Drug: Pembrolizumab	Subject incidence DLTs separately in Group A and B observed in monotherapy and combination|To evaluate in Part 2 ORR per irRC‑RECIST separately by tumor type (BC, CRC, GEC, melanoma, NSCLC, RCC, and HCC)|Safety: Subject incidence of treatment-related and treatment-emergent adverse events in monotherapy and combination of Part 1 and each separate tumour type in Part 2|Safety: To estimate the incidence of detectable talimogene laherparepvec DNA in blood and urine|Safety: To estimate the incidence of clearance of talimogene laherparepvec DNA from blood and urine|Safety: To estimate the rate of detection and incidence of talimogene laherparepvec DNA and virus at the surface of talimogene laherparepvec injection site, the exterior of the occlusive dressing, and the oral mucosa|Safety: To estimate the incidence of talimogene laherparepvec DNA detection in lesions suspected to be herpetic in origin	Phase 1	https://ClinicalTrials.gov/show/NCT02509507
NCT00083226	Completed	Has Results	Drug: doxorubicin|Drug: bortezomib	Objective Response Rate Measured by Response Evaluation Criteria In Solid Tumors (RECIST)|Overall Survival|Progression Free Survival	Phase 2	https://ClinicalTrials.gov/show/NCT00083226
NCT00077441	Completed	No Results Available	Drug: bortezomib|Other: laboratory biomarker analysis	Proportion of confirmed tumor responses, defined to be either a CR or PR noted as the objective status on 2 consecutive evaluations at least 6 weeks apart|Survival time|Time to disease progression|Duration of response is defined for all evaluable patients who have achieved an objective response as the date at which the patient's objective status is first noted to be either a CR or PR to the date progression is documented|Time to treatment failure	Phase 2	https://ClinicalTrials.gov/show/NCT00077441
NCT00858429	Active, not recruiting	No Results Available	Drug: capecitabine|Radiation: yttrium Y 90 glass microspheres	Maximal tolerated dose of yttrium Y 90|Toxicity|Time to tumor progression	Phase 1	https://ClinicalTrials.gov/show/NCT00858429
NCT00775073	Completed	No Results Available	Drug: Everolimus, Bevacizumab	Time to Progression|Overall Survival	Phase 2	https://ClinicalTrials.gov/show/NCT00775073
NCT00001576	Completed	No Results Available	Drug: Melphalan|Drug: Floxuridine|Drug: Leucovorin		Phase 1	https://ClinicalTrials.gov/show/NCT00001576
NCT01375569	Completed	Has Results	Drug: TRC105	Time to Tumor Progression (TTP) for TRC105 in Hepatocellular Carcinoma (HCC).|Count of Participants With Adverse Events	Phase 2	https://ClinicalTrials.gov/show/NCT01375569
NCT00071994	Completed	No Results Available	Drug: gefitinib|Other: laboratory biomarker analysis	Progression-free survival rate in patients treated with ZD 1839|Response (CR+PR) measured by RECIST|Grade 3 or higher toxicity|EGFR expression	Phase 2	https://ClinicalTrials.gov/show/NCT00071994
NCT00047346	Completed	No Results Available	Drug: erlotinib hydrochloride|Other: pharmacological study|Other: laboratory biomarker analysis	Dose-limiting toxicity and maximum tolerated dose as measured by NCI CTCAE v3.0 continuously|Pharmacokinetic (PK) and pharmacodynamic profile, as measured by Cmax, Tmax, AUC0-24, AUC0-infinity, Cl/F, T1/2, accumulation ratio, and Cssmin|Objective response rates (partial, complete, stable disease), as measured by CT scans using RECIST criteria	Phase 1	https://ClinicalTrials.gov/show/NCT00047346
NCT03259867	Recruiting	No Results Available	Drug: Opdivo Injectable Product or Keytruda Injectable Product|Combination Product: Trans-arterial tirapazamine embolization	Response rate|Overall Response rate|Duration of Response|Progression Free Survival|Overall survival	Phase 2	https://ClinicalTrials.gov/show/NCT03259867
NCT00076609	Completed	No Results Available	Drug: PHY906|Drug: capecitabine	Tumor imaging and evaluation every 6 weeks|Alphafetoprotein measurements every 3 weeks for first 3 courses, then every 6 weeks thereafter|QoL assessment every 3 weeks|Survival follow-up every 2 months	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT00076609
NCT02695628	Recruiting	No Results Available	Drug: 18F-Fluoromisonidazole|Procedure: Arterial Embolization|Diagnostic Test: Computed Tomography|Diagnostic Test: Positron Emission Tomography	Change in SUVmax and TLR of tumors|Comparison of SUVmax and TLR of tumors with recurrence to tumors without recurrence|Incidence of unanticipated toxicities related to 18F-fluoromisonidazole use over a 10 half-life period beginning from injection according to the Common Terminology Criteria for Adverse Events version 4|Measurement of SUVmax and TLR of untreated HCC tumor compared to normal liver, defined as any tumor that has not undergone any locoregional or systemic treatment within 3 months	Phase 2	https://ClinicalTrials.gov/show/NCT02695628
NCT03059238	Recruiting	No Results Available	Drug: Celecoxib 200mg oral capsule|Drug: parecoxib sodium|Drug: controlled-release oxycodone	Pain score|Adverse events|Trouble sleeping|Fatigue|Lacked appetite|Spiritual state	Phase 3	https://ClinicalTrials.gov/show/NCT03059238
NCT00980239	Completed	No Results Available	Drug: Irinotecan|Drug: Bevacizumab|Drug: Oxaliplatin|Drug: Cetuximab	Maximum Tolerated Doses (MTDs)|Dose-limiting toxicities (DLTs)	Phase 1	https://ClinicalTrials.gov/show/NCT00980239
NCT02744248	Completed	No Results Available	Drug: IOP Injection|Drug: 0.9% normal saline	Dose limiting toxicities (DLTs) of IOP|Maximum tolerated dose (MTD) of IOP|Pharmacokinetic parameters-Cmax|Pharmacokinetic parameters-Tmax|Pharmacokinetic parameters-AUC0-t|Pharmacokinetic parameters-AUC0-inf|Pharmacokinetic parameters-T1/2|Changes in laboratory safety tests (hematology, biochemistry, urinalysis, bleeding time) from baseline	Phase 1	https://ClinicalTrials.gov/show/NCT02744248
NCT00555334	Unknown status	No Results Available	Procedure: RFA|Drug: lamivudine or entecavir	Overall survivals|Recurrence rates	Phase 4	https://ClinicalTrials.gov/show/NCT00555334
NCT02794337	Recruiting	No Results Available	Radiation: SBRT|Procedure: TACE|Drug: Sorafenib	In-field Progression Free Survival|Cause Specific Survival|Response assessment after treatment|Quality of Life|Toxicity Assessment	Phase 2|Phase 3	https://ClinicalTrials.gov/show/NCT02794337
NCT02940496	Recruiting	No Results Available	Drug: Pembrolizumab	Predictive Biomarkers of Pembrolizumab as Second-Line After Sorafenib Systemic Monotherapy in Participants with Advanced Hepatocellular Carcinoma|Objective Response Rate (ORR) of Pembrolizumab as Second-Line After Sorafenib Systemic Monotherapy in Participants with Advanced Hepatocellular Carcinoma	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT02940496
NCT00829413	Completed	No Results Available	Drug: SonoVue®	To demonstrate the Sensitivity and Specificity of SonoVue®-enhanced US to that of unenhanced US for the characterization of benign versus malignant FLLs using final diagnosis based on histology or combined imaging clinical data as truth standard.|To evaluate the accuracy and other performance parameters (positive predictive value [PPV], negative predictive value [NPV]) of SonoVue®-enhanced ultrasound for characterization of benign versus malignant FLLs in comparison to unenhanced ultrasound.|To evaluate the ability of SonoVue®-enhanced ultrasound to obtain a specific diagnosis of FLLs in comparison to unenhanced ultrasound.|To evaluate the inter-reader agreement in ultrasound images assessment (unenhanced and SonoVue®-enhanced separately).|To provide evidence of the safety and tolerability of intravenously administered SonoVue® in subjects with focal liver disease	Phase 3	https://ClinicalTrials.gov/show/NCT00829413
NCT00788697	Completed	Has Results	Drug: SonoVue-enhanced ultrasound|Other: Unenhanced ultrasound	Sensitivity: Percentage of True Positive Lesions Among All Malignant Lesions Per Truth Standard|Specificity: Percentage of True Negative Lesions Among All Malignant Lesions Per Truth Standard|Accuracy: Percentage of True Positive and True Negative Among All Lesions|Positive Predictive Value (PPV): Percentage of True Positive Lesions Among All Malignant Lesions Per Ultrasound|Negative Predictive Value (NPV): Percentage of True Negative Lesions Among All Malignant Lesions Per Ultrasound|Specific Diagnosis of Malignant FLLs|Specific Diagnosis of Benign FLLs|Inter-reader Agreement	Phase 3	https://ClinicalTrials.gov/show/NCT00788697
NCT00587067	Completed	Has Results	Drug: FLOXURIDINE	Treatment Response|Number of Patients With Treatment Related Toxicity|Disease Progression	Phase 2	https://ClinicalTrials.gov/show/NCT00587067
NCT00844168	Completed	No Results Available	Drug: sorafenib tosylate|Other: laboratory biomarker analysis	Dose-limiting toxicity (DLT) as defined by the Common Terminology for Adverse Events (CTAE) version 3	Phase 1	https://ClinicalTrials.gov/show/NCT00844168
NCT02911961	Not yet recruiting	No Results Available	Drug: Acetaminophen	APAP-CYS Concentrations Over Time - Acetaminophen Group|APAP-CYS Concentrations Over Time - Non-Acetaminophen Group|Relationship between APAP-CYS and other biochemical markers of liver function|Accuracy of Medication History Assessment Tool (MedHAT)	Phase 4	https://ClinicalTrials.gov/show/NCT02911961
NCT01853618	Active, not recruiting	No Results Available	Drug: Tremelimumab|Procedure: RFA|Procedure: TACE|Procedure: Cryoablation	Safety and feasibility of combining Tremelimumab with trans-arterial catheter chemoembolization (TACE) or radiofrequency ablation (RFA) in patients with advanced HCC|To evaluate clinical indicators of efficacy (response rate, time totumor progression, overall survival) in patients with advanced HCC undergoing TACE, radiofrequency ablation (RFA), cryoablation orstereotactic body radiation therapy (SBRT)...|Progression free survival (PFS)|Overall survival	Phase 1	https://ClinicalTrials.gov/show/NCT01853618
NCT03151213	Recruiting	No Results Available	Drug: Pregabalin 150mg|Other: Placebo	visual analogue pain scale (VAS Pain) post operatively	Phase 4	https://ClinicalTrials.gov/show/NCT03151213
NCT02202564	Completed	No Results Available	Procedure: LT|Drug: ADV-TK|Drug: ganciclovir	Overall survival rate|Recurrence-free survival rate	Phase 2	https://ClinicalTrials.gov/show/NCT02202564
NCT01008566	Completed	No Results Available	Biological: Cixutumumab|Other: Laboratory Biomarker Analysis|Drug: Sorafenib Tosylate	MTD defined as the highest IMC-A12 dose tested in which none or only one patient had a dose-limiting toxicity (DLT) attributed to IMC-A12 as assessed by NCI CTCAE version 4.0|Toxicities and tolerability of this regimen as assessed by NCI CTCAE version 4.0|Impact of cixutumumab on biomarkers related to the IGF-1R/IGF pathway|Objective response rate according to RECIST|Progression-free rate according to the Response Evaluation Criteria in Solid Tumors (RECIST)	Phase 1	https://ClinicalTrials.gov/show/NCT01008566
NCT03211416	Recruiting	No Results Available	Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab|Drug: Sorafenib Tosylate	Overall response rate defined as partial or complete response per immune-related Response Evaluation Criteria in Solid Tumors|Overall survival|Time to tumor progression	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT03211416
NCT00542048	Completed	No Results Available	Drug: EndoTAG®-1	Pharmacokinetic profile|Tumor response, Tumor perfusion, Soluble markers of angiogenesis, Pharmacodynamics, Safety	Phase 2	https://ClinicalTrials.gov/show/NCT00542048
NCT00081848	Completed	No Results Available	Drug: rV-CEA(6D)/TRICOM-rF-CEA(6D)/TRICOM|Drug: rF-CEA(6D)/TRICOM|Drug: Recombinant Fowlpox-GM-CSF|Drug: Celecoxib		Phase 1	https://ClinicalTrials.gov/show/NCT00081848
NCT03533582	Recruiting	No Results Available	Drug: Carboplatin|Drug: Cisplatin|Drug: Doxorubicin|Drug: Etoposide|Drug: Fluorouracil|Drug: Gemcitabine|Drug: Irinotecan|Other: Laboratory Biomarker Analysis|Drug: Oxaliplatin|Other: Patient Observation|Drug: Sorafenib|Drug: Vincristine Sulfate	Event-free survival (EFS)|Response in hepatocellular carcinoma (HCC), defined as complete (CR) or partial (PR) response according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria|Failure free survival|Overall survival|Incidence of adverse events|Chemotherapy-related cardiac, nephro- and oto-toxicity|Hearing loss measured according to the SIOP Boston Scale for oto-toxicity|Best response defined as compete response (CR) or partial response (PR) based on radiological response (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) and AFP decline|Surgical resectability defined as complete resection, partial resection or transplant following randomization (or enrollment for non-randomized patients)|Adherence to surgical guidelines defined as the local clinician's surgical decision to resect or not compared to the current SIOPEL surgical guidelines	Phase 2|Phase 3	https://ClinicalTrials.gov/show/NCT03533582
NCT01775501	Active, not recruiting	No Results Available	Drug: Leucovorin|Drug: Fluorouracil|Drug: Oxaliplatin|Drug: Sorafenib	Time to Progression|Number of patients experiencing Adverse Events|Overall response rate|Median progression free survival|Median Overall survival|Duration of response	Phase 2	https://ClinicalTrials.gov/show/NCT01775501
NCT00960557	Completed	No Results Available	Drug: Combretastatin A1 Diphosphate (OXi4503)	To determine the safety and tolerability of OXi4503 in subjects with relapsed or refractory carcinomas with hepatic tumor burden.|To determine progression-free survival (PFS).	Phase 1	https://ClinicalTrials.gov/show/NCT00960557
NCT01782573	Completed	No Results Available	Drug: Chlorhexidine gluconate|Drug: 0.9% Sodium Chloride	the positive rate of the baseline culture , the preoperative culture , and the postoperative culture|the post - operative surgical site infection	Phase 4	https://ClinicalTrials.gov/show/NCT01782573
NCT00183885	Active, not recruiting	No Results Available	Drug: mitomycin-c, cisplatin	Tumor Response|Number of participants with grade 3 or higher toxicity	Phase 2	https://ClinicalTrials.gov/show/NCT00183885
NCT00732836	Completed	No Results Available	Drug: HAI Abraxane|Procedure: Hepatic Artery Catheter|Drug: IV Abraxane	Maximum Tolerated Dose (MTD) of HAI Abraxane	Phase 1	https://ClinicalTrials.gov/show/NCT00732836
NCT01642186	Active, not recruiting	No Results Available	Drug: everolimus|Drug: letrozole plus leuprolide|Drug: combination of everolimus, letrozole and leuprolide	efficacy endpoints for Part 1 of the study is progression-free survival at 6 months (PFS6)|median PFS|median overall survival (OS)|response rate|to evaluate toxicity in patients|correlative serum|tissue biomarker studies|to evaluate safety in patients	Phase 2	https://ClinicalTrials.gov/show/NCT01642186
NCT01306058	Completed	Has Results	Drug: TRC 105|Drug: Sorafenib	Phase I: Maximum Tolerated Dose (MTD) of TRC105 When Given With Standard-dose Sorafenib for Hepatocellular Cancer (HCC)|Phase II: Time to Progression (TTP) for the Combination of TR105 With Sorafenib in Hepatocellular Cancer (HCC)|Overall Response Rate (ORR) as Determined by the Standard Response Evaluation Criteria in Solid Tumors (RECIST) Criteria|Overall Response Rate (ORR) as Determined by the European Association for the Study of the Liver (EASL)-Modified Response Evaluation Criteria in Solid Tumors (RECIST) Criteria|Patients Who Developed Antidrug Antibodies|Immunogenicity of TRC105 as Measured by Human Anti-mouse Antibody (HAMA) Formation|Number of Participants With Serious and Non-serious Adverse Events by Common Terminology Criteria in Adverse Events (CTCAE)v4.0|Number of Participants With Dose Limiting Toxicity (DLT)|Treatment-emergent Adverse Events|Median Progression-free Survival (PFS)|Percentage of Participants With Progression Free Survival (PFS) at 3 and 6 Months|Median Overall Survival (OS)|Percentage of Participants With Overall Survival (OS) at 6 and 12 Months|Number of Participants With Stable Disease, Partial Response, and Progressive Disease on Phase I and Phase II of the Clinical Trial|Area Under the Plasma Concentration|Changes in Biomarkers Vascular Endothelial Growth Factor (VEGF) and Placenta Growth Factor (PIGF)|Changes in Biomarker Cluster of Differentiation 105 (CD105)|Percentage Signal Change in Response on Magnetic Resonance Imaging (MRI)	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT01306058
NCT01666756	Active, not recruiting	No Results Available	Dietary Supplement: Chinese herbal formulation PHY906|Drug: sorafenib tosylate|Other: laboratory biomarker analysis|Other: pharmacological study	Recommended phase II dose, determined according to incidence of dose-limiting toxicity (DLT) graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4|Adverse events as determined by NCI CTCAE version 4|Serious adverse events as determined by NCI CTCAE version 4|Discontinuation rate|Dose adjustment rate|Tumor response in terms of best overall response, assessed using RECIST|Sorafenib tosylate concentration after co-administration with Chinese herbal formulation PHY906	Phase 1	https://ClinicalTrials.gov/show/NCT01666756
NCT02191878	Completed	No Results Available	Drug: TKM-080301	Maximum tolerated dose (MTD)|Preliminary assessment of anti-tumor activity by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1)|Clinical Benefit Rate at maximum tolerated dose (MTD) in Expansion Cohort	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT02191878
NCT00149396	Completed	Has Results	Drug: NV1020	Incidence of Adverse Events and Dose Limiting Adverse Events|NV1020 Pharmacokinetics - Presence of NV1020 in Body Fluids/Skin|Clinical Laboratory Safety - Hematology|Clinical Laboratory Safety - Chemistry|Clinical Laboratory Safety - Coagulation|Mean Change From Baseline in Serum Carcinoembryonic Antigen (CEA) After Administration of NV1020 and 2 Cycles of Chemotherapy|Liver Tumor Response After Administration of NV1020 Followed by Chemotherapy, Determined by Radiological (Computed Tomography [CT] Scan) Assessment|Pharmacodynamic Effects of NV1020: NV1020 Neutralizing Antibody Titer Assay|Time to Disease Progression; Survival Time|Pharmacodynamic Effects of NV1020: Serum Cytokines (INF Gamma)|Pharmacodynamic Effects of NV1020: Serum Cytokines (IL-6)|Pharmacodynamic Effects of NV1020: Serum Cytokines (TNF-alpha)	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT00149396
NCT00304135	Completed	No Results Available	Drug: cisplatin|Drug: gemcitabine hydrochloride|Drug: oxaliplatin	Progression rate at 3 months|Overall survival|Toxicity|Biliary complication rate	Phase 2|Phase 3	https://ClinicalTrials.gov/show/NCT00304135
NCT00096083	Completed	No Results Available	Drug: isolated perfusion|Drug: melphalan	To determine the response rate and duration of response to intra-hepatic infusion of melphalan with subsequent venous hemofiltration in patients with primary and metastatic hepatic malignancies|To determine the patterns of recurrence following percutaneous hepatic perfusions (PHP) with melphalan|To determine the progression free and overall survival in patients with hepatic malignancies following this therapy	Phase 2	https://ClinicalTrials.gov/show/NCT00096083
NCT01640808	Unknown status	No Results Available	Drug: NIK-333(peretinoin)|Drug: Placebo	Recurrence-free survival|Disease-free survival|Time to recurrence	Phase 3	https://ClinicalTrials.gov/show/NCT01640808
NCT00575523	Completed	No Results Available	Drug: Atropine|Drug: Placebo	Occurrence of dysrhythmias|Clinical complications	Phase 4	https://ClinicalTrials.gov/show/NCT00575523
NCT00059865	Completed	No Results Available	Drug: gemcitabine hydrochloride|Drug: pemetrexed disodium	Survival after 6 months of treatment|Response as assessed by RECIST criteria every 8-16 weeks|Toxicity as assessed by CTC v3 every 4 weeks	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT00059865
NCT02575339	Active, not recruiting	No Results Available	Drug: MLN0128|Drug: MLN0128 (RP2D)|Drug: Sorafenib	Phase I: Maximum Tolerated Dose (MTD) of MLN0128|Phase II: Time to Progression (TTP)|Phase I: Characterize Adverse Effects (AE)|Phase I: Overall Survival (OS) Rate|Phase I: Time to Progression (TTP)|Phase I: Progression-free survival (PFS)|Phase I: Objective Response Rate (ORR)|Phase I: Disease Control Rate (DCR)|Phase II: Overall Survival (OS) Rate|Phase II: Progression Free Survival (PFS)|Phase II: Characterize Adverse Effects (AE)|Phase II: Radiographic Response Rate (RRR)	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT02575339
NCT02044224	Completed	No Results Available	Drug: Dexmedetomidine	Patient Satisfaction With Anaesthesia Technique|Evaluation of anaesthetic consumption|Vital signs: blood pressure, oxygen saturation, heart rate, breathing rate|Postoperative analgesic requirements|Maximal pain intensity|Description of patient characteristics	Phase 4	https://ClinicalTrials.gov/show/NCT02044224
NCT01213030	Completed	No Results Available	Drug: [F-18] FMISO|Drug: [F-18] HX4	Efficacy of a hypoxia imaging agent, HX4, in patients with solitary tumors (i.e., locally advanced head and neck cancer)|Resolution, signal to background ratio, and tumor/blood ratio of PET images with [F-18] FMISO and [F-18]HX4	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT01213030
NCT00441376	Completed	No Results Available	Drug: ThermoDox	To determine the maximum tolerated dose (MTD) of systemically delivered, heat-activated liposome encapsulated doxorubicin (ThermoDox) in combination with radiofrequency ablation (RFA) of liver neoplasms.|To test alternative infusion reaction prophylaxis regimens|To assess the safety of ThermoDox plus RFA afer administration of potential multiple cycles|To determine the Pharmacokinetics (PK) of ThermoDox|To document any anti-tumor activity and assess recurrences.|To measure post ablation lesion volume.|To determine the cardiotoxicity of ThermoDox through enhanced ECG monitoring.	Phase 1	https://ClinicalTrials.gov/show/NCT00441376
NCT00122876	Completed	No Results Available	Procedure: Photodynamic therapy|Drug: Talaporfin Sodium	Safety|Tumor Response|Survival	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT00122876
NCT01525069	Recruiting	No Results Available	Drug: Floxuridine|Drug: Dexamethasone|Drug: Gemcitabine|Drug: Oxaliplatin	Dose-limiting toxicities (DLTs)|Time to progression (TTP)|Response rates|Overall survival|Number and grade of adverse events|Imaging biomarkers of tumor response	Phase 1	https://ClinicalTrials.gov/show/NCT01525069
NCT00101036	Completed	Has Results	Drug: lapatinib ditosylate|Other: laboratory biomarker analysis	Response Rate|Overall Survival|Progression-free Survival|Disease Control Rate.	Phase 2	https://ClinicalTrials.gov/show/NCT00101036
NCT02016391	Completed	No Results Available	Drug: Dexmedetomidine	Patient Satisfaction With Sedation Technique|Vital signs: blood pressure, oxygen saturation, heart rate, breathing rate|Ramsey Sedation Scale Score|Maximal pain intensity	Phase 4	https://ClinicalTrials.gov/show/NCT02016391
NCT01665937	Completed	No Results Available	Drug: STA-9090	Phase 2 dose of STA 9090 given once weekly in patients with advanced hepatocellular carcinoma|Number of patients with adverse events when treated with STA 9090 for advanced hepatocellular carcinoma|Median time to progression (TTP)|Median progression-free survival (PFS)|Response Rate|Overall Survival	Phase 1	https://ClinicalTrials.gov/show/NCT01665937
NCT00143403	Completed	Has Results	Drug: Irinotecan + 5 FU + folinic acid|Drug: Folinic Acid + 5 FU	Disease Free Survival (DFS)|Overall Survival Rates	Phase 3	https://ClinicalTrials.gov/show/NCT00143403
NCT02989870	Recruiting	No Results Available	Radiation: Stereotactic Body Radiation Therapy (SBRT)|Drug: Sorafenib|Drug: Bavituximab	Occurrence of Treatment Related Adverse Events|Objective Response Rate (ORR)|Progression Free Survival (PFS)|Overall Survival (OS)	Phase 1	https://ClinicalTrials.gov/show/NCT02989870
NCT00003296	Unknown status	No Results Available	Biological: filgrastim|Drug: pegylated liposomal doxorubicin hydrochloride		Phase 2	https://ClinicalTrials.gov/show/NCT00003296
NCT00003557	Completed	No Results Available	Drug: dolastatin 10	Objective Response Rate	Phase 2	https://ClinicalTrials.gov/show/NCT00003557
NCT00537121	Completed	No Results Available	Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Drug: vorinostat|Other: pharmacological study	Maximum tolerated dose (MTD) of vorinostat (SAHA) when administered continuously and intermittently with standard doses of irinotecan hydrochloride, fluorouracil, and leucovorin calcium (FOLFIRI)|Recommended phase II dose (RPTD) of SAHA when administered continuously and intermittently with standard doses of FOLFIRI|Toxicity of the SAHA and FOLFIRI combination|Effects of SAHA and FOLFIRI combination on TGF-β signaling and survivin expression|Response rate|Progression-free survival|Overall survival	Phase 1	https://ClinicalTrials.gov/show/NCT00537121
NCT00659022	Unknown status	No Results Available	Procedure: immediate surgery (resection of primary colorectal tumor)|Drug: neo-adjuvant treatment with bevacizumab|Drug: neoadjuvant treatment with capecitabine and oxaliplatin|Drug: neo-adjuvant treatment with bevacizumab, capecitabine and oxaliplatin	Difference in response of liver metastases between control group and experimental groups determined by histopathological scoring of vascular density,apoptotic and mitotic index|Difference in response of liver metastases between control group and experimental groups determined by FDG-PET|Toxicity of neo-adjuvant treatment|Complications of surgery	Phase 2	https://ClinicalTrials.gov/show/NCT00659022
NCT00009893	Completed	No Results Available	Drug: fluorouracil|Drug: gemcitabine hydrochloride|Drug: leucovorin calcium	survival at 6 months|overall survival|tumor response rate	Phase 2	https://ClinicalTrials.gov/show/NCT00009893
NCT00005938	Completed	No Results Available	Drug: exatecan mesylate		Phase 2	https://ClinicalTrials.gov/show/NCT00005938
NCT01502410	Completed	Has Results	Drug: sorafenib tosylate|Other: pharmacological study|Other: laboratory biomarker analysis	Objective Response by RECIST Criteria v 1.1|Progression-free Survival According to RECIST Version 1.1|The Number of Patients Who Experience at Least One Grade 3 or Higher CTC Version 4 Toxicity,|Pharmacokinetic (PK) Parameters of Sorafenib Tosylate|Change in VEGF and VEGFR-2|Presence of BRAF Mutation or RET/PTC Rearrangement	Phase 2	https://ClinicalTrials.gov/show/NCT01502410
NCT01313377	Completed	No Results Available	Drug: gemcitabine hydrochloride|Drug: oxaliplatin|Other: clinical observation|Procedure: adjuvant therapy|Procedure: quality-of-life assessment	Disease-free survival|Quality of life|Overall survival|Toxicity of adjuvant chemotherapy	Phase 3	https://ClinicalTrials.gov/show/NCT01313377
NCT00363584	Completed	No Results Available	Drug: capecitabine|Other: clinical observation|Procedure: adjuvant therapy	Survival at 2 years|Survival at 5 years|Relapse-free survival|Toxicity|Quality of life|Health economics	Phase 3	https://ClinicalTrials.gov/show/NCT00363584
NCT00437424	Completed	No Results Available	Drug: Brivanib	The primary objective of this study is to determine the effect of BMS-582664 on subjects with varying levels of hepatic impairment and guide prescribers with regards to dosing in specialized populations|To assess safety and tolerability of BMS-582664 in subjects with HCC with mild, moderate, and severe hepatic impairment and in subjects with advanced malignancies with normal hepatic function|To assess efficacy of BMS-582664 in subjects with advanced solid tumor malignancies and subjects with HCC by CT or MRI	Phase 1	https://ClinicalTrials.gov/show/NCT00437424
NCT03159585	Recruiting	No Results Available	Drug: Cyclophosphamide|Biological: TAEST16001	adverse events|clinical response rate	Phase 1	https://ClinicalTrials.gov/show/NCT03159585
NCT00844883	Completed	Has Results	Drug: sorafenib|Procedure: LC Bead-TACE	Safety Will be Assessed by Grading Toxicities Reported at Intervals Throughout the Study. Higher Grade Toxicities Will be Assessed for Their Degree of Relatedness to the Study Treatment.|Efficacy Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) to Determine Response and Disease Control Rate|Efficacy Assessed by European Association for the Study of the Liver (EASL) Criteria to Determine Response and Disease Control Rate|Efficacy - Median TTP After Combination Treatment With Sorafenib and TACE|Efficacy - Overall Survival (OS) After Combination Treatment With Sorafenib and TACE|Efficacy - Factors Associated With Overall Survival (OS) After Combination Treatment With Sorafenib and TACE	Phase 2	https://ClinicalTrials.gov/show/NCT00844883
NCT03316222	Recruiting	No Results Available	Drug: GNS561	Dose-Limiting Toxicity	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT03316222
NCT02273362	Recruiting	No Results Available	Drug: Erlotinib Hydrochloride|Other: Laboratory Biomarker Analysis|Other: Quality-of-Life Assessment	Minimum effective dose (MED) of erlotinib hydrochloride that inhibits EGFR signaling in the target organ (liver) as assessed by phospho-EGFR staining|Overall adverse event profile for erlotinib hydrochloride graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT02273362
NCT02650375	Recruiting	No Results Available	Drug: Metatinib Tromethamine	incidence of adverse events|Objective response rate|Disease control rate|Progression free survival|Overall survival|Cmax for Metatinib|Cmin for Metatinib|Tmax for Metatinib|AUC for Metatinib|T1/2 for Metatinib|CL for Metatinib	Phase 1	https://ClinicalTrials.gov/show/NCT02650375
NCT03107416	Recruiting	No Results Available	Procedure: Hepatic artery embolization (HAE)|Drug: Bumetanide	Maximum tolerated dose (MTD) (phase I)|estimate the local tumor progression (LTP) rates (phase II)	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT03107416
NCT01835223	Active, not recruiting	No Results Available	Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Tivozanib	PFS, assessed using standard RECIST criteria|Clinical benefit rate (CR, PR, and SD) by RECIST|Incidence of adverse events and toxicities, assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 4|OS	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT01835223
NCT00999843	Unknown status	No Results Available	Drug: Sorafenib	The safety and tolerability of maintenance Sorafenib.|Time to progression (TTP), progression-free survival (PFS) and overall survival (OS)	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT00999843
NCT01819961	Unknown status	No Results Available	Drug: MCT/LCT and fish oil|Drug: MCT/LCT	infective complications|length of hospital stay|plasma immunological markers	Phase 4	https://ClinicalTrials.gov/show/NCT01819961
NCT01658878	Active, not recruiting	No Results Available	Biological: Nivolumab|Drug: Sorafenib|Drug: Ipilimumab|Drug: Cabozantinib	Safety of nivolumab as evaluated by incidence of adverse events (AEs), serious adverse events (SAEs), adverse events leading to discontinuation, deaths and clinical laboratory test abnormalities|Tolerability of nivolumab as evaluated by incidence of adverse events (AEs), serious adverse events (SAEs), adverse events leading to discontinuation, deaths and clinical laboratory test abnormalities|Objective response rate (ORR) for Expansion phase of nivolumab|ORR for Nivolumab vs Sorafenib Cohort|Safety of nivolumab plus ipilimumab as evaluated by incidence of adverse events (AEs), serious adverse events (SAEs), adverse events leading to discontinuation, deaths and clinical laboratory test abnormalities|Tolerability of nivolumab plus ipilimumab as evaluated by incidence of adverse events (AEs), serious adverse events (SAEs), adverse events leading to discontinuation, deaths and clinical laboratory test abnormalities|ORR for Nivolumab plus Ipilimumab Combination Cohort|ORR for Child-Pugh B Cohort|Safety of nivolumab plus ipilimumab plus cabozantinib as evaluated by incidence of adverse events (AEs), serious adverse events (SAEs), adverse events leading to discontinuation, deaths and clinical laboratory test abnormalities|Tolerability of nivolumab plus ipilimumab plus cabozantinib as evaluated by incidence of adverse events (AEs), serious adverse events (SAEs), adverse events leading to discontinuation, deaths and clinical laboratory test abnormalities|ORR for Nivolumab plus Ipilimumab plus Cabozantinib Combination Cohort|Complete response (CR) Rate|Disease control rate (DCR)|Duration of response (DOR)|Time to response (TTR)|Time to progression (TTP)|TTP Rate|Progression free survival (PFS)|Overall survival (OS)|Overall survival rate (OSR)|PD-L1 expression|Maximum observed serum concentration (Cmax) of nivolumab|Time of maximum observed serum concentration (Tmax) of nivolumab|Area under the serum concentration time curve in the dosing interval AUC(TAU) of nivolumab|Serum concentration achieved at the end of dosing interval (trough concentration) (Ctrough) of nivolumab|Serum concentration achieved at the end of the infusion (Ceoinf) of nivolumab|Cmax at Cycle 3/ Cmax at Cycle 1 (AI_Cmax) of nivolumab|AUC(TAU) at Cycle 3/ AUC(TAU) at Cycle 1 (AI_AUC) of nivolumab|Effective T-Half of nivolumab	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT01658878
NCT03572582	Recruiting	No Results Available	Drug: Nivolumab|Drug: TACE	Objective Response Rate (ORR)|Progression Free Survival (PFS)|Time to Progression (TTP)|Overall survival (OS)|Duration of Response (OR)|Objective Response Rate according to RECIST 1.1|Time to Failure of Strategy (TTFS)|Quality of Life (QoL)|Incidence of Treatment Emergent Adverse Events as assessed by NCI CTCAE V4.03 (Safety and Tolerability)	Phase 2	https://ClinicalTrials.gov/show/NCT03572582
NCT03316872	Recruiting	No Results Available	Drug: Pembrolizumab|Radiation: Stereotactic Body Radiotherapy (SBRT)	Overall response rate|Response rate in non-irradiated tumor lesions|Progression-free survival rate|Overall survival rate	Phase 2	https://ClinicalTrials.gov/show/NCT03316872
NCT01437007	Completed	No Results Available	Drug: TKM-080301	To evaluate feasibility of administering TKM-080301 via HAI, and establish MTD and DLT.|Characterize PK &amp; pharmacodynamics of TKM 080301|Eval biological effects of TKM-080301 on biopsies performed before &amp; after 1 cycle of tx|To evaluate the potential conversion rate from unresectable to resectable disease.	Phase 1	https://ClinicalTrials.gov/show/NCT01437007
NCT03203304	Recruiting	No Results Available	Drug: Nivolumab|Drug: Ipilimumab	Number of participants with adverse events|Overall response rate|Number of long-term adverse events|Time to progression free survival|Time of overall survival|Rate of disease control|Rate of local control of the SBRT treated lesion	Phase 1	https://ClinicalTrials.gov/show/NCT03203304
NCT00988195	Completed	No Results Available	Biological: Pegylated Recombinant Human Arginase I|Drug: Doxorubicin	Plasma arginase and arginine levels,as well as tumour response, i.e. an effect on growth in the milieu of arginine depletion.|Overall Survival, Time to Progression	Phase 1	https://ClinicalTrials.gov/show/NCT00988195
NCT02081755	Recruiting	No Results Available	Drug: Everolimus|Drug: Tacrolimus|Drug: Myfortic|Drug: CellCept|Drug: Imuran	Disease free survival (DFS) defined as the time from randomization to the time of tumor recurrence or death, whichever occurs first.|Tumor recurrence sites|Hepatitis C recurrence rate|Renal function|Acute cellular rejection|Post-transplant diabetes|Hypertension|Hyperlipidemia|Wound healing and associated risk factors|Hernia repair|Hepatic arterial thrombosis	Phase 4	https://ClinicalTrials.gov/show/NCT02081755
NCT02101593	Completed	No Results Available	Drug: ADI-PEG 20	Number of Participants with Adverse Events as a Measure of Safety and Tolerability of ADI-PEG 20 in combination with sorafenib in advanced HCC	Phase 1	https://ClinicalTrials.gov/show/NCT02101593
NCT02069041	Completed	No Results Available	Biological: Ramucirumab|Drug: FOLFOX4	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration|Pharmacokinetics: Maximum Concentration (Cmax) of Ramucirumab|Pharmacokinetics: Area Under the Concentration Curve (AUC) of Ramucirumab|Number of Participants with Anti-Ramucirumab Antibodies|Objective Responses Rate (ORR)	Phase 1	https://ClinicalTrials.gov/show/NCT02069041
NCT01298284	Unknown status	No Results Available	Drug: propranolol	Rebleeding|complication surivial	Phase 4	https://ClinicalTrials.gov/show/NCT01298284
NCT01936233	Unknown status	No Results Available	Drug: Aspirin|Drug: Lamivudine	recurrence free survival|overall survival|adverse events	Phase 3	https://ClinicalTrials.gov/show/NCT01936233
NCT01204177	Completed	No Results Available	Drug: BAY86-9766 MEK Inhibitor + Sorafenib	Disease Control Rate (DCR)|Overall Survival (OS)|Time To Progression (TTP)|Response Rate (RR)|Duration Of Response (DOR)|Safety: physical examination, vital signs, adverse events, safety lab|Patients reported hepatobiliary cancer symptoms and Health Related Quality of Life (HRQoL)|Pharmacokinetic (PK) profiles of BAY86-9766 and sorafenib to evaluate drug exposure (not in all patients)|Biomarkers	Phase 2	https://ClinicalTrials.gov/show/NCT01204177
NCT00920192	Completed	No Results Available	Drug: Foretinib	The maximum tolerated dose (MTD)|Safety and tolerability of foretinib at the MTD as measured by number and severity of AEs|The antitumor activity of foretinib at the MTD according to RECIST|PK profile of foretinib	Phase 1	https://ClinicalTrials.gov/show/NCT00920192
NCT01972503	Unknown status	No Results Available	Drug: 5-FU and oxaliplatin|Procedure: colorectal cancer resection+ adjuvant chemotherapy (mFOLFOX6)	3 years disease-free survival|3 years overall survival and metastasis-free survival	Phase 4	https://ClinicalTrials.gov/show/NCT01972503
NCT03439891	Recruiting	No Results Available	Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Drug: Sorafenib	Maximum tolerated dose (MTD) (Part 1)|Overall response rate (ORR) assessed using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Part 2)|Duration of response (DOR)|Incidence of adverse classified using NCI CTCAE version 4.03|ORR assessed by RECIST 1.1 for overall study|Overall survival (OS)|Progression-free survival (PFS)|Rate of immune-related adverse event (irAE) for combination	Phase 2	https://ClinicalTrials.gov/show/NCT03439891
NCT00877071	Completed	Has Results	Drug: LC Bead loaded with doxorubicin	The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM|The Objective Tumor Response Rate in Patients With HCC Treated With LC BeadTM Using EASL and RECIST Criteria|Symptomatic and Quality-of-life Measures in Patients Treated With the LC BeadTM|The Local Effects of the LC BeadTM in the Explanted Liver of Those Patients Who go on to Receive Liver Transplantation	Phase 2	https://ClinicalTrials.gov/show/NCT00877071
NCT02576964	Completed	No Results Available	Drug: Capecitabine|Drug: Peginterferon alfa-2a	Objective response rate|Time to disease progression|Duration of response|Overall survival|Incidence of adverse events	Phase 2	https://ClinicalTrials.gov/show/NCT02576964
NCT03199274	Recruiting	No Results Available	Procedure: Yttrium-90 Microsphere Radioembolization|Drug: Perflutren Protein-Type A Microspheres|Procedure: Dynamic Contrast-Enhanced Ultrasound Imaging	Treatment response to yttrium Y-90 radioembolization measured using the modified Response Evaluation Criteria in Solid Tumors|Tumor perfusion measured by contrast-enhanced ultrasound between ultrasound-triggered microbubble destruction pulses	Early Phase 1	https://ClinicalTrials.gov/show/NCT03199274
NCT00999882	Completed	No Results Available	Drug: AZD8055	Safety and tolerability (Adverse events, vital signs, ECG, chemistry, haematology, urinalysis, physical examination)|Evaluate the pharmacokinetics of AZD8055 following both single and multiple dosing|To make a preliminary assessment of efficacy|To investigate the possible relationship between plasma concentration of AZD8055 concentrations and the extent of liver impairment.|Evaluate the change in Phosphorylation levels of certain biomarkers before and after treatment with AZD8055|To collect and store DNA for future exploratory research that may influence response to AZD8055	Phase 1	https://ClinicalTrials.gov/show/NCT00999882
NCT00746317	Completed	No Results Available	Drug: GC33	Determine the safety and tolerability of escalating doses of GC33|Characterize the pharmacokinetics of GC33|Perform a preliminary assessment of anti-tumor activity of GC33	Phase 1	https://ClinicalTrials.gov/show/NCT00746317
NCT00073905	Completed	No Results Available	Drug: capecitabine plus gemcitabine	Ability of palliative capecitabine and gemcitabine|Clinical benefit response alone as measured after 3 courses	Phase 2	https://ClinicalTrials.gov/show/NCT00073905
NCT01564810	Unknown status	No Results Available	Drug: Cetuximab|Drug: chemotherapy of mFOLFOX6 or FOLFIRI	the rate of patients converted to resection for liver metastases|progression free survival|overall survival|tumor response	Phase 4	https://ClinicalTrials.gov/show/NCT01564810
NCT00976170	Completed	No Results Available	Drug: GC33(RO5137382)|Drug: Sorafenib	Toxicity evaluation in accordance with CTCAE v3.0|Dose limiting toxicity and maximum tolerated dose|RECIST criteria (version 1.0) for response evaluation by CT/MRI in target and non-target lesions of HCC|Repeat-dose pharmacokinetic behavior of GC33 and Sorafenib	Phase 1	https://ClinicalTrials.gov/show/NCT00976170
NCT01540461	Completed	No Results Available	Drug: Brivanib	Maximum observed plasma concentration (Cmax) of Brivanib|Trough observed plasma concentration (Cmin) of Brivanib|Time of maximum observed plasma concentration (Tmax) of Brivanib|Area under the plasma concentration-time curve from time zero to the end of the dosing interval [AUC(TAU)] of Brivanib|Average steady state concentration calculated as AUC(TAU)/24 (Css_av) of Brivanib|Degree of fluctuation calculated as ((Cmax- Cmin)/Css_av) [Degree of fluctuation] of Brivanib|Terminal half-life (T-HALF) of Brivanib|Accumulation index calculated as the ratio: AUC(TAU) at steady-state (Day 8) divided by AUC(TAU) after the first dose (Day 1) [AI] of Brivanib|Safety assessments based on adverse event reports and the results of vital sign measurements, electrocardiograms (ECGs), 2-D Echocardiograms, physical examinations and clinical laboratory tests|Preliminary evidence of anti-tumor activity as measured by objective response rate (ORR) and disease control rate (DCR) in Chinese subjects with advanced HCC treated with Brivanib	Phase 1	https://ClinicalTrials.gov/show/NCT01540461
NCT01004978	Active, not recruiting	No Results Available	Drug: Cisplatin|Drug: Doxorubicin Hydrochloride|Drug: Doxorubicin-Eluting Beads|Other: Laboratory Biomarker Analysis|Drug: Mitomycin|Other: Pharmacological Study|Other: Placebo|Drug: Sorafenib Tosylate	Progression free survival (PFS)|Overall survival|Incidence of adverse events, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0	Phase 3	https://ClinicalTrials.gov/show/NCT01004978
NCT02968810	Recruiting	No Results Available	Other: Laboratory Biomarker Analysis|Other: Placebo|Other: Questionnaire Administration|Drug: Simvastatin	Change in serum AFP-L3% assessed by liquid-phase binding assay|Change in serum AFP assessed by liquid-phase binding assay|Change in serum IL-6 assessed by enzyme-linked immunosorbent assay|Change in serum bile acid levels assessed by liquid chromatography-tandem mass spectrometry|Change in liver stiffness assessed by liver elastography|Change in fibrosis 4 index (FIB-4) score|Change in Model for End-Stage Liver Disease (MELD) score	Phase 2	https://ClinicalTrials.gov/show/NCT02968810
NCT01015833	Active, not recruiting	Has Results	Drug: Doxorubicin Hydrochloride|Other: Laboratory Biomarker Analysis|Other: Pharmacogenomic Study|Drug: Sorafenib Tosylate	Overall Survival|Incidence of Toxicities, as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0|Progression Free Survival|Time to Progression (TTP)|Best Overall Response Rate	Phase 3	
NCT02762266	Recruiting	No Results Available	Procedure: Computed Tomography|Other: Laboratory Biomarker Analysis|Procedure: Magnetic Resonance Imaging|Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Radiation: Stereotactic Body Radiation Therapy|Procedure: Transarterial Chemoembolization|Drug: Chemotherapy agent|Drug: embolic agent|Drug: lipiodol	Median FFLP|Comparison of median freedom from extra hepatic progression|Median extra hepatic PFS for patients with tumors smaller than 3 cm and greater than 3 cm per treatment group|Median FFLP for patients with tumors smaller than 3 cm and with tumors greater than 3 cm per treatment group|Median OS|Median OS for patients with tumors smaller than 3 cm and greater than 3 cm per treatment group|Median PFS|Median PFS for patients with tumors smaller than 3 cm and greater than 3 cm per treatment group|Serum Alpha-Fetoprotein level (AFP)	Phase 3	https://ClinicalTrials.gov/show/NCT02762266
NCT00906373	Completed	Has Results	Biological: IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg)|Biological: IMC-A12 (cixutumumab) - 20 mg/kg|Drug: Sorafenib	Progression Free Survival (PFS)|Number of Participants With Adverse Events (AEs)|Pharmacokinetic (PK): Maximum Concentration (Cmax) Cycle 1|PK: Minimum Concentration (Cmin) Cycle 1|PK: Half-Life (t1/2) Cycle 1|PK: Clearance (CL) Cycle 1|PK: Area Under the Concentration Versus Time Curve (AUC) Cycle 1|PK: Volume of Distribution at Steady State (Vss) Cycle 1|PK: Cmax Cycle 3|PK: Cmin Cycle 3|PK: t1/2 Cycle 3|PK: CL Cycle 3|PK: AUC Cycle 3|PK: Vss Cycle 3|Percentage of Participants With Complete Response (CR) and Partial Response (PR) [Objective Response Rate (ORR)]|Overall Survival (OS)|Time to Disease Progression (TTP)|Duration of Response (DOR)|The Number of Participants With Serum Anti-Cixutumumab Antibody Assessment (Immunogenicity)	Phase 2	https://ClinicalTrials.gov/show/NCT00906373
NCT03278925	Not yet recruiting	No Results Available	Drug: Defined Green Tea Catechin Extract|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study	Maximum tolerated dose of Polyphenon E|Change in gamma-OHPdG expression in cirrhotic liver assessed by immunohistochemistry (IHC)|Fraction of patients with liver cirrhosis that have high levels of gamma-OHPdG|Change in mutation frequency in cirrhotic liver tissue|Polyphenon E pharmacokinetic data in blood and urine in patients with cirrhosis	Phase 1	https://ClinicalTrials.gov/show/NCT03278925
NCT00980460	Active, not recruiting	No Results Available	Drug: Cisplatin|Drug: Doxorubicin Hydrochloride|Drug: Fluorouracil|Drug: Irinotecan Hydrochloride|Other: Laboratory Biomarker Analysis|Procedure: Liver Transplantation|Drug: Temsirolimus|Procedure: Therapeutic Conventional Surgery|Drug: Vincristine Sulfate	Event-free survival|Incidence of adverse events graded according to Common Terminology Criteria for Adverse Events version 4.0|Rate of death|Disease status at the end of 2 courses of therapy|Feasibility of referral for liver transplantation	Phase 3	https://ClinicalTrials.gov/show/NCT00980460
NCT00327652	Completed	No Results Available	Drug: CRS-100	Dose-limiting toxicities (DLTs) for 7 days after dosing	Phase 1	https://ClinicalTrials.gov/show/NCT00327652
NCT00094003	Completed	No Results Available	Drug: NS-9 [Poly I: Poly C]		Phase 1	https://ClinicalTrials.gov/show/NCT00094003
NCT00567216	Unknown status	No Results Available	Drug: Nadolol	Rebleeding|Complication Survival	Phase 4	https://ClinicalTrials.gov/show/NCT00567216
NCT00003923	Completed	No Results Available	Drug: porfimer sodium		Phase 2	https://ClinicalTrials.gov/show/NCT00003923
NCT01766219	Active, not recruiting	No Results Available	Drug: 6,8-bis(benzylthio)octanoic acid	Overall survival|Response rate defined as proportion of patients with complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD), using based on the RECIST version 1.1|Progression-free survival|Adverse events, based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT01766219
NCT01217034	Active, not recruiting	No Results Available	Drug: TACE with sorafenib|Procedure: TACE alone	Progression Free Survival|Overall Survival|Time To Progression|Objective Response Rate|Tumor markers|Safety|Time To Untreatable Progression(TTUP)|Time to Child-Pugh C|Time to intrahepatic tumor progression|Time to vascular invasion|Time to Extrahepatic spread	Phase 2	https://ClinicalTrials.gov/show/NCT01217034
NCT02767375	Recruiting	No Results Available	Drug: Oxaliplatin(OXA), 5-fluorouracil (5-FU)|Procedure: Hepatic arterial catheter implantation	Recurrence Free Survival|Time to recurrence|Overall survival|Visual Analog Score for pain|Physicians Global Assessment to measure quality of life|Number of Participants With Abnormal Laboratory Values|Adverse Events That Are Related to Treatment	Phase 2|Phase 3	https://ClinicalTrials.gov/show/NCT02767375
NCT01655641	Unknown status	No Results Available	Drug: Tranexamic acid|Other: Standard of care	Primary objective of the study is to compare transfusion requirements and Mortality in patients receiving Tranexamic acid (Cyklokapron®) and those not receiving it.|Secondary outcome measure|Secondary Outcome measure	Phase 2|Phase 3	https://ClinicalTrials.gov/show/NCT01655641
NCT00986661	Recruiting	No Results Available	Drug: PV-10 (10% rose bengal disodium)	Safety. Systemic and locoregional Adverse Events (AEs) will be graded by CTCAE v4.0 and coded according to MedDRA. AE data for all subjects in the 1st cohort will be assessed prior to dose escalation. Final assessment use AE data for all subjects.|Lesion distribution and retention of PV-10 following injection.|Objective response rate (ORR) of Target and measurable Bystander Lesions (if present) by 2D EASL criteria.|Changes in markers of hepatic function, including ALP, ALT, AST, total bilirubin and GGT.|Pharmacokinetics of PV-10 in the bloodstream following intralesional injection. Samples will be obtained immediately prior to PV-10 injection and at 2, 4, 8, 24 and 72 hours, and 7, 14 and 28 days to assess uptake and excretion of PV-10.|Pharmacokinetics of sorafenib in the bloodstream following intralesional injection. Samples will be obtained immediately prior to PV-10 injection and at 2, 4, 8, 24 and 72 hours, and 7, 14 and 28 days to assess impact of PV-10 on sorafenib levels.	Phase 1	https://ClinicalTrials.gov/show/NCT00986661
NCT01171924	Completed	Has Results	Drug: CUDC-101	Number of Participants With Adverse Events	Phase 1	https://ClinicalTrials.gov/show/NCT01171924
NCT01562821	Completed	No Results Available	Drug: activated recombinant human factor VII|Drug: placebo	The RBC transfusion requirements|Number of transfusion product units|Change in coagulation-related parameters|Adverse events	Phase 2	https://ClinicalTrials.gov/show/NCT01562821
NCT02528526	Unknown status	No Results Available	Drug: OXY111A	Safety and tolerability as measured by collection of adverse effects information|Efficacy as measured by FDG-PET scan|Efficacy as measured by MRI	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT02528526
NCT01307878	Unknown status	No Results Available	Drug: chemotherapy ± targeted therapy	liver metastasis resection rate|progression free survival|recurrence rate|overall survival	Phase 4	https://ClinicalTrials.gov/show/NCT01307878
NCT00486356	Completed	No Results Available	Drug: capecitabine|Drug: carboplatin|Drug: epirubicin hydrochloride|Genetic: microarray analysis|Genetic: polymorphism analysis|Other: pharmacological study	Recommended phase II dose of capecitabine|Toxicities|Correlation of end-of-infusion levels of epirubicin hydrochloride and its metabolites with epirubicin hydrochloride dosing and clinical toxicity|Correlation of the pharmacokinetics of capecitabine with clinical toxicity|Possible correlation between polymorphisms in the promoter region of the thymidylate synthase gene with clinical toxicity|Antitumor activity	Phase 1	https://ClinicalTrials.gov/show/NCT00486356
NCT01075399	Completed	Has Results	Drug: [F 18]HX4	Reproducibility of [F18]HX4 PET Imaging in Measuring Hypoxia in Tumors	Phase 2	https://ClinicalTrials.gov/show/NCT01075399
NCT01423708	Unknown status	No Results Available	Drug: Everolimus	Biopsy-proven rejection episodes (BPAR)|Graft survival|Patient post-Liver Transplantation survival|Everolimus monotherapy|Renal function evaluation|Requests for dialysis|Incidence of Adverse Events	Phase 2	https://ClinicalTrials.gov/show/NCT01423708
NCT02240433	Active, not recruiting	No Results Available	Drug: LY2157299|Drug: Sorafenib	Number of Participants with LY2157299 Dose-Limiting Toxicities (DLT)|Pharmacokinetics (PK): Area Under the Plasma Concentration-time Curve (AUC) of LY2157299|PK: Maximum Observed Plasma Concentration (Cmax) of LY2157299|Time to Progression (TTP)|Progression-free Survival (PFS)|The Number of Participants with Best Response of Partial Response (PR), Complete Response (CR), Stable Disease (SD), or Progressive Disease (PD)	Phase 1	https://ClinicalTrials.gov/show/NCT02240433
NCT00872014	Completed	No Results Available	Drug: AMG 386|Drug: Sorafenib	Progression free survival (PFS) rate at 4 months|Incidence of adverse events and significant laboratory abnormalities|Objective response rate, Disease control rate, Progression free survival, Overall survival, Time to progression|Pharmacokinetic parameters for AMG 386 when used in combination with Sorafenib|Pharmacokinetic parameter for Sorafenib when used in combination with AMG 386|Incidence of the occurrence of anti-AMG 386 antibody formation|Baseline values of and changes from baseline in pharmacodynamic, immunologic, biochemical, transcriptional, pharmacogenetic and angiogenic markers	Phase 2	https://ClinicalTrials.gov/show/NCT00872014
NCT00355238	Completed	No Results Available	Drug: brivanib (active)	To estimate the 6 month progression free locally advanced or metastatic hepatocellular carcinoma (HCC) with no prior chemotherapy for HCC treated with BMS-582664.|Estimate tumor response rate, time to response, duration of response, overall survival, progression free survival & disease control rate for subjects with no prior systemic therapy & for subjects with 1 prior regimen of angiogenesis inhibitor therapy.|To estimate the safety and tolerability for all BMS582664 (brivanib) treated patients|To obtain population PK, PD	Phase 2	https://ClinicalTrials.gov/show/NCT00355238
NCT00553332	Completed	Has Results	Drug: selumetinib|Other: laboratory biomarker analysis	Objective Response Rate (CR and PR)|Toxicity Profile of AZD6244|Median Progression Free Survival for Patients|Overall Survival|RAS/RAF/MEK/ERK Signaling Pathway Activation|Protein Levels of RAS/RAF/MEK/ERK Signaling Pathway Activation	Phase 2	https://ClinicalTrials.gov/show/NCT00553332
NCT00019630	Completed	No Results Available	Drug: doxorubicin HCl liposome		Phase 1	https://ClinicalTrials.gov/show/NCT00019630
NCT02842125	Not yet recruiting	No Results Available	Drug: Ad-P53|Drug: Xeloda|Drug: Keytruda|Drug: Opdivo	Safety assessed by CTCAE|Incidence of dose-limiting toxicities (DLTs)|Determination of maximum-tolerated dose (MTD)|Progression-Free Survival (PFS) of patients using RECIST 1.1|Efficacy determined by Immune Related Response Criteria (irRC) [Wolchok 2009]|Efficacy as determined by biomarker testing and immunohistochemistry testing	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT02842125
NCT01347424	Unknown status	No Results Available	Drug: Paclitaxel , carboplatin, endostatin|Drug: Paclitaxel and Carboplatin	The changes of blood flow perfusion in secondary malignant neoplasm of liver|Comparing the difference of OS(Overall Survival) and ORR(Objective Response Rate) according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria in the two different arms.|Number of Participants with Adverse Events in the two different arms	Phase 2	https://ClinicalTrials.gov/show/NCT01347424
NCT00661622	Completed	Has Results	Drug: GM-CSF|Procedure: Embolization	Response of Liver Metastases|Overall Response Rate|Overall Survival|Median Progression Free Survival|Systemic Progression Free Survival	Phase 2	https://ClinicalTrials.gov/show/NCT00661622
NCT01743469	Completed	Has Results	Drug: Tasquinimod	Progression Free Survival (PFS) Rate, Defined as the Percentage of Patients Who Had Neither Progressed Nor Died as Measured by Centrally Analysed RECIST v1.1 (All Cohorts).|PFS Rate Measured by Choi Criteria (Hepatocellular Carcinoma Cohort).|Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed).|Best Overall Response and Response Rate Based on Choi Criteria (Hepatocellular Carcinoma Cohort).|Clinical Benefit (All Cohorts).|PFS From First Study Treatment to Progression or Death Due to Any Cause Based on Choi Criteria (Hepatocellular Carcinoma Cohort).|PFS From First Study Treatment to Progression or Death Due to Any Cause Based on RECIST v1.1 Criteria (All Cohorts).|Time to Progression (TTP) by Choi Criteria (Hepatocellular Carcinoma Cohort).|TTP by RECIST v1.1 (All Cohorts).|Overall Survival (OS), Defined as the Time From First Study Treatment to Death Due to Any Cause (All Cohorts).|Further Cancer-related Treatment During Follow-up Period (All Cohorts).	Phase 2	https://ClinicalTrials.gov/show/NCT01743469
NCT00021047	Completed	No Results Available	Drug: capecitabine|Drug: carboplatin|Drug: epirubicin hydrochloride		Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT00021047
NCT00103298	Completed	No Results Available	Drug: FOLFOX regimen|Drug: fluorouracil|Drug: isolated perfusion|Drug: leucovorin calcium|Drug: melphalan|Drug: oxaliplatin	Response and duration of response|Patterns of recurrence|Progression-free and overall survival|Correlation of health-related quality of life with length of survival	Phase 2	https://ClinicalTrials.gov/show/NCT00103298
NCT00089401	Completed	No Results Available	Drug: isolated perfusion|Drug: melphalan|Procedure: conventional surgery	Response|Duration of response|Patterns of tumor recurrence (liver vs systemic)|Progression-free survival|Overall survival|Quality of life	Phase 2	https://ClinicalTrials.gov/show/NCT00089401
NCT00020501	Completed	No Results Available	Drug: FOLFIRI regimen|Drug: floxuridine|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Drug: melphalan|Procedure: hyperthermia treatment		Phase 3	https://ClinicalTrials.gov/show/NCT00020501
NCT02174575	Unknown status	No Results Available	Drug: Sevoflurane|Drug: Desflurane	Postoperative acute kidney injury|Urine IL-6 concentration|Plasma NGAL concentration|Urine NGAL concentration|Serum cystatin C concentration|Urine L-FABP concentration|Urine NAG concentration|Urine albumin concentration	Phase 4	https://ClinicalTrials.gov/show/NCT02174575
NCT03058289	Recruiting	No Results Available	Drug: INT230-6|Biological: anti-PD-1|Biological: anti-PD-1 antibody	Rate and severity of treatment-emergent adverse events ≥ grade 3 attributed to study drug using the NCI Common Terminology Criteria for Adverse Events (CTCAE v.4.03) (Scale 1 to 5)|Preliminary Efficacy: Control or Regression of Injected Tumors by Measurement of Length, Width and Height (in centimeters) Radio-graphically Using Computer Tomography or Magnetic Resonance Imaging to Calculate Tumor Volumes (cubic centimeters) Over Time.|Determine pharmacokinetic parameter Peak Plasma (Cmax in ng/mL) of each of the 3 main components of INT230-6.|Determine key pharmacokinetic parameter, Area Under the Curve (AUC) (ng*hr/mL) of each of the 3 main components of INT230-6.|Key pharmacokinetic parameters, half live (hours) of each of the 3 main components of INT230-6.	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT03058289
NCT02435433	Recruiting	No Results Available	Drug: Ramucirumab|Drug: Placebo	Overall Survival (OS)|Progression Free Survival (PFS)|Time to Radiographic Progression|Percentage of Participants with a Best Overall Response of Complete Response (CR) or Partial Response (PR): Objective Response Rate (ORR)|Pharmacokinetics (PK): Serum Concentration of Ramucirumab|Number of Participants with Anti-Ramucirumab Antibodies|Functional Assessment of Cancer Therapy (FACT) Hepatobiliary Symptom Index-8 (FHSI-8)|EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire|Time to Deterioration in Eastern Cooperative Oncology Group Performance Status (ECOG PS)	Phase 3	https://ClinicalTrials.gov/show/NCT02435433
NCT01214343	Unknown status	No Results Available	Drug: Sorafenib with Low-dose FP|Drug: Sorafenib	Overall survival|Time to progression|Progression Free Survival|Change of tumor marker|Biomarker predicting the efficacy	Phase 3	https://ClinicalTrials.gov/show/NCT01214343
NCT00712855	Completed	No Results Available	Biological: mapatumumab|Drug: sorafenib	Type, frequency, and severity of adverse events.	Phase 1	https://ClinicalTrials.gov/show/NCT00712855
NCT00054951	Unknown status	No Results Available	Drug: MTC-DOX for Injection		Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT00054951
NCT03419897	Recruiting	No Results Available	Drug: BGB-A317	Objective Response Rate (ORR) assessed by Independent Review Committee (IRC)|Duration of Response (DOR)|Progression-free survival (PFS)|Disease Control Rate (DCR)|Clinical benefit rate (CBR)|Overall Survival|Percentage of patients with adverse events|Health-Related Quality of Life (HRQoL)|Percentage of Participants With Clinically Significant Changes in Vital Signs Findings|Percentage of Participants With Clinically Significant Changes in Physical Examination Findings|Percentage of Participants With Clinically Significant Changes in Clinical Laboratory Results Findings|Percentage of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Findings	Phase 2	https://ClinicalTrials.gov/show/NCT03419897
NCT03412773	Recruiting	No Results Available	Drug: BGB-A317|Drug: Sorafenib	Overall Survival (OS)|Safety Run-In Substudy[Japan only]: Percentage of patients with adverse events|Safety Run-In Substudy[Japan only]: Percentage of patients with dose-limiting toxicities (DLT) [Determination of the pivotal Phase 3 dose of BGB-A317 in Japanese patients]|Safety Run-In Substudy[Japan only]: Maximum Concentration (Cmax) of BGB-A317|Safety Run-In Substudy[Japan only]: Trough Serum Concentration (Cmin) of BGB-A317|Safety Run-In Substudy[Japan only]: Area Under the Curve (AUC) of BGB-A317|Safety Run-In Substudy[Japan only]:Anti-Drug Antibodies (ADA) against BGB-A317 at Cmin|Safety Run-In Substudy[Japan only]: Percentage of Participants With Clinically Significant Changes in Vital Signs Findings|Safety Run-In Substudy[Japan only]: Percentage of Participants With Clinically Significant Changes in Physical Examination Findings|Safety Run-In Substudy[Japan only]: Percentage of Participants With Clinically Significant Changes in Clinical Laboratory Results Findings|Safety Run-In Substudy[Japan only]: Percentage of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Findings|Objective Response Rate (ORR)|Progression-free survival (PFS)|Duration of Response (DOR)|Time to Progression (TTP)|Health-Related Quality of Life (HRQoL)|Disease Control Rate (DCR)|Clinical Benefit Rate (CBR)|Percentage of patients with adverse events|Safety Run-In Substudy[Japan only]: Objective Response Rate (ORR)|Safety Run-In Substudy[Japan only]: Progression-free survival (PFS)|Safety Run-In Substudy[Japan only]: Duration of Response (DOR)|Safety Run-In Substudy[Japan only]: Overall Survival (OS)|Safety Run-In Substudy[Japan only]: Anti-BGB-A317 antibody|Percentage of Participants With Clinically Significant Changes in Vital Signs Findings|Percentage of Participants With Clinically Significant Changes in Physical Examination Findings|Percentage of Participants With Clinically Significant Changes in Clinical Laboratory Results Findings|Percentage of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Findings	Phase 3	https://ClinicalTrials.gov/show/NCT03412773
NCT00019474	Unknown status	No Results Available	Biological: filgrastim|Biological: recombinant interferon alfa|Drug: fluorouracil|Drug: hydroxyurea		Phase 2	https://ClinicalTrials.gov/show/NCT00019474
NCT00187109	Completed	No Results Available	Drug: Recombinant Human Thrombopoietin	To evaluate the safety of recombinant human thrombopoietin following chemotherapy which includes ifosfamide, carboplatin and etoposide for solid tumors and lymphoma.|To evaluate whether recombinant human thrombopoietin will reduce the time necessary for platelet counts to recover following chemotherapy.	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT00187109
NCT00987766	Completed	No Results Available	Drug: erlotinib hydrochloride|Drug: gemcitabine hydrochloride|Drug: oxaliplatin|Other: laboratory biomarker analysis	Maximum tolerated dose and recommended phase II dose of erlotinib hydrochloride in combination with gemcitabine hydrochloride and oxaliplatin|Antitumor activity|E-cadherin, vimentin, fibronectin, amphiregulin, and Kras status in the tumors and their relationship to response	Phase 1	https://ClinicalTrials.gov/show/NCT00987766
NCT02869217	Recruiting	No Results Available	Drug: Cyclophosphamide|Biological: TBI-1301	Safety profile (i.e. adverse events, presence/absence of RCR, analysis of clonality and PK of TBI-1301) assessed by CTCAE v.4.0 and laboratory testings.|Recommended phase 2 (RP2D) dose o TBI-1301 when administered following cyclophosphamide pre-treatment|Evidence of efficacy (i.e. anti-tumor effect) of TBI-1301 measured using RECIST v1.1	Phase 1	https://ClinicalTrials.gov/show/NCT02869217
NCT00788125	Active, not recruiting	No Results Available	Drug: carboplatin|Drug: dasatinib|Drug: etoposide phosphate|Drug: ifosfamide|Genetic: microarray analysis|Genetic: western blotting|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Procedure: therapeutic conventional surgery|Radiation: radiation therapy	Maximum tolerated dose of dasatinib (Phase I)|Toxicity as measured by NCI CTCAE v3.0 (Phase I)|Overall survival at 1 year in patients with relapsed sarcoma (Phase II, Stratum A)|Response rate prior to consolidation therapy as measured by RECIST criteria (Phase II)|Progression-free survival (Phase II)|Exploratory correlative studies	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT00788125
NCT02381561	Recruiting	No Results Available	Radiation: Intensity-Modulated Radiation Therapy|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Ropidoxuridine	Maximum tolerated dose (MTD) defined as the dose below which 2 or more of 6 patients experience dose-limiting toxicity|%iododeoxyuridine (IUdR)-deoxyribonucleic acid (DNA) incorporation in tumor biopsies|Pharmacokinetic (PK) incorporation in tumor biopsies|%iododeoxyuridine (IUdR)-deoxyribonucleic acid (DNA) incorporation in peripheral (circulating) granulocytes|Pharmacokinetic (PK) incorporation in peripheral (circulating) granulocytes|Tumor response relationship to the %iododeoxyuridine (IUdR)-deoxyribonucleic acid (DNA) incorporation using Response Evaluation Criteria in Solid Tumors (RECIST) criteria based on high-pressure liquid chromatography (HPLC) and flow cytometry measurements	Phase 1	https://ClinicalTrials.gov/show/NCT02381561
NCT00107536	Completed	Has Results	Drug: lapatinib ditosylate|Other: laboratory biomarker analysis	Proportion of Patients Demonstrating Objective Response (PR+CR) as Defined by RECIST|Progression-free Survival|Toxicity Profile Assessed Using NCI CTCAE Version 3.0|Median Overall Survival|Overall Survival|Target-EGFR/EGFR-P Protein Expression|Expression Profile and Mutations of Genes Critical for EGFR and ERBB2 Signaling Pathways	Phase 2	https://ClinicalTrials.gov/show/NCT00107536
NCT01120288	Completed	No Results Available	Drug: EZN-2968	Determine the modulation of HIF-1 alpha mRNA in tumor biopsies pre- and post- administration of EZN-2968.|Assess the safety of EZN-2968 in patients with liver-predominant solid tumors. Determine the modulation of HIF-1 alpha protein levels in tumor biopsies pre- and post-administration of EZN-2968.	Phase 1	https://ClinicalTrials.gov/show/NCT01120288
NCT01394497	Completed	No Results Available	Drug: N-acetylcystein	Graft survival|Patient survival|Primary graft dysfunction	Phase 2	https://ClinicalTrials.gov/show/NCT01394497
NCT01967823	Recruiting	No Results Available	Biological: Anti-NY ESO-1 mTCR PBL|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Aldesleukin	Response Rate|In vivo survival of TCR gene-engineered cells|Frequency severity of treatment related adverse events	Phase 2	https://ClinicalTrials.gov/show/NCT01967823
NCT00033462	Completed	No Results Available	Drug: erlotinib hydrochloride|Other: laboratory biomarker analysis	Proportion of patients who are progression-free at 24 weeks|Objective response, defined by the RECIST criteria in terms of tumor/lesion size and change|Overall survival|Time to disease progression|EGFR protein levels|Overall response rate in EGFR positive patients	Phase 2	https://ClinicalTrials.gov/show/NCT00033462
NCT00002608	Completed	No Results Available	Drug: cisplatin|Drug: doxorubicin hydrochloride|Drug: tamoxifen citrate|Procedure: conventional surgery|Radiation: radiation therapy		Phase 2	https://ClinicalTrials.gov/show/NCT00002608
NCT03253289	Recruiting	No Results Available	Drug: Meclizine Oral Tablet	Change in mRNA levels|Change in Ki-67 proliferation index|change in TUNEL assay|Tumor response|Change in Serum AFP|Change in growth differentiation factor (GDF-15)|A panel of CAR downstream target genes	Phase 1	https://ClinicalTrials.gov/show/NCT03253289
NCT00516165	Completed	Has Results	Drug: RAD001	Maximum Tolerated Dose of RAD001 in Patients With Advanced Hepatocellular Carcinoma (HCC).|Progression-free Survival Rate at 24 Weeks|Number of Patients With Adverse Events Who Were Treated With RAD001 for Advanced HCC|Overall Response Rate|Time to Progression|Overall Survival	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT00516165
NCT00716976	Completed	Has Results	Drug: sodium thiosulfate|Procedure: examination	Incidence of Hearing Loss|Change in Hearing Thresholds For Key Frequencies at 500 hz|Change in Hearing Thresholds For Key Frequencies at 1000 hz|Change in Hearing Thresholds For Key Frequencies at 2000 hz|Change in Hearing Thresholds For Key Frequencies at 4000 hz|Change in Hearing Thresholds For Key Frequencies at 8000 hz|Event-Free Survival (EFS)|Overall Survival (OS)|Hearing Loss Among Patients Carrying/Not-carrying Two Key Gene Mutations (TPMT and COMT)	Phase 3	https://ClinicalTrials.gov/show/NCT00716976
NCT00654160	Completed	No Results Available	Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Other: pharmacogenomic studies|Other: pharmacological study	Maximum tolerated dose of genotype-based dosing of FOLFIRI with or without monoclonal antibody therapy|Response rate of genotype-based dosing in the subset of patients that has colorectal cancer	Phase 1	https://ClinicalTrials.gov/show/NCT00654160
NCT01498952	Completed	No Results Available	Drug: MEDI-573 (1 of 3 doses)|Drug: Sorafenib	Phase Ib: (Dose Evaluation Phase): Safety and Tolerability of 2 Dose Levels of MEDI-573 Combined with Standard of Care (SOC)|Pharmacokinetics (PK) of MEDI-573|Immunogenicity of MEDI-573	Phase 1	https://ClinicalTrials.gov/show/NCT01498952
NCT00024258	Completed	Has Results	Drug: arsenic trioxide	Response Rate After Every 3 Courses During Treatment and Then Every 2-3 Months for 1 Year After Completion of Treatment	Phase 2	https://ClinicalTrials.gov/show/NCT00024258
NCT00041808	Completed	No Results Available	Drug: MTC-DOX for Injection|Procedure: Chemotherapy		Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT00041808
NCT00007813	Unknown status	No Results Available	Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Drug: etoposide|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation		Phase 1	https://ClinicalTrials.gov/show/NCT00007813
NCT00002515	Completed	No Results Available	Biological: filgrastim|Drug: carboplatin|Drug: thiotepa|Drug: topotecan hydrochloride|Procedure: autologous bone marrow transplantation|Procedure: bone marrow ablation with stem cell support|Procedure: in vitro-treated bone marrow transplantation		Phase 2	https://ClinicalTrials.gov/show/NCT00002515
NCT00036959	Completed	No Results Available	Drug: ABT-751		Phase 1	https://ClinicalTrials.gov/show/NCT00036959
NCT02145559	Active, not recruiting	No Results Available	Drug: Metformin XR|Drug: Delayed Metformin|Drug: Sirolimus	Pharmacodynamic Biomarker p70S6K|Pharmacodynamic Biomarkers p4EBP1 and pAKT|Tolerability - Full physical Exam|Fasting Serum Glucose and Triglycerides	Phase 1	https://ClinicalTrials.gov/show/NCT02145559
NCT00003427	Completed	No Results Available	Drug: irinotecan hydrochloride|Drug: oxaliplatin		Phase 1	https://ClinicalTrials.gov/show/NCT00003427
NCT00019331	Completed	No Results Available	Biological: aldesleukin|Biological: ras peptide cancer vaccine|Biological: sargramostim|Drug: DetoxPC		Phase 2	https://ClinicalTrials.gov/show/NCT00019331
NCT00019513	Completed	No Results Available	Drug: fluorouracil|Drug: gemcitabine hydrochloride|Drug: leucovorin calcium		Phase 1	https://ClinicalTrials.gov/show/NCT00019513
NCT01042691	Completed	No Results Available	Drug: Oxaliplatin	To determine the maximum tolerated dose and dose limiting toxicity of oxaliplatin delivered via isolated hepatic perfusion (IHP).|To determine if isolated hepatic perfusion with oxaliplatin can increase the response rate, duration of response and survival of patients being treated with standard HAI with FUDR when compared to historical controls.|To determine the tissue absorption of oxaliplatin in normal liver versus tumor during IHP.	Phase 1	https://ClinicalTrials.gov/show/NCT01042691
NCT03347292	Recruiting	No Results Available	Drug: Regorafenib(Stivarga, BAY73-4506)|Drug: Pembrolizumab	Incidence of treatment-emergent adverse event(TEAEs)|Severity of TEAEs|Dose Limiting Toxicities(DLTs)|Maximum Tolerated Dose (MTD)|Progression-free survival (PFS)|Time to progression (TTP)|Overall survival (OS)|Overall response rate (ORR)|Disease control rate (DCR)|Duration of response (DOR)|Duration of stable disease	Phase 1	https://ClinicalTrials.gov/show/NCT03347292
NCT02042443	Completed	Has Results	Drug: Capecitabine|Drug: Fluorouracil|Other: Laboratory Biomarker Analysis|Drug: Leucovorin Calcium|Drug: Trametinib	Overall Survival|Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug|Objective Response Rate|Progression-free Survival	Phase 2	https://ClinicalTrials.gov/show/NCT02042443
NCT03199586	Recruiting	No Results Available	Drug: NP-G2-044	Number of participants with treatment related adverse events|Anti tumor activity	Phase 1	https://ClinicalTrials.gov/show/NCT03199586
NCT00303940	Completed	No Results Available	Drug: carboplatin|Drug: talabostat mesylate|Drug: temozolomide|Other: pharmacological study		Phase 1	https://ClinicalTrials.gov/show/NCT00303940
NCT02431676	Active, not recruiting	No Results Available	Drug: Metformin|Behavioral: Coach Directed Behavioral Weight Loss|Behavioral: Self-control weight loss	IGF-1 levels|IGF-1 levels :IGFBP3 levels (Ratio)	Phase 2	https://ClinicalTrials.gov/show/NCT02431676
NCT02094625	Recruiting	No Results Available	Drug: N-Acetylcysteine	Target Serum Level NAC|Adverse events during infusion of NAC|NAC Level|Hearing assessment|Renal Toxicity|Response of tumor to treatment|Effect of Genotype on Hearing Loss and Hearing Protection|Glutathione serum level	Phase 1	https://ClinicalTrials.gov/show/NCT02094625
NCT00105443	Completed	Has Results	Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Placebo	Overall Survival (OS)|Time to Symptomatic Progression (TTSP)|Time to Progression (TTP)|Disease Control (DC)|Patients Reported Outcome (PRO) by Use of the FACT-Hep Questionnaire	Phase 3	https://ClinicalTrials.gov/show/NCT00105443
NCT02662348	Unknown status	No Results Available	Drug: Recombinant Human Interleukin-2|Drug: HER2Bi-Armed T Cells	Safety as measured by local and systemic toxicities|Changes in cytokine profiles and tumor markers in serum before and after treatment|Changes in phenotyping induced by immunotherapy in peripheral blood mononuclear cells (PBMC)|Clinical response rate (including clinical symptoms and signs, complete response, partial response, progressive disease, and stable disease, imaging examination of pretherapy and post-treatment) will be measured by follow-up investigation.|Overall survival|Progression free survival	Phase 1	https://ClinicalTrials.gov/show/NCT02662348
NCT00617981	Completed	Has Results	Drug: ThermoDox|Drug: 5% Dextrose Solution	Progression Free Survival Will be Measured From the Date of Randomization to the First Date on Which One of the Following Occurs. o Local Recurrence o Any New Distant Intrahepatic HCC Tumor o Any New Extrahepatic HCC Tumor o Death From Any Cause|Overall Survival as Measured by Time From Randomization to Death or the End of the Study.|Time to Definite Worsening as Per Patient-Reported Outcomes|Time to Local Recurrence.|Safety	Phase 3	https://ClinicalTrials.gov/show/NCT00617981
NCT00020150	Completed	No Results Available	Drug: O6-benzylguanine|Drug: temozolomide		Phase 1	https://ClinicalTrials.gov/show/NCT00020150
NCT00030108	Completed	No Results Available	Drug: ixabepilone	Maximum tolerated dose and dose-limiting toxicity of ixabepilone|Toxicity spectrum|Plasma pharmacokinetics|Pharmacodynamics|Nerve growth factor levels before and after drug administration|Objective tumor response|Tubulin polymerization in PBMCs prior to the start of the infusion, just before the end of the infusion, 5 hours after the end of the infusion and before the start of the infusion on day 2 of the ixabepilone on course 1	Phase 1	https://ClinicalTrials.gov/show/NCT00030108
NCT00666978	Completed	Has Results	Behavioral: smoking cessation intervention|Drug: bupropion hydrochloride|Genetic: gene expression analysis|Genetic: polymerase chain reaction|Other: counseling intervention|Other: educational intervention|Procedure: psychosocial assessment and care	Number of Participants With Salivary Cotinine-verified Smoking Abstinence at 6 Months|Number of Slow and Fast Metabolizers by Metabolite Ratio|Number of Participants for Each CYP2B6 Allele|Number of Slow and Fast Metabolizers by Genotype	Phase 4	https://ClinicalTrials.gov/show/NCT00666978
NCT00273312	Completed	No Results Available	Drug: Patupilone	Tumor response as assessed by radiologic techniques and/or physical examination based on Response Evaluation Criteria in Solid Tumors (RECIST)|Time to progression|Overall survival	Phase 2	https://ClinicalTrials.gov/show/NCT00273312
NCT00534001	Completed	Has Results	Drug: bupropion hydrochloride|Other: placebo	Prequit Change in Cigarettes Per Day|Abstinence	Phase 2	https://ClinicalTrials.gov/show/NCT00534001
NCT00365508	Completed	Has Results	Drug: nicotine lozenge|Drug: nicotine patch	24-hour Point Prevalence Abstinence at the 6-month Follow up|Rate of Compliance During the First 2 Weeks	Phase 4	https://ClinicalTrials.gov/show/NCT00365508
NCT02529774	Not yet recruiting	No Results Available	Drug: Floxuridine (FUDR),Dexamethasone (DXM), Heparin in combination with Oxaliplatin and Capecitabine (CapeOX) or in combination with Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6)|Drug: Oxaliplatin and Capecitabine (CapeOX) or Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6)	Overall Survival|Liver Relapse-Free Survival Rate|Disease free survival	Phase 2|Phase 3	https://ClinicalTrials.gov/show/NCT02529774
NCT02316028	Completed	No Results Available	Drug: Decitabine	toxicity of escalating doses of decitabine administered by HAI|overall survival|progression free survival|best objective tumor response|measuring Global DNA methylation of tumoral DNA|measuring Global DNA methylation of cell free DNA	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT02316028
NCT00031681	Completed	No Results Available	Drug: 7-hydroxystaurosporine|Drug: irinotecan hydrochloride|Other: diagnostic laboratory biomarker analysis	MTD of irinotecan hydrochloride in combination with 7-hydroxystaurosporine in patients with resistant solid tumor malignancies (Part I)|DLT of irinotecan hydrochloride in combination with 7-hydroxystaurosporine in patients with resistant solid tumor malignancies (Part I)|Toxicities associated with irinotecan hydrochloride in combination with 7-hydroxystaurosporine in patients with resistant solid tumor malignancies (Part I)|Anti-tumor activity of 7-hydroxystaurosporine in combination with irinotecan hydrochloride in ER-negative, PgR-negative, HER-2 not-amplified (triple negative) recurrent breast cancer (Part II)|Side effect profile of 7-hydroxystaurosporine in combination with irinotecan hydrochloride in triple negative recurrent breast cancer (Part II)|Anti-tumor activity of the combination of irinotecan hydrochloride and 7-hydroxystaurosporine in treatment of patients with resistant solid tumor malignancies|Pharmacokinetics of irinotecan hydrochloride and 7-hydroxystaurosporine when administered in combination|Serum alpha-acid glycoprotein and correlate this level with free 7-hydroxystaurosporine concentrations|In vivo mechanistic basis for 7-hydroxystaurosporine activity	Phase 1	https://ClinicalTrials.gov/show/NCT00031681
NCT00397384	Completed	No Results Available	Drug: cetuximab|Drug: erlotinib hydrochloride|Other: laboratory biomarker analysis	Incidence of DLT, defined as recurring grade 2 or greater non-hematological or grade 3 or greater hematological toxicities or skin rash graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE-v3)|MTD defined as the dose level at which fewer than 2 out of 6 patients experience DLT graded using CTCAE-v3|Change in molecular inhibition of the EGFR signaling pathway|OBD defined as the dose at which either a >= 75% inhibition of phosphorylation of the EGF receptor or of its downstream effectors p44/42 MAPK or Akt is observed, or Ki67 is decreased by >= 25%|Antitumor effect observed	Phase 1	https://ClinicalTrials.gov/show/NCT00397384
NCT00030498	Completed	No Results Available	Drug: erlotinib hydrochloride|Other: laboratory biomarker analysis	Maximum tolerated dose (MTD) of OSI-774 determined by dose-limiting toxicities	Phase 1	https://ClinicalTrials.gov/show/NCT00030498
NCT01643499	Active, not recruiting	No Results Available	Drug: oxaliplatin|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Drug: fluorouracil|Other: laboratory biomarker analysis	DLT rate in course 1 for each of the two most common genotype groups (*1*1 and *1*28)|Response rates (by RECIST 1.1) for patients with each different type of gastrointestinal malignancy|Cumulative dose intensity of irinotecan hydrochloride	Phase 1	https://ClinicalTrials.gov/show/NCT01643499
NCT03329950	Recruiting	No Results Available	Drug: CDX-1140	Safety and Tolerability of CDX1140-01 as assessed by CTCAE v4.0	Phase 1	https://ClinicalTrials.gov/show/NCT03329950
NCT00892424	Active, not recruiting	No Results Available	Drug: Sorafenib	Determine the MTD of sorafenib and RT in patients with liver metastases using an iso-toxicity radiation dose allocation scheme. Determine the acute toxicity (< 3 months) of sorafenib when combined with RT in patients with liver metastases.|Document any observed late toxicities of treatment. Determine 1) the in-field local control based on CT response at 3 months;2)the time to progression and overall survival of this cohort, 3)changes in quality of life in these patients	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT00892424
NCT02557490	Unknown status	No Results Available	Drug: oxaliplatin and raltitrexed	Progression-free survival (PFS)|overall survival (OS)	Phase 4	https://ClinicalTrials.gov/show/NCT02557490
NCT02015169	Completed	No Results Available	Drug: Lapatinib	complete resection rate (R0 resection rate) (defined as no macroscopic or microscopic residual tumor).|response rate based on RECIST 1.1|disease-free survival|progression-free survival|safety and toxicity based on NCI CTCAE ver. 4.0|Exploratory biomarker analysis	Phase 2	https://ClinicalTrials.gov/show/NCT02015169
NCT02380131	Unknown status	No Results Available	Drug: Oxaliplatin plus Capecitabine|Drug: Herceptin	progression-free survival(PFS)|Objective response rate (ORR)	Phase 4	https://ClinicalTrials.gov/show/NCT02380131
NCT00208260	Completed	No Results Available	Drug: FOLFIRI|Drug: FOLFOX-4|Drug: FOLFIRI-HD|Drug: FOLFOX-7|Drug: FOLFIRINOX	Response|Safety|Survival|Secondary resection	Phase 2|Phase 3	https://ClinicalTrials.gov/show/NCT00208260
NCT00608361	Completed	No Results Available	Drug: Dasatinib|Other: Pharmacological Study	Maximum tolerated dose of dasatinib, defined as the highest dose level at which less than 33% of 6-9 evaluable patients experience dose-limiting toxicity|Pharmacokinetic parameters of dasatinib	Phase 1	https://ClinicalTrials.gov/show/NCT00608361
NCT03101475	Not yet recruiting	No Results Available	Drug: Durvalumab (MEDI4736)|Drug: Tremelimumab|Radiation: Sterotactic body radiation therapy (SBRT)|Other: Radiofrequency ablation (RFA)	Best overall immune response rate (iBOR) of lesions not treated by ablation/radiotherapy including the extrahepatic lesions according to iRECIST (with response confirmation)|Best overall immune response rate of liver lesions not treated with local therapy according to iRECIST (with response confirmation)|Best overall response rate of lesions not treated by ablation/radiotherapy including or not the extrahepatic lesions according to RECIST v1.1 (with response confirmation)|Response duration|Stable disease duration|Progression free survival according to iRECIST and to RECIST v1.1|Overall survival|Safety: Safety analyses will be performed on the Safety population. The worst toxicity grade per patient over the treatment period according to the CTCAE criteria version 4.0 will be displayed.	Phase 2	https://ClinicalTrials.gov/show/NCT03101475
NCT01322178	Unknown status	No Results Available	Drug: Cetuximab; mFOLFOX6	Resection rate (R0)|Response rate,Progression-free Survival,Overall Survival,R1 resection rate|Number of Participants with Adverse Events as a Measure of Safety and Tolerability	Phase 2	https://ClinicalTrials.gov/show/NCT01322178
NCT01763450	Unknown status	No Results Available	Drug: bevacizumab plus chemotherapy	To assess the objective response rate(ORR)|To assess the R0 resection rate of liver metastases	Phase 2	https://ClinicalTrials.gov/show/NCT01763450
NCT00630045	Unknown status	No Results Available	Drug: neoadjuvant chemotherapy with oxaliplatin and capecitabine|Procedure: resection of liver metastasis	disease free survival rate|R0 resection rate|survival rate and over survival|surgery related mortality|response rate and safety of XELOX as a neoadjuvant regimen	Phase 3	https://ClinicalTrials.gov/show/NCT00630045
NCT00501605	Completed	No Results Available	Drug: AZD2171	primary objective is to evaluate the safety and tolerability of ascending single&multiple oral doses of AZD2171 by assessment of AEs,BP,HR,RR,ECG,clinical chemistry,haematology,urinalysis incl 24hr collection for protein&creatinine and physical exam.|PK,assess the effects of AZD2171 on surrogate markets of activity and to make a preliminary assessment of anti-tumor activity by measurement of tumor response and time to progression	Phase 1	https://ClinicalTrials.gov/show/NCT00501605
NCT00806663	Completed	No Results Available	Drug: sunitinib added to FOLFIRI	reduction of tumor vessel permeability (TVP) and blood flow (BF) measured by DCE-MRI and DCE-USI, measured on liver metastases.|Antitumour response|Time to progression (TTP)|pharmacokinetics|drug treatment safety	Phase 2	https://ClinicalTrials.gov/show/NCT00806663
NCT02082210	Completed	No Results Available	Drug: LY2875358|Drug: Ramucirumab	Part A: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)|Part B: Proportion of Participants Who Exhibit Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)]|Pharmacokinetics: Maximum Plasma Concentration (Cmax) of LY2875358|Proportion of Participants who Exhibit Stable Disease (SD) or Confirmed Response (CR) or Partial Response (PR) [Disease Control Rate (DCR)]|Progression Free Survival (PFS)|Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of LY2875358|Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of Ramucirumab|Number of Participants with Anti-Ramucirumab and Anti-LY2875358 Antibodies|Pharmacokinetics: Maximum Plasma Concentration (Cmax) of Ramucirumab	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT02082210
NCT01010126	Completed	No Results Available	Biological: Bevacizumab|Drug: Temsirolimus	Progression free survival rate, defined as the proportion of efficacy-evaluable patients on study without documentation of disease progression 6 months from registration|Tumor response rate defined as the total number of efficacy-evaluable patients who achieved a complete or partial response according to the RECIST criteria divided by the total number of efficacy evaluable patients enrolled on study|Duration of response|Incidence of adverse events, defined as adverse events that are classified as either possibly, probably, or definitely related to study treatment, graded per National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0|Overall survival|Time to disease progression|Time to treatment failure	Phase 2	https://ClinicalTrials.gov/show/NCT01010126
NCT02465112	Recruiting	No Results Available	Drug: In111-Pentetréotide|Other: simple monitoring without active therapy	relapse-free survival (RFS)|Quality of life (EORTC QLQ-C30)|Tolerability|Overall survival (1)|Overall survival (2)|Identify predictive factors of RFS|Impact of the therapy on 1-year RFS in treatment and control group|Impact of the therapy on 5-year RFS in treatment and control group	Phase 3	https://ClinicalTrials.gov/show/NCT02465112
NCT02453490	Recruiting	No Results Available	Drug: Raltitrexed-based chemotherapy|Drug: 5-fluorouracil-based chemotherapy	Objective response rate|R0 resection rate of liver	Phase 3	https://ClinicalTrials.gov/show/NCT02453490
NCT01425879	Completed	Has Results	Drug: Akt Inhibitor MK2206|Other: Diagnostic Laboratory Biomarker Analysis|Other: Pharmacological Study	Overall Response Rate (Complete and Partial Response) as Defined by RECIST 1.1|Frequency of Adverse Events Related to MK-2206|Overall Survival|Progression-free Survival	Phase 2	https://ClinicalTrials.gov/show/NCT01425879
NCT03493048	Recruiting	No Results Available	Drug: Irinotecan|Drug: Cetuximab|Drug: 5-fluorouracil|Drug: Oxaliplatin|Drug: Leucovorin	overall response rate in each cohort	Phase 2	https://ClinicalTrials.gov/show/NCT03493048
NCT03493061	Recruiting	No Results Available	Drug: Irinotecan|Drug: Oxaliplatin|Drug: Floxuridine	Complete resection rates (R0 resection rates)	Phase 2	https://ClinicalTrials.gov/show/NCT03493061
NCT01456078	Recruiting	No Results Available	Drug: 177Lu-DOTA-TATE	Objective tumor response after a cumulative kidney biologically effective dose (BED) of 27 +/- 2 Gy|Objective tumor response after receiving a cumulative BED to the kidneys of 40 +/- 2 Gy as per RECIST v 1.1	Phase 2	https://ClinicalTrials.gov/show/NCT01456078
NCT01511146	Unknown status	No Results Available	Drug: Oxaliplatin|Drug: Mitomycin + Gemcitabine	tumor response according to RECIST 1.1. Number of patients with CR, PR, SD and PR will be recorded.|Progression free survival, adverse events	Phase 2	https://ClinicalTrials.gov/show/NCT01511146
NCT01384994	Unknown status	No Results Available	Drug: Folic Acid|Drug: 5-FU|Drug: Oxaliplatin|Drug: Panitumumab	Progression Free Survival|Tolerability and side effects|Overall Survival	Phase 2	https://ClinicalTrials.gov/show/NCT01384994
NCT01186263	Completed	No Results Available	Drug: MAA for diagnostic SPECT imaging|Drug: Diagnostic B20- SPECT imaging.	Percentage of liver volume for which the accumulation of SIR spheres was correctly predicted by the preceding Tc-99m MAA scintigraphy|Percentage of liver volume for which the accumulation of SIR spheres was correctly predicted by the preceding Tc-99m B20 scintigraphy|Pharmacokinetic parameters of the intrahepatic distribution of MAA and B20.|Adverse events as elicited upon indirect questioning.	Phase 2	https://ClinicalTrials.gov/show/NCT01186263
NCT01469572	Active, not recruiting	No Results Available	Drug: Pasireotide|Procedure: Sir-sphere Radioembolization|Drug: Everolimus	Evaluate the number of patients who develop side effects from combination therapy.|Compare the size of the tumor before and three months after treatment using cross sectional imaging (CT ro MRI)	Phase 1	https://ClinicalTrials.gov/show/NCT01469572
NCT00707681	Unknown status	No Results Available	Drug: MS-20|Drug: Placebo	To evaluate Quality of Life (QoL) score of MS-20 versus placebo in advanced HCC patients|Overall survival, Overall survival rate, Change from baseline of the highest weight observed, Change from baseline of body weight	Phase 2	https://ClinicalTrials.gov/show/NCT00707681
NCT00153998	Completed	No Results Available	Drug: Cetuximab|Procedure: Liver resection|Drug: Cetuximab and FOLFIRI|Drug: Cetuximab and FOLFOX	Tumor response, defined as partial and complete response according to RECIST (Response Evaluation Criteria in Solid Tumors) - criteria in the intention-to-treat [ITT-] population|Rate of R0 liver resection (ITT- population)|Progression free survival (ITT- population)|Disease free survival after resection (ITT- population)|Overall survival (ITT- population)|Safety (all patients that received any study drug)|Molecular predictive markers for response and toxicity	Phase 2	https://ClinicalTrials.gov/show/NCT00153998
NCT03500874	Recruiting	No Results Available	Drug: FUDR|Drug: Oxaliplatin|Drug: Leucovorin|Drug: 5FU	3 Year Relapse Free Survival Rate|Overall Survival	Phase 3	https://ClinicalTrials.gov/show/NCT03500874
NCT02070549	Recruiting	No Results Available	Other: Laboratory Biomarker Analysis|Other: Pharmacogenomic Study|Other: Pharmacological Study|Drug: Trametinib	Maximum tolerated dose of trametinib|Dose-limiting toxicity assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 5.04|Pharmacokinetic profile of trametinib|Non-dose-limiting toxicities associated with the administration of trametinib|Objective response to treatment assessed using the Response Evaluation Criteria in Solid Tumors criteria 1.1|Predictive biomarkers for individual cancer patients utilizing genomic sequencing technologies	Phase 1	https://ClinicalTrials.gov/show/NCT02070549
NCT01858207	Unknown status	No Results Available	Procedure: Transcatheter Arterial Chemoembolization|Procedure: Radiofrequency ablation|Drug: Doxorubicin	The rate of complete necrosis (CN)|Primary technique effectiveness|local tumor progression of HCC|Survival|Major complication	Phase 2	https://ClinicalTrials.gov/show/NCT01858207
NCT01203787	Completed	Has Results	Drug: Sorafenib Standard Dosing Regimen|Drug: Sorafenib Ramp-Up Regimen	Total (Cumulative) Dose Delivery of Sorafenib|Cumulative Dose of Sorafenib|Safety and Efficacy of Sorafenib Dosing Regimens|Safety of Dosing Regimens as Assessed by the Frequency and Severity of Adverse Events According to National Cancer Institute- CTCAE|Frequency and Severity of Adverse Events According to National Cancer Institute- CTCAE|Number of Subjects With Dose Interruptions|Number of Subjects With Dose Reductions	Phase 4	https://ClinicalTrials.gov/show/NCT01203787
NCT01959061	Recruiting	No Results Available	Drug: Raltitrexed|Drug: Oxaliplatin|Drug: lipiodol	Progression-free survivial	Phase 4	https://ClinicalTrials.gov/show/NCT01959061
NCT00264446	Completed	No Results Available	Drug: ADH300004		Phase 1	https://ClinicalTrials.gov/show/NCT00264446
NCT00044512	Completed	Has Results	Drug: Sorafenib (Nexavar, BAY43-9006)	Percentage of Participants for Each Type of Response|Duration of Response|Time to Response|Time to Progression|Duration of Stable Disease|Time to Minor Response|Duration of Minor Response|Overall Survival	Phase 2	https://ClinicalTrials.gov/show/NCT00044512
NCT00557557	Completed	No Results Available	Drug: Drug: 5-FU|Drug: Drug: Oxaliplatin	Primary endpoint is to determine the maximum tolerated dose and dose limiting toxicity of 5-FU delivered with 40mg/m² of Oxaliplatin via IHP.|Secondary endpoints will be to determine the response rate and survival after IHP with 5-FU and Oxaliplatin.	Phase 1	https://ClinicalTrials.gov/show/NCT00557557
NCT00101270	Completed	No Results Available	Drug: irinotecan hydrochloride|Drug: oxaliplatin	MTD of oxaliplatin, defined as the maximum dose at which fewer than one-third of patients experience DLT|Overall response assessed using RECIST criteria	Phase 1	https://ClinicalTrials.gov/show/NCT00101270
NCT00091182	Completed	No Results Available	Drug: oxaliplatin	Response rate	Phase 2	https://ClinicalTrials.gov/show/NCT00091182
NCT03458975	Not yet recruiting	No Results Available	Radiation: MRI|Radiation: Perfusion CT scan|Other: Contrast enhanced ultrasound|Drug: Sonoporation	Objective response for liver metastases|Safety|Tolerance|Maximum percent reduction in tumor density on CT scan|Maximum percent reduction in tumor density on MRI|Assessment of tumor vascularity by Perfusion CT scan|Assessment of tumor vascularity by MRI|Assessment of tumor vascularity by Dynamic Contrast-Enhanced US (DCE-US)|Dosage of bevacizumab|Dosage of bevacizumab by ELISA test|Dosage of cytokines	Phase 2	https://ClinicalTrials.gov/show/NCT03458975
NCT00012181	Completed	No Results Available	Drug: alvocidib|Other: pharmacological study	MTD defined as the dose at which fewer than one-third of patients experience DLT assessed using Common Toxicity Criteria version 2.0	Phase 1	https://ClinicalTrials.gov/show/NCT00012181
NCT01442935	Active, not recruiting	No Results Available	Drug: Oxaliplatin|Drug: Folinic Acid|Drug: 5-FU|Drug: Irinotecan|Drug: Bevacizumab|Drug: Cetuximab	The main objective is to compare resection rates (R0 or R1) for hepatic metastases|The objective response rate (CR and PR) after 4 cycles of treatment|Complete remission rate (CR) 6 months after the last study treatment (hepatic surgery or last chemotherapy cycle)|Specific resection rates R0/R1/R2|Complete pathological response|Toxicity of treatment|Post operatory complications|Progression-free survival (PFS)|Overall survival (OS)	Phase 2	https://ClinicalTrials.gov/show/NCT01442935
NCT00200200	Active, not recruiting	No Results Available	Drug: Bevacizumab HAI plus systemic chemotherapy|Drug: HAI plus systemic chemotherapy	To determine whether the addition of concurrent intravenous bevacizumab to HAI plus systemic chemotherapy increases the time to progression in patients with completely resected hepatic metastases from colorectal cancer|To assess toxicity|To determine survival|To assess the expression pattern of VEGFR1, VEGFR2 (angiogenesis), and VEGFR3 (lymphangiogenesis) and their cognate ligands (VEGF-A, VEGF-C, VEGF-D), and correlate with patient progression and survival following|To compare plasma levels of VEGF-A, VEGF-C, VEGF-D, and CD133+ VEGFR2+ circulating endothelial progenitors	Phase 2	https://ClinicalTrials.gov/show/NCT00200200
NCT02947165	Recruiting	No Results Available	Drug: NIS793|Drug: PDR001	Incidence of DLTs, AEs, SAEs and dose reductions / interruptions for NIS793|Incidence of DLTs, AEs, SAEs and dose reductions/interruptions for NIS793 in combination with PDR001|Best overall response (BOR)|Disease control rate (DCR)|Overall response rate (ORR)|Progression free survival (PFS)|Duration of response (DOR)|Serum concentration-time profiles of NIS793 single agent and NIS793 in combination with PDR001|Presence of anti-NIS793 and anti-PDR001 antibodies|Concentration of anti-NIS793 and anti-PDR001 antibodies|Area under the curve (AUC) for NIS793 single agent and NIS793 in combination with PDR001.|Cmax for NIS793 single agent and NIS793 in combination with PDR001.|Tmax for NIS793 single agent and NIS793 in combination with PDR001.|Half life of NIS793 as single agent and in combination with PDR001.|Characterization of tumor infiltrating lymphocytes (TILs) by H&E|Characterization of tumor infiltrating lymphocytes by immunohistochemistry (CD8, FOXP3, PD-L1, TIM-3, LAG-3)	Phase 1	https://ClinicalTrials.gov/show/NCT02947165
NCT01008917	Completed	No Results Available	Drug: sorafenib with temsirolimus	Maximum tolerated dose|Determine safety/toxicity profile of temsirolimus in combination with sorafenib|Describe pharmacokinetics of temsirolimus alone in the cohort of 6 subjects treated at MTD|Describe pharmacokinetics of temsirolimus in combination with sorafenib in the cohort of 6 subjects treated at MTD|Incidence of progression-free survival, overall survival, and disease control rate	Phase 1	https://ClinicalTrials.gov/show/NCT01008917
NCT02086656	Active, not recruiting	No Results Available	Drug: capecitabine, oxaliplatin, irinotecan and bevacizumab	Pathological response rate|RECIST Response rate	Phase 2	https://ClinicalTrials.gov/show/NCT02086656
NCT03195699	Recruiting	No Results Available	Drug: C188-9	Maximum Tolerated Dose of C188-9|Pharmacokinetics - Cmax|Pharmacokinetics - Tmax|Pharmacokinetics - AUC(0-t)|Pharmacodynamics of C188-9 in peripheral blood mononuclear cells (PBMC) of patients|Pharmacodynamics of C188-9 in tumors of patients|Complete Response (CR) - Target Lesions|Partial Response (PR) - Target Lesions|Progressive Disease (PD) - Target Lesions|Stable Disease (SD) - Target Lesions|Complete Response (CR) - Non-target Lesions|Non-CR/Non-PD - Non-target Lesions|Progressive Disease (PD) - Non-target Lesions|Best Overall Response	Phase 1	https://ClinicalTrials.gov/show/NCT03195699
NCT01901692	Completed	No Results Available	Radiation: TACE+External beam RT|Drug: Sorafenib	Progression-free survival (PFS) rate|Radiologic response rate|treatment-crossover rate|time to progression|Overall patient survival rate|Exploratory analysis for overall patient survival rate	Phase 2|Phase 3	https://ClinicalTrials.gov/show/NCT01901692
NCT00790218	Completed	Has Results	Drug: CF102	Dose Limiting Toxicity|Repeat-dose Pharmacokinetic Behavior of CF102|Maximum Tolarated Dose|Therapeutic Effect of CF102 in Hepatocellular Carcinoma|Relationship Between Biomarkers of Peripheral Blood Mononuclear Cell (PBMC) Adenosine A3 Receptor (A3AR) Expression and Clinical Effects of CF102	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT00790218
NCT01035385	Unknown status	No Results Available	Drug: FOFLOX4	progression free survival (PFS)|response rate, incidence of postoperative complications,pathological response rate,R0 resection rate, 5-year overall survival,duration of disease control	Phase 3	https://ClinicalTrials.gov/show/NCT01035385
NCT03053466	Recruiting	No Results Available	Drug: CBT-501	Number of participants with treatment related adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE v4.03) in patients with advance solid tumors|Determine the recommended Phase 2 dose and schedule|Area under the plasma concentration versus time curve (AUC)|Maximum plasma concentration|Time to reach Cmax|Overall Objective Response Rate|Duration of Response|Time to Response|Disease Control Rate|Progression Free Survival	Phase 1	https://ClinicalTrials.gov/show/NCT03053466
NCT01962376	Unknown status	No Results Available	Drug: Oxaliplatin;Capecitabine|Drug: Oxaliplatin;Capecitabine;Bevacizumab	progression-free survival(PFS)|Objective response rate (ORR)	Phase 4	https://ClinicalTrials.gov/show/NCT01962376
NCT02754856	Recruiting	No Results Available	Drug: Tremelimumab|Drug: MEDI4736|Procedure: Liver Resection	Feasibility of Tremelimumab plus MEDI4736 with FOLFOX and Bevacizumab in Candidates for Resection of Colorectal Cancer Liver Metastases|Relapse-free survival (RFS) of Tremelimumab plus MEDI4736 with FOLFOX and Bevacizumab in Candidates for Resection of Colorectal Cancer Liver Metastases	Phase 1	https://ClinicalTrials.gov/show/NCT02754856
NCT01643070	Unknown status	No Results Available	Drug: Capecitabine, Oxaliplatin|Radiation: Radiotherapy	R0 resection rate after simultaneous surgery of the rectum and the liver	Phase 2	https://ClinicalTrials.gov/show/NCT01643070
NCT01387295	Unknown status	No Results Available	Drug: oxaliplatin, capecitabine, trastuzumab	Response rate|Number of patients suitable for local therapy (radiofrequency)|Survival|toxicity|PFS	Phase 2	https://ClinicalTrials.gov/show/NCT01387295
NCT01260415	Completed	No Results Available	Drug: Panitumumab, Oxaliplatin, 5-FU	To determine the 2 year disease-free survival rate in patients with resectable colorectal liver metastases treated with FOLFOX/FOLFIRI + panitumumab for 2 months pre-operatively and 4 months post-operatively, followed by panitumumab alone for 6 months.|To evaluate the objective response rate (ORR) to preoperative FOLFOX/FOLFIRI plus panitumumab (by RECIST criteria) in patients with wild type KRAS.|To evaluate the pathologic complete response rate.|To determine overall survival and toxicity.|To explore correlative biomarkers of clinical response (EGFR, PTEN, MET, BRAF and PI3KCA).|To explore for correlation between available tissue from biopsy, primary tumor and metastatic lesion with regards to aforementioned pathologic biomarkers.|To determine the incidence of hepatocellular damage (fibrosis, steatosis) in normal liver tissue induced by preoperative chemotherapy.	Phase 2	https://ClinicalTrials.gov/show/NCT01260415
NCT03135652	Recruiting	No Results Available	Radiation: adjuvant SBRT|Drug: Chemotherapy	Disease free survival|Overall survival|Intrahepatic disease free survival|Toxicities	Phase 2	https://ClinicalTrials.gov/show/NCT03135652
NCT00234182	Completed	No Results Available	Drug: Interferon alpha-2b	Occurrence of recurrent disease|Death of the patient	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT00234182
NCT01387373	Unknown status	No Results Available	Drug: oxaliplatin, capecitabine, trastuzumab	Response rate|Time to progression a) Intrahepatic progression b) Extrahepatic progression|Number of patients suitable for local therapy (radiofrequency)|Survival|Toxicity	Phase 2	https://ClinicalTrials.gov/show/NCT01387373
NCT02172651	Recruiting	No Results Available	Drug: Vitamin D3	VDR Binding Sites|RNA transcriptome|Number of Participants with Serious and Non-Serious Adverse Events	Early Phase 1	https://ClinicalTrials.gov/show/NCT02172651
NCT01348412	Completed	No Results Available	Drug: oxaliplatin|Drug: raltitrexed|Drug: other intravenous chemotherapy drugs	progression-free survival|Estimate the parameters of tumor perfusion using arterial CT Scan data|Estimate the rate of objective response according to the criteria of CHOI and RECIST|Estimate the overall survival which will be compared with the median of overall survival in other studies published in the literature|Estimate the rate of secondary resectable hepatic metastases|Estimate the tolerance of the treatment (NCI-CTCAE version 4.0)|Estimate the quality of life (QLQ C30) and the fatigue MFI20	Phase 2	https://ClinicalTrials.gov/show/NCT01348412
NCT00743678	Completed	No Results Available	Drug: FOLFOX6/cetuximab	To evaluate overall R0 resection rates following neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis|Response rate (according to RECIST)|Progression-free survival time|Overall survival timeToxicity profile (according to NCI CTCAE v3)|Correlative analyses between pretreatment EGFR, KRAS mutation and response rate/survival	Phase 2	https://ClinicalTrials.gov/show/NCT00743678
NCT00997685	Unknown status	No Results Available	Drug: Capecitabine plus oxaliplatin	To investigate the progression free survival (PFS) advantage of Xeloda plus oxaliplatin in the peri-operative treatment of potential resectable metastatic colorectal cancer|To investigate the response rate|To evaluate the R0 resection rate|To evaluate the safety profile of XELOX peri-operative treatment	Phase 2	https://ClinicalTrials.gov/show/NCT00997685
NCT03428477	Recruiting	No Results Available	Drug: Icosapent Ethyl|Other: Placebo	Progression Free Survival (PFS)|Overall Survival (OS)|Safety and Tolerability of Icosapent Ethyl|Patient reported quality of life 1|Patient reported quality of life 2|Patient reported quality of life 3|New Primary Cancers	Phase 3	https://ClinicalTrials.gov/show/NCT03428477
NCT00645710	Completed	No Results Available	Drug: gemcitabine hydrochloride|Drug: floxuridine|Genetic: proteomic profiling|Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry|Other: liquid chromatography|Radiation: yttrium Y 90 anti-CEA monoclonal antibody cT84.66|Other: laboratory biomarker analysis|Other: mass spectrometry|Other: pharmacological study	Progression-free survival|Overall survival|Sites of recurrence	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT00645710
NCT00852228	Unknown status	No Results Available	Drug: IV cetuximab|Drug: HAI chronomodulated chemotherapy|Drug: HAI conventional chemotherapy	Incidence of complete macroscopic resections (R0+R1) of unresectable liver metastases following chemotherapy.|The rate and site(s) of relapse in the resected patients throughout the 3-year span that follows hepatectomy|The relapse-free survival in the resected patients|The progression-free and the overall survival in the patients receiving at least 4 full courses of HAI therapy and in all the patients (intent to treat)|The objective response rate|The rate of adverse events|The per-operative and post-operative complications associated to liver surgery	Phase 2	https://ClinicalTrials.gov/show/NCT00852228
NCT02151864	Active, not recruiting	No Results Available	Drug: LDE225	Rate of dose limiting toxicities	Phase 1	https://ClinicalTrials.gov/show/NCT02151864
NCT02006030	Completed	No Results Available	Drug: ADI-PEG 20	Determine time to tumor progression (TTP)|Tumor response rates	Phase 2	https://ClinicalTrials.gov/show/NCT02006030
NCT01488487	Completed	Has Results	Drug: Everolimus|Drug: Pasireotide	Time to Progression (TTP)|Number of Individuals Experiencing Toxicity|Overall Survival (OS)|Objective Response Rate (ORR)	Phase 2	https://ClinicalTrials.gov/show/NCT01488487
NCT00866944	Completed	No Results Available	Drug: Adecatumumab|Drug: Adecatumumab and FOLFOX|Drug: FOLFOX 4	Disease free survival rate (DFS)|time to relapse|Incidence of AEs|Quality of Life	Phase 2	https://ClinicalTrials.gov/show/NCT00866944
NCT00108953	Completed	Has Results	Drug: Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin|Drug: Doxorubicin/Placebo	Time to Progression (TTP)|Overall Survival|Progression Free Survival (PFS)|Percentage of Participants in Each Category of Best Tumor Response|Time to Symptomatic Progression (TTSP)|Duration of Response|Time to Response (TTR)|Percentage of Participants for Whom Disease Control Was Achieved	Phase 2	https://ClinicalTrials.gov/show/NCT00108953
NCT00494299	Completed	Has Results	Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Placebo	Time to Progression (TTP)|Overall Survival (OS)	Phase 3	https://ClinicalTrials.gov/show/NCT00494299
NCT00156975	Unknown status	No Results Available	Drug: Capecitabine|Drug: Oxaliplatin	Primary outcomes:|Disease free survival|Secondary outcomes:overall survival,acute- and longtime toxicity of chemotherapy, molecular predictive markers for the risk of relapse and toxicity	Phase 3	https://ClinicalTrials.gov/show/NCT00156975
NCT01149304	Completed	No Results Available	Drug: Pentoxifylline|Drug: Ursodeoxycholic Acid|Drug: Enoxaparin	HDR-brachytherapy isodose (measured in Gy) that corresponds to the metastases without enhancement of Gd-EOB-DTPA in MR imaging using an axial T1 THRIVE sequence.|HDR-brachytherapy isodose (measured in Gy) that corresponds to the irradiated liver tissue without enhancement of Gd-EOB-DTPA in MR imaging using an axial T1 THRIVE sequence.|Correlation between the HDR brachytherapy isodose that corresponds to damaged live tissue as defined by missing Gd-EOB-DTPA enhancement in MR imaging and liver-specific laboratory values.|Quality of live.|Safety of the study drugs.	Phase 2	https://ClinicalTrials.gov/show/NCT01149304
NCT03590119	Not yet recruiting	No Results Available	Drug: Lutetium Lu 177-DOTATATE	The difference in post-treatment tumor-to-non-tumor (T/N) activity concentration ratio on SPECT/CT between the intra-arterial treated liver lobe and the intravenous treated liver lobe.|The difference in absolute values of mean tumor and healthy liver absorbed dose on post-treatment SPECT/CT between the intra-arterial treated liver lobe and the intravenous treated liver lobe|The difference in post-treatment tumor response between the intra-arterial treated liver lobe and the intravenous treated liver lobe|The dose-response relation between tumor absorbed dose and post-treatment tumor response|Toxicity and how toxicity is compared to historical controls|Sufficient uptake of 177Lu-dotatate in extrahepatic lesions|Sufficient uptake of 177Lu-dotatate in the contralateral lobe, compared to historical controls|The difference in kidney uptake of 177Lu-dotatate between the IA treated patients and historical controls	Phase 2|Phase 3	https://ClinicalTrials.gov/show/NCT03590119
NCT02727309	Recruiting	No Results Available	Drug: Apatinib	Progression free survival|Overall survival|Objective response rates	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT02727309
NCT00168155	Completed	No Results Available	Drug: perioperative chemotherapy	disease free survival	Phase 2	https://ClinicalTrials.gov/show/NCT00168155
NCT03582618	Not yet recruiting	No Results Available	Drug: Sorafenib|Drug: CVM-1118	Objective Response Rate (ORR)|Overall survival (OS)|Progression-free survival (PFS)|Time to progression (TTP)|Duration of response (DoR)|Disease control rate (DCR)|Rate of Adverse event (AE) and Serious Adverse Event (SAE)|Assessed the baseline and out-of-range vital signs_ body temperature, blood pressure, heart rate, and respiratory rate by CTCAE v4.03|Assessed the baseline and out-of range laboratory parameters_hematology, chemistry, coagulation, and urinalysis by CTCAE v4.03|Abnormalities in electrocardiography (ECG)|Maximum Plasma Concentration [Cmax] of sorafenib, CVM-1118, and its metabolite CVM-1125 after CVM-1118 dosing|Area Under the Curve [AUC] of sorafenib, CVM-1118, and its metabolite CVM-1125 after CVM-1118 dosing|Pharmacodynamics analysis for the relationship of Cmax and ORR|Pharmacodynamics analysis for the relationship of AUC and ORR|Pharmacodynamics analysis for the relationship of Cmax and Adverse Event (AE)|Pharmacodynamics analysis for the relationship of AUC and Adverse Event (AE)	Phase 2	https://ClinicalTrials.gov/show/NCT03582618
NCT02363049	Recruiting	No Results Available	Procedure: Colectomy|Drug: Chemotherapy	overall survival|quality of life|Post-operative complications|Progression free survival (PFS)|Time to metastatic progression (TTP)|Rate of secondary curative resection (R0)	Phase 3	https://ClinicalTrials.gov/show/NCT02363049
NCT03326791	Recruiting	No Results Available	Drug: Acetylsalicylic acid|Drug: Placebo Oral Tablet	Disease Free Survival (DFS) after three years treatment|Time to recurrence (TTR) of disease after randomization|Overall survival (OS) three years after treatment start|Health-related Quality of Life with 36-item Short Form Health Survey (SF-36)|Health-related Quality of Life with EuroQoL 5 Dimensions (EQ-5D)|ASA in CRC and Cost-Effectiveness Analyses I|ASA in CRC and Cost-Effectiveness Analyses II|ASA in CRC and Cost-Effectiveness Analyses III	Phase 2	https://ClinicalTrials.gov/show/NCT03326791
NCT01334112	Active, not recruiting	No Results Available	Drug: Axitinib (AG-013736)	Response rate|Feasibility|Overall survival|Response rate comparison|Progression-free survival|Quality of life|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Number of Participants with Adverse Events as a Measure of Safety	Phase 2	https://ClinicalTrials.gov/show/NCT01334112
NCT01777594	Completed	No Results Available	Drug: G-202	Time to progression|Overall response rate|Progression-free survival|Overall survival	Phase 2	https://ClinicalTrials.gov/show/NCT01777594
NCT01232296	Completed	Has Results	Drug: dovitinib|Drug: sorafenib	Overall Survival - Overall Survival|Time to Tumor Progression (Tumor Assessment)|Disease Control Rate (Tumor Assessment)|Time to Definitive Deterioration in ECOG Performance Status (PS)|Pharmacokinetic (PK) Parameter of Cmax Following a Single Dose of TKI258|Pharmacokinetic (PK) Parameter of Tmax Following a Single Dose of TKI258|Pharmacokinetic (PK) Parameter of AUCtau Following a Single Dose of TKI258	Phase 2	https://ClinicalTrials.gov/show/NCT01232296
NCT02988440	Recruiting	No Results Available	Drug: PDR001|Drug: Sorafenib	Number of participants with Adverse Events (AEs) as a measure of safety and tolerability|Pharmacokinetics (PK): Ctrough|Pharmacokinetics (PK): Cmax|Pharmacokinetics (PK): AUC|Overall response rate (ORR) using RECIST v1.1 criteria)|Progression free survival (PFS)|Time to Progression (TTP)|Duration of response (DOR)|Time to response (TTR)|Disease control rate (DCR) per RECIST v1.1|Overall survival (OS)|Antidrug antibodies (ADA) prevalence at baseline and on treatment	Phase 1	https://ClinicalTrials.gov/show/NCT02988440
NCT00247728	Completed	No Results Available	Drug: PI-88	Tumour non-recurrence rate|Time to first recurrence|Survival rate	Phase 2	https://ClinicalTrials.gov/show/NCT00247728
NCT03507699	Not yet recruiting	No Results Available	Radiation: Liver radiation therapy|Drug: Nivolumab Injection [Opdivo]|Drug: Ipilimumab Injection [Yervoy]|Drug: CMP-001	Number of participants with serious dose-limiting treatment-related adverse events as assessed by CTCAE v5.0|Response rate as assessed by RECIST v1.1|Progression free survival	Phase 1	https://ClinicalTrials.gov/show/NCT03507699
NCT02939807	Recruiting	No Results Available	Drug: ABC294640	To assess objective response rate (per modified RECIST) of single agent ABC294640 in second line treatment of HCC|To estimate the time to tumor progression (TTP) in HCC patients treated with ABC294640|To estimate the overall survival (OS) in HCC patients treated with ABC294640|To evaluate the pharmacokinetic behavior of ABC294640 in HCC patients [Peak Plasma Concentration (Cmax)]|To evaluate the pharmacokinetic behavior of ABC294640 in HCC patients [Area Under the drug concentration over time curve, (AUC)]|To describe the relationship between changes in marker levels of sphingolipids in peripheral blood mononuclear cells in patients being given ABC294640|To explore the relationship between changes in c-Myc marker levels in peripheral blood mononuclear cells in patients being given ABC294640|To assess the relationship between changes in marker levels of sphingolipids in tumor tissue from patients being given ABC294640.|To assess the relationship between changes in c-myc marker levels in tumor tissue from patients being given ABC294640.|Descriptive statistics of adverse events reported in all subjects treated with ABC294640|Descriptive statistics of adverse events reported in subjects who discontinued study drug due to adverse events|Descriptive statistics of adverse events reported in subjects with adverse events related to study drug.	Phase 2	https://ClinicalTrials.gov/show/NCT02939807
NCT02508467	Recruiting	No Results Available	Drug: BLU-554	Maximum tolerated dose (MTD) on qd and bid schedules|Recommended Phase 2 dose of BLU-554 on qd and bid schedules|Number of patients with adverse events, serious adverse events and changes in physical findings, vital signs, clinical laboratory results and ECG findings|Maximum plasma concentration of BLU-554 on qd and bid schedules|Time to maximum plasma concentration of BLU-554 on qd and bid schedules|Fibroblast growth factor 19 (FGF19) status in tumor tissue|Levels of FGF19 in blood and tumor samples|Preliminary evidence of BLU-554 antineoplastic activity	Phase 1	https://ClinicalTrials.gov/show/NCT02508467
NCT01171651	Completed	No Results Available	Drug: JX-594 followed by sorafenib	Determine safety and tolerability of intravenous infusion of JX-594 followed by intratumoral injections with JX-594 prior to standard sorafenib therapy|Determine Disease Control Rate (DCR) at 12 weeks|Determine radiographic response rate|Determine overall survival time	Phase 2	https://ClinicalTrials.gov/show/NCT01171651
NCT01721941	Unknown status	No Results Available	Drug: Phase I Dose level -1|Drug: Phase I dose level 1|Drug: Phase I Dose level 2|Drug: Phase I Dose level 3	Maximum tolerated dose of TH-302 use in TACE|Objective response rate	Phase 1	https://ClinicalTrials.gov/show/NCT01721941
NCT03366155	Not yet recruiting	No Results Available	Drug: Floxuridine|Drug: Oxaliplatin|Drug: Leucovorin|Drug: 5-Fluorouracil|Drug: Irinotecan|Drug: Panitumumab|Procedure: HAIP	Response rate RR|Hepatic progression-free survival|Extra-hepatic progression-free survival|Overall survival	Phase 2	https://ClinicalTrials.gov/show/NCT03366155
NCT02942329	Recruiting	No Results Available	Drug: apatinib|Drug: SHR-1210	Overall survival rate|Tumor response rate|Disease control rate|Duration of response|Safety as measured by the rate of AEs, deaths and laboratory abnormalities (e.g. Grade 3 or higher per CTCAE v4 )	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT02942329
NCT01869088	Active, not recruiting	No Results Available	Drug: Recombinant Human Adenovirus Type 5 Injection|Procedure: Transartery Chemoembolization	Overall survival time|Number of adverse events|Tumor response	Phase 3	https://ClinicalTrials.gov/show/NCT01869088
NCT01102335	Unknown status	No Results Available	Procedure: Transcatheter arterial chemoembolization (TACE)|Drug: Telbivudine	Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Overall survival	Phase 4	https://ClinicalTrials.gov/show/NCT01102335
NCT03029988	Recruiting	No Results Available	Drug: Tilmanocept (Technetium Tc 99m tilmanocept Injection)|Procedure: SPECT/CT Imaging	Concordance|Adverse Drug Reaction|Localization	Phase 1	https://ClinicalTrials.gov/show/NCT03029988
NCT03299946	Recruiting	No Results Available	Drug: Cabozantinib|Drug: Nivolumab	Number of adverse events in participants of neoadjuvant cabozantinib plus nivolumab.|Number of patients who complete pre-op treatment and proceed to surgery.|Percentage of participants who obtain R0 resection.|Percentage of participants who obtain a pathologic complete response (CR).|Percentage of participants who obtain a major pathologic responses (MPR)|Objective response rate (ORR)|Median Overall Survival (OS)|Disease free survival (DFS)	Phase 1	https://ClinicalTrials.gov/show/NCT03299946
NCT00956436	Completed	No Results Available	Drug: BIIB022|Drug: Sorafenib	To evaluate the safety and tolerability of BIIB022 given once every 3 weeks in combination with sorafenib in subjects with advanced HCC.|To evaluate the PK profile of BIIB022 and sorafenib in this study population|To assess the anti-tumor response in this study population	Phase 1	https://ClinicalTrials.gov/show/NCT00956436
NCT01908426	Active, not recruiting	No Results Available	Drug: Cabozantinib tablets|Drug: Placebo tablets	Overall Survival (OS)|Progression-Free Survival (PFS)|Objective Response Rate (ORR)	Phase 3	https://ClinicalTrials.gov/show/NCT01908426
NCT03230318	Recruiting	No Results Available	Drug: ARQ 087	Anti-cancer activity of ARQ 087 by Objective Response Rate (ORR)|Safety of ARQ 087 as assessed by adverse events|Anti-cancer activity of ARQ 087 by progression free survival (PFS)|Anti-cancer activity of ARQ 087 by overall survival (OS)|Anti-cancer activity of ARQ 087 by duration of response (DoR)	Phase 2	https://ClinicalTrials.gov/show/NCT03230318
NCT02018757	Unknown status	No Results Available	Drug: TACE containing As2O3|Drug: TACE containing placebo	time to progression|objective response rate|progression free survival|overall survival|Proportion of Participants with Adverse Events	Phase 2	https://ClinicalTrials.gov/show/NCT02018757
NCT01348256	Recruiting	No Results Available	Drug: Dendritic cells vaccine	Progression Free survival|Overall survival	Phase 2	https://ClinicalTrials.gov/show/NCT01348256
NCT00692770	Completed	Has Results	Drug: Nexavar (Sorafenib, BAY43-9006)|Drug: Placebo	Recurrence Free Survival (RFS) by Independent Assessment|Time to Recurrence (TTR) by Independent Assessment|Overall Survival (OS)	Phase 3	https://ClinicalTrials.gov/show/NCT00692770
NCT00003958	Completed	No Results Available	Biological: dactinomycin|Drug: vincristine sulfate|Drug: cyclophosphamide|Procedure: therapeutic conventional surgery|Radiation: radiation therapy|Drug: topotecan hydrochloride|Biological: filgrastim|Biological: sargramostim|Other: laboratory biomarker analysis	Long-term failure-free survival (FFS) between the two treatment groups|Overall survival between treatments|Rate of second look surgery|Proportion of patients rendered tumor-free or with microscopic tumor only|Estimation of the rate of local failure for the patients who undergo second look surgery	Phase 3	https://ClinicalTrials.gov/show/NCT00003958
NCT00827554	Completed	No Results Available	Drug: LMWH|Procedure: TACE	time-to-progression(TTP)|The overall response rate|Overall survival (OS)|bleeding complication rate|Progression Free Survival (PFS)	Phase 2|Phase 3	https://ClinicalTrials.gov/show/NCT00827554
NCT00057395	Unknown status	No Results Available	Drug: Aroplatin (Liposomal NDDP, L-NDDP)		Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT00057395
NCT03008512	Recruiting	No Results Available	Drug: Genexol-PM	Progression-free survival rate at 6 months|Progression-free survival|Overall survival|Objective response rate|Adverse events	Phase 2	https://ClinicalTrials.gov/show/NCT03008512
NCT02112656	Recruiting	No Results Available	Drug: ThermoDox|Drug: Dummy infusion	Overall Survival (OS)|Progression-free survival (PFS)	Phase 3	https://ClinicalTrials.gov/show/NCT02112656
NCT02959151	Recruiting	No Results Available	Drug: CAR-T cell	Number of patients with adverse event|Number of patients with tumor response|Detection of transferred T cells in the circulation using quantitative -PCR	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT02959151
NCT01417546	Recruiting	No Results Available	Drug: NHS-IL-12	Dose-limiting toxicities (DLTs) and Maximum Tolerated Dose (MTD)	Phase 1	https://ClinicalTrials.gov/show/NCT01417546
NCT03291379	Recruiting	No Results Available	Drug: BTG-002814 (vandetanib-eluting radiopaque beads)	Adverse events (AEs) related to treatment with BTG-002814 using the National Cancer Institute- Common Terminology Criteria for Adverse Events- Version 4.0 (NCI-CTCAE v4.0)|Concentration of vandetanib and N-desmethyl vandetanib in plasma following treatment with BTG-002814|Concentration of vandetanib and N-desmethyl vandetanib in resected liver tissue following treatment with BTG-002814|BTG-002814 distribution|Evaluation of histopathological features|Assessment of changes in blood flow	Early Phase 1	https://ClinicalTrials.gov/show/NCT03291379
NCT00354835	Completed	Has Results	Drug: Irinotecan Hydrochloride|Biological: Dactinomycin|Drug: Cyclophosphamide|Drug: Vincristine Sulfate|Radiation: Radiation Therapy|Other: Laboratory Biomarker Analysis|Other: Questionnaire Administration	Event Free Survival (EFS)|Response Rate (RR)|Overall Survival (OS)|Event Free Survival (EFS) Probability VAC and Early (Week 4) Radiotherapy Compared to Delayed (Week 10) Radiotherapy, Using IRSIV for Historic Comparison|Local Failure|Overall Survival (OS) Probability VAC and Early (Week 4) Radiotherapy Compared to Delayed (Week 10) Radiotherapy, Using IRSIV for Historic Comparison|Incidence of Toxicity|Acute and Late Effects of VAC as Delivered on This Study to D9803 VAC|Compare Event Free Survival (EFS) With Respect to the Level of % Change in FDG PET Maximum Standard Uptake Value (SUVmax) at Week 4|Compare Event Free Survival (EFS) With Respect to the Level of % Change in FDG PET Maximum Standard Uptake Value (SUVmax) at Week 15|Incidence of Toxicity Related to VI Treatment in Patients With UGT1A1 Genotype|Toxicity With CYP2B6 Genotypes|Toxicity With GSTA1 and CYP2C9 Genotypes|Event Free Survival (EFS) by PAX Status|Incidence of Bladder Dysfunction	Phase 3	https://ClinicalTrials.gov/show/NCT00354835
NCT03189992	Recruiting	No Results Available	Drug: Bushen-Jianpi Dedoction|Drug: cinobufotalin injection	Complete patient recruitment	Phase 1	https://ClinicalTrials.gov/show/NCT03189992
NCT00538850	Completed	Has Results	Drug: Fentanyl sublingual spray|Drug: Placebo	Summed Pain Intensity Differences (SPID) at 30 Minutes After Dosing (SPID30)|Summed Pain Intensity Differences (SPID) at 5, 10, 15, 45, and 60 Minutes After Dosing|Total Pain Relief (TOTPAR) at 5, 10, 15, 30, 45, and 60 Minutes After Dosing|Global Evaluation of the Study Medication at 30 and 60 Minutes After Dosing	Phase 3	https://ClinicalTrials.gov/show/NCT00538850
NCT00274885	Unknown status	No Results Available	Drug: oxaliplatin|Procedure: management of therapy complications	Relationship between residual platinum levels in the blood and persistent neurotoxicity|Pharmacokinetics	Phase 4	https://ClinicalTrials.gov/show/NCT00274885
NCT00016380	Completed	No Results Available	Drug: dexamethasone|Drug: ondansetron|Procedure: quality-of-life assessment		Phase 3	https://ClinicalTrials.gov/show/NCT00016380
NCT02204930	Completed	No Results Available	Drug: PeproStat	Safety of PeproStat|Assessment of efficacy of PeproStat in achieving haemostasis in open liver resection surgery	Phase 1	https://ClinicalTrials.gov/show/NCT02204930
NCT00005842	Completed	No Results Available	Biological: trastuzumab|Drug: tipifarnib		Phase 1	https://ClinicalTrials.gov/show/NCT00005842
NCT00003867	Unknown status	No Results Available	Drug: capecitabine|Drug: irinotecan hydrochloride		Phase 1	https://ClinicalTrials.gov/show/NCT00003867
NCT00010023	Completed	No Results Available	Drug: capecitabine|Drug: cisplatin		Phase 1	https://ClinicalTrials.gov/show/NCT00010023
NCT00020579	Completed	No Results Available	Drug: entinostat	Dose-limiting toxicities and maximum tolerated dose|Pharmacology and pharmacokinetics|Acetylation of histones in peripheral blood|Tumor response by CT scan every 12 weeks	Phase 1	https://ClinicalTrials.gov/show/NCT00020579
NCT02867592	Recruiting	No Results Available	Drug: Cabozantinib S-malate|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study	Objective response assessed by Response Evaluation Criteria in Solid Tumors version 1.1|Incidence of adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Pharmacokinetics (PK) parameters of cabozantinib s-malate	Phase 2	https://ClinicalTrials.gov/show/NCT02867592
NCT00019760	Completed	No Results Available	Drug: floxuridine|Drug: leucovorin calcium|Drug: melphalan		Phase 2	https://ClinicalTrials.gov/show/NCT00019760
NCT03257761	Recruiting	No Results Available	Biological: Durvalumab|Drug: Guadecitabine	Incidence of adverse events|Tumor response (dose expansion)|Overall survival|Progression-free survival	Phase 1	https://ClinicalTrials.gov/show/NCT03257761
NCT00005860	Completed	No Results Available	Drug: floxuridine|Drug: leucovorin calcium|Drug: oxaliplatin		Phase 1	https://ClinicalTrials.gov/show/NCT00005860
NCT00003548	Completed	No Results Available	Drug: aminocamptothecin colloidal dispersion		Phase 1	https://ClinicalTrials.gov/show/NCT00003548
NCT00720174	Completed	No Results Available	Biological: Cixutumumab|Drug: Doxorubicin Hydrochloride|Other: Laboratory Biomarker Analysis	Maximally tolerated dose (MTD) of cixitumumab when administered in a combination regimen with fixed dose doxorubicin hydrochloride, in patients with locally advanced or metastatic soft tissue sarcoma|Changes in cardiac function as measured by MUGA scans of the left ventricular ejection fraction|Confirmed response rate (CR + PR) for comparison with doxorubicin treatment in similar historical patient populations|Overall survival|Progression-free survival	Phase 1	https://ClinicalTrials.gov/show/NCT00720174
NCT00049296	Completed	No Results Available	Drug: docetaxel|Drug: thalidomide	Determine the maximum tolerated dose of docetaxel when administered with thalidomide in patients with advanced solid tumors, multiple myeloma, and non-Hodgkin's lymphoma.	Phase 1	https://ClinicalTrials.gov/show/NCT00049296
NCT00002854	Completed	No Results Available	Biological: filgrastim|Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: ifosfamide|Drug: mesna|Drug: paclitaxel|Procedure: peripheral blood stem cell transplantation	Feasibility of two cycles of high dose chemotherapy with stem cell reinfusion|Toxicity of two cycles of high dose chemothearpy and stem cell reinfusion|Maximum tolerated dose of two cycles of high dose chemothearpy and stem cell reinfusion	Phase 1	https://ClinicalTrials.gov/show/NCT00002854
NCT00250796	Completed	No Results Available	Drug: Thalidomide, alpha interferon|Drug: Thalidomide, interferon, Octreotide	Determine the response rate and time to progression of the combination of thalidomide, interferon, and octreotide in patients with unresectable hepatocellular carcinoma.	Phase 2	https://ClinicalTrials.gov/show/NCT00250796
NCT00346164	Completed	Has Results	Drug: doxorubicin hydrochloride|Other: clinical observation|Procedure: therapeutic conventional surgery|Radiation: 3-dimensional conformal radiation therapy|Drug: ifosfamide	Probability for Event Free Survival.|Toxicity Rate|Complete or Partial Response Rate|Percent Tumor Necrosis|Event Free Survival Probability Disease Extent|Event Free Survival Probability Histologic Grade|Overall Survival Probability Disease Extent|Overall Survival Probability Extent of Resection of the Primary Tumor|Incidence of Distant Metastasis|Genetic and Gene Expression Profiles|Degree of Agreement in Histologic Grade Determined by the Enrolling Institution Versus by Central Pathology Reviewers|Degree of Agreement in Histologic Grade Between Pediatric Oncology Group (POG) and Fédération Nationale Des Centres de Lutte Contre le Cancer (FNCLCC) Pathologic Grading Systems	Phase 3	https://ClinicalTrials.gov/show/NCT00346164
NCT00398814	Completed	No Results Available	Drug: Perifosine|Drug: Sorafenib	Toxicity|Response or progression	Phase 1	https://ClinicalTrials.gov/show/NCT00398814
NCT02580253	Not yet recruiting	No Results Available	Drug: Individualized Chemotherapy|Drug: mFOLFOX6	Desease free Survival|Overall Survival	Phase 2	https://ClinicalTrials.gov/show/NCT02580253
NCT03592264	Recruiting	No Results Available	Drug: OBI-3424	Incidence and severity of adverse events (AEs)|Assess safety changes in electrocardiogram (ECG)|Assess safety changes of body weight.|Number of participants with dose limiting toxicities (DLTs)|Define the Recommended Phase 2 Dose (RP2D)|Pharmacokinetics (PK) - Time to maximum concentration (Tmax)|PK - Maximum peak plasma concentration (Cmax)|PK - The magnitude of the slope of the linear regression of the log concentration vs. time profile during the terminal phase (Kel)|PK - Half-life (T1/2)|PK - Area under the concentration-time curve (AUClast)	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT03592264
NCT03035006	Recruiting	No Results Available	Drug: Lipotecan	Maximum tolerated dose determination for Lipotecan based CCRT|Best objective response evaluation of portal vein tumor thrombosis|Conversion rate (CR) of portal vein tumor thrombosis|Best overall response of overall disease|Disease control rate of portal vein tumor thrombosis, liver tumors and overall disease|Time to progression of overall disease|Progression free survival of overall disease|Overall survival of overall disease	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT03035006
NCT03439761	Recruiting	No Results Available	Drug: PT-112 Injection	Adverse Event (AE)|Dose Limited Toxicity (DLT)|AE|Disease Control Rate (DCR)|DCR|Objective Response Rate (ORR)|Progress Free Survival(PFS)|Peak Plasma Concentration （Cmax）|Area under the plasma concentration versus time curve (AUC)|Peak time （Tmax）	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT03439761
NCT03475953	Recruiting	No Results Available	Drug: Phase 1 : Regorafenib|Drug: Phase 1 : Avelumab|Drug: Phase 2 : Regorafenib|Drug: Phase 2 : Avelumab	PHASE I : Recommended phase II dose (RP2D)|PHASE II (4 cohorts) : Assessment of the antitumor activity of regorafenib|PHASE I : Maximum Tolerated Dose (MTD)|PHASE I : Dose Limiting Toxicities (DLT)|PHASE I : Toxicity|PHASE I : Assessment of the antitumor activity of regorafenib - Best overall response|PHASE I :Assessment of the antitumor activity of regorafenib - objective response rate under treatment|PHASE I :Assessment of the antitumor activity of regorafenib - objective response rate|PHASE I :Assessment of the antitumor activity of regorafenib - non-progression|PHASE I :Assessment of the antitumor activity of regorafenib - progression-free survival (PFS)|PHASE I : Assessment of the antitumor activity of regorafenib - overall survival (OS)|PHASE I :Pharmacocinetics (PK) - Area Under Curve (AUC)|PHASE I :Pharmacocinetics (PK) - half-life for regorafenib.|PHASE I :PK - concentration peak for regorafenib.|Phase I: Predictive blood biomarkers analysis (cytokines levels) by ELISA.|Phase I: Predictive blood biomarkers analysis (lymphocytes) by flow cytmetry.|Phase I: Predictive tumor growth factor biomarkers analysis by immunohistochemistry.|Phase I: Adverses events graded using the common toxicity criteria from the NCI v4.03 to determine the safety profile of regorafenib plus avelumab.|PHASE II : Assessment of the antitumor activity of regorafenib - Best overall response|PHASE II : Assessment of the antitumor activity of regorafenib - objective response rate|PHASE II :Assessment of the antitumor activity of regorafenib - non progression|PHASE II : Assessment of the antitumor activity of regorafenib - Progression-Free Survival (PFS)|PHASE II : Assessment of the antitumor activity of regorafenib - Overall Survival|Phase II: Predictive blood biomarkers analysis (cytokines levels) by ELISA.|Phase II: Predictive blood biomarkers analysis (lymphocytes) by flow cytmetry.|Phase II: Predictive tumor growth factor biomarkers analysis by immunohistochemistry.	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT03475953
NCT02423343	Recruiting	No Results Available	Drug: Galunisertib|Drug: Nivolumab	Phase 1b: Maximum Tolerated Dose of Galunisertib in Combination with Nivolumab|Pharmacokinetics (PK): Minimum Concentration (Cmin) of Nivolumab|PK: Steady State Concentration of Galunisertib|Number of Participants with Anti-Nivolumab Antibodies When Administered in Combination with Galunisertib|Phase 2: Progression Free Survival (PFS)|Phase 2: Number of Participants who Achieve Best Overall Tumor Response of Complete Response or Partial Response: Objective Response Rate (ORR)|Phase 2: Duration of Response (DoR)|Phase 2: Time to Response|Phase 2: Overall Survival (OS)	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT02423343
NCT02759601	Active, not recruiting	No Results Available	Drug: Tefinostat	Determine Maximum Tolerated Dose|Response Assessment|Phase I & II: To determine pharmacokinetic parameters for tefinostat and CHR-2847 when administered orally at different dose levels and dose schedules.	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT02759601
NCT02102022	Recruiting	No Results Available	Drug: ADI-PEG 20	Number of Participants with Adverse Events as a Measure of Safety and Tolerability of ADI-PEG 20 in combination with folinic acid (leucovorin), fluorouracil and oxaliplatin (FOLFOX) in advanced GI malignancies.	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT02102022
NCT02178722	Active, not recruiting	No Results Available	Drug: MK-3475|Drug: INCB024360	Phase 1: Number of subjects with dose limiting toxicities (DLTs) of INCB024360 in combination with MK-3475|Phase 2: Objective response rate|Progression free survival|Number of subjects with Adverse Events as a Measure of Safety and Tolerability of INCB024360 in combination with MK-3475|Overall survival (OS)	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT02178722
NCT01631552	Active, not recruiting	No Results Available	Drug: IMMU-132	Safety|Efficacy	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT01631552
NCT02638857	Unknown status	No Results Available	Procedure: TACE|Biological: Dendritic Cell|Drug: lipiodol|Drug: Mitomycin (MMC)|Drug: Epirubicin(EADM)|Biological: Precision Multiple Antigen T Cell	Overall survival|Progress-free survival|Quality of life	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT02638857
NCT01752920	Active, not recruiting	No Results Available	Drug: ARQ 087	Adverse events graded by CTCAE v4.03 as a measure of the safety and tolerability profile of ARQ 087|Characterize the pharmacokinetic (PK) profile of ARQ 087|Assess pharmacodynamic (PD) activity of ARQ 087|Evaluate dose limiting toxicity (DLT) graded per CTCAE v4.03 to determine the recommended Phase 2 dosing (RP2D) regimen|Evaluate further the RP2D of ARQ 087 in subjects with FGFR genetic alterations, including subjects with iCCA with FGFR2 gene fusion (Part 2; Expanded Cohort, signal finding)|Evaluate tumor response assessed by RECIST v1.1 after treatment with ARQ 087	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT01752920
NCT01177397	Completed	No Results Available	Drug: CC-223	Safety|Pharmacokinetics|Pharmacodynamics|Efficacy	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT01177397
NCT00073736	Completed	No Results Available	Drug: MB07133 300mg/m2/day|Drug: MB07133 600 mg/m2/day|Drug: MB07133 1200 mg/m2/day|Drug: MB07133 1800 mg/m2/day|Drug: MB07133 2400 mg/m2/day	Safety and tolerability|Determine effect of MB07133 on tumor size	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT00073736
NCT00328770	Completed	Has Results	Drug: Sirolimus	Percentage of Participants Surviving at One and Four Years After Liver Transplant|Percentage of Participants Surviving With no Evidence of Recurrent Tumor at One and Four Years After Liver Transplant|Sirolimus Toxicity/Intolerance	Phase 2|Phase 3	https://ClinicalTrials.gov/show/NCT00328770
NCT03563170	Not yet recruiting	No Results Available	Biological: ALT-803|Biological: ETBX-011|Biological: GI-4000|Biological: haNK for infusion|Biological: avelumab|Drug: Capecitabine|Drug: Cyclophosphamide|Drug: 5-Fluorouracil|Drug: Leucovorin|Drug: nab-Paclitaxel|Drug: Sorafenib|Procedure: SBRT|Biological: Aldoxorubicin hydrochloride|Biological: ETBX-051|Biological: ETBX-061|Biological: GI-6207|Biological: GI-6301|Drug: Cetuximab	Incidence of treatment-emergent AEs and SAEs, graded using the NCI CTCAE Version 4.03|Progression Free Survival from baseline to progression, per RECIST 1.1|Overall Response Rate, as determined by the percentage of patients achieving Partial or Complete Response per RECIST 1.1|ORR for Phase 1b and Phase 2 Randomized Component|PFS for Phase 1b and Phase 2 Single Arm Component|OS for Phase 1b, Phase 2 Randomized, and Phase 2 Single Arm Component|DOR for Phase 1b, Phase 2 Randomized, and Phase 2 Single Arm Component|DCR for Phase 1b, Phase 2 Randomized, and Phase 2 Single Arm Component|QoL for Phase 1b, Phase 2 Randomized, and Phase 2 Single Arm Component|PFS for Phase 2 Randomized Component|Safety for Phase 2 Randomized and Single Arm Component|ORR for Phase 2 Single Arm Component	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT03563170
NCT03499626	Recruiting	No Results Available	Drug: ASLAN001	Definition of MTD (maximum tolerable dose)|Objective Response Rate|Progression Free Survival	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT03499626
NCT02115373	Completed	No Results Available	Drug: MSC2156119J	Number of Dose limiting toxicities (DLTs) occurring in Cycle 1|Time to Progression according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1|Progression free survival (PFS) according to RECIST version 1.1 and modified Response Evaluation Criteria in Solid Tumors (mRECIST) for HCC|Time-to-symptomatic progression according to RECIST version 1.1|Overall survival|Best overall response rate|Disease control rate|Biological response rate	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT02115373
NCT01988493	Active, not recruiting	No Results Available	Drug: MSC2156119J|Drug: Sorafenib	Number of Subjects Experiencing Dose Limiting Toxicity (DLT)|Number of Subjects With Adverse Events (AEs)|Time to Progression (TTP) Based on Tumor Assessment by an Independent Review Committee (IRC)|Progression Free Survival (PFS) Time Based on Tumor Assessment by the IRC|Overall Survival (OS) Time|TTP Assessed by Investigator|Time-to-Symptomatic Progression (TTSP)|Pharmacokinetic parameters: selected pharmacokinetics (PK) parameters calculated from observed plasma concentrations|Percentage of subjects with Objective Response (OR) Based on Tumor Assessment by the IRC|Percentage of Subjects With Disease Control by the IRC according to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) criteria|PFS Based on Tumor Assessment by the Investigator|OR Based on Tumor Assessment by the Investigator|Percentage of Subjects With Disease Control by the Investigator According to RECIST v1.1 criteria	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT01988493
NCT03203005	Recruiting	No Results Available	Drug: IMA970A plus CV8102 and Cyclophosphamide	Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)|Immunogenicity (T-cell response in peripheral blood)|Additional immunological parameters in blood (e.g. regulatory T-cells, myeloid-derived suppressor cells)|Infiltrating T-lymphocytes, immune cells and potential other (bio)markers in tumor tissue|Assessment of the potential impact of the standard therapy on the natural imune response to peptides contained in IMA970A|Time to progression (TTP)|Overall survival (OS)	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT03203005
NCT03130712	Recruiting	No Results Available	Drug: GPC3-CART cells	Safety of CAR-T cell infusion mediated by intratumoral injection as measured by number of participants with adverse Events|Number of participants with tumor response as measured by RECIST|Serum cytokine levels	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT03130712
NCT03084380	Not yet recruiting	No Results Available	Biological: Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs|Drug: Fludarabine|Drug: Cyclophosphamide	Safety: Measured by occurrence of study related adverse effects defined by NCI CTCAE 4.0|Efficacy: Overall complete remission rate defined by the standard response criteria|Persistence: Duration of CAR-positive T cells in circulation	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT03084380
NCT03071094	Recruiting	No Results Available	Biological: Pexastimogene Devacirepvec (Pexa Vec)|Drug: Nivolumab	Phase I part: To evaluate the safety profile of intratumoral (IT) Pexa-Vec combined with intravenous (IV) nivolumab in patients with advanced HCC. Dose Limiting Toxicities (DLTs)|Phase IIa part: To evaluate the anti-tumor activity and efficacy of IT Pexa-Vec combined with IV nivolumab in patients with advanced HCC with respect to Overall Response Rate (ORR) (RECIST 1.1).|Disease Control Rate (DCR) at 4 months|Overall Survival (OS)	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT03071094
NCT02859324	Recruiting	No Results Available	Drug: CC-122|Drug: Nivolumab	Dose Limiting Toxicity (DLT)|Adverse Events (AEs)|Overall Response Rate (ORR) - Phase 2|Disease control rate (DCR)|Duration of response (DoR)|Progression free survival (PFS)|Overall survival (OS)|Time to progression (TTP)|Pharmacokinetic - Cmax|Pharmacokinetic - AUC|Pharmacokinetic - Tmax|Pharmacokinetic - t1/2|Pharmacokinetic - CL/F|Pharmacokinetic - Vz/F	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT02859324
NCT02795429	Recruiting	No Results Available	Drug: PDR001|Drug: INC280	Number of participants with Dose Limiting Toxicities (DLTs)|Overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)|Best overall response (BOR)|Duration of overall response (DOR)|Time to response (TTR)|Progression-free survival (PFS)|Time to progression (TTP)|Overall survival (OS)|Overall response rate (ORR)|Tiime to progression (TTP)|Pharmacokinetics: Area under the plasma concentration versus time curve (AUC) (INC280)|PK: Area under the serum concentration versus time curve (AUC) (PDR001)|PK: Plasma concentration vs. time profiles (INC280)|PK:Serum concentration vs. time profiles (PDR001)|PK: Peak Plasma Concentration (Cmax) (INC280)|PK:Time of Maximum concentration observed (Tmax) (INC280)|PK: Peak Serum Concentration (Cmax) (PDR001)|PK: Time of Maximum concentration observed (Tmax) (PDR001)	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT02795429
NCT02772029	Unknown status	No Results Available	Drug: Apatinib Mesylate Tablets	time to progression|overall survival	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT02772029
NCT02715362	Recruiting	No Results Available	Drug: TAI-GPC3-CART cells	Safety of CAR-T cell infusion mediated by TAI as measured by number of participants with adverse Events|Number of participants with tumor response as measured by RECIST|Detection of CART cells in the circulation using quantitative -PCR|Serum cytokine levels	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT02715362
NCT02650271	Recruiting	No Results Available	Drug: Entecavir|Drug: Lamivudine	overall survival|Recurrence rate	Phase 2|Phase 3	https://ClinicalTrials.gov/show/NCT02650271
NCT02642913	Recruiting	No Results Available	Drug: Enzalutamide|Drug: Enzalutamide with Sorafenib	Progression-free survival	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT02642913
NCT02584556	Unknown status	No Results Available	Drug: systemic chemotherapy|Drug: Transcatheter Arterial Chemoembolization	recurrence free survival|Overall survival|Time to Recurrence|Time to Recurrence within liver|Time of tumor distant metastasis	Phase 2|Phase 3	https://ClinicalTrials.gov/show/NCT02584556
NCT02560779	Recruiting	No Results Available	Drug: TRC105|Drug: Sorafenib	Maximum Tolerated Dose of TRC105 in Combination with Sorafenib (Phase 1b).|Preliminary evidence of antitumor activity when TRC105 is added to sorafenib will be assessed by Overall Response Rate (ORR). (Phase 1b)|Preliminary evidence of antitumor activity when TRC105 is added to sorafenib will be assessed by Progression-Free Survival (PFS). (Phase 1b)|Pharmacokinetic profile of TRC105 and sorafenib when given together (Phase 1b and Phase 2)|TRC105 immunogenicity as assessed by Anti-Product Antibody (APA). (Phase 1b and Phase 2)|Changes in circulating angiogenic biomarkers following treatment with TRC105 and sorafenib. (Phase 1b and Phase 2)|Frequency and severity of adverse events as assessed by NCI CTCAE (Version 4.03). (Phase 1b and Phase 2)	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT02560779
NCT02534337	Unknown status	No Results Available	Drug: GEMOX|Drug: FOLFOX4	Progression-Free-Survival|Objective response rate|Overall survival|Disease control rate|Time-to-Progression	Phase 2|Phase 3	https://ClinicalTrials.gov/show/NCT02534337
NCT02527772	Active, not recruiting	No Results Available	Drug: Liposomal Doxorubicin+Gemcitabine|Drug: FOLFOX4	Progression-Free-Survival|Objective response rate|Overall survival|Disease control rate|Time-to-Progression	Phase 2|Phase 3	https://ClinicalTrials.gov/show/NCT02527772
NCT02400788	Completed	No Results Available	Drug: Resminostat|Drug: Sorafenib	Phase 1 : Number of participants with dose limited toxicities as measure of safety and tolerability|Phase 2 : Time To Progression (TTP)	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT02400788
NCT02279719	Recruiting	No Results Available	Drug: BBI608|Drug: BBI503|Drug: Sorafenib	Determination of the Recommended Phase 2 Dose (RP2D) by assessing dose-limiting toxicities (DLTs) (Phase 1 portion)|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Assessment of the preliminary anti-tumor activity by performing tumor assessments every 8 weeks (Phase 2 portion)|Pharmacokinetic profile of BBI608 or BBI503 when administered in combination with sorafenib as assessed by maximum plasma concentration and area under the curve|Pharmacodynamic activity of BBI608 or BBI503 when administered in combination with sorafenib as assessed by tumor biopsy and Cancer Stem Cell assays as well as the concentration of study drug in tumors	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT02279719
NCT02240771	Unknown status	No Results Available	Procedure: Transarterial chemotherapy|Drug: Oral chemotherapy	Survival rate-|Tumor response	Phase 2|Phase 3	https://ClinicalTrials.gov/show/NCT02240771
NCT01271504	Completed	No Results Available	Drug: Sorafenib	Safety Parameters-Adverse Event (AEs)|Safety Parameter-Concomitant Meds|Safety Parameter- Clinical Laboratory Evaluations|Safety Parameter-ECGS|Safety Parameters-Vital signs|Safety Parameters- ECOG PS|Efficacy Parameter	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT01271504
NCT02645981	Recruiting	No Results Available	Drug: Donafenib|Drug: Sorafenib	Overall Survival|Progress Free Survival|Percentage of adverse events	Phase 2|Phase 3	https://ClinicalTrials.gov/show/NCT02645981
NCT02024087	Completed	No Results Available	Drug: Dalantercept plus sorafenib	Number of participants with Adverse Events as a measure of safety and tolerability.|Progression free survival (PFS)|Overall survival (OS)|Time to progression (TTP)|Disease control rate (DCR)|PD biomarker activities (e.g., ALK1 expression on new or archived tumor biopsy tissue; BMP9/10 levels in serum)	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT02024087
NCT02013778	Recruiting	No Results Available	Drug: HCQ	Number of Adverse Events	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT02013778
NCT01906216	Recruiting	No Results Available	Drug: Sorafenib|Procedure: TACE	Overall survival|Time to progression|Tumor response|Adverse events	Phase 2|Phase 3	https://ClinicalTrials.gov/show/NCT01906216
NCT00768937	Completed	No Results Available	Drug: Sorafenib|Procedure: Transarterial chemoembolisation (TACE)	Time to Progression (Efficacy)|Safety of Sorafenib in combination with TACE	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT00768937
NCT01747642	Unknown status	No Results Available	Dietary Supplement: Oncoxin|Drug: Suranix	Number of patients who have prolonged survival|Reduction in serum alpha-fetoprotein level and decrease in tumor size	Phase 2|Phase 3	https://ClinicalTrials.gov/show/NCT01747642
NCT02229071	Completed	No Results Available	Drug: Donafenib(200mg)|Drug: Donafenib(300mg)	Safety|Time to progression(TTP)	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT02229071
NCT00561522	Unknown status	No Results Available	Drug: Capecitabine|Other: No other preventive treatment	The primary end point was to determine the effect on disease-free survival and overall survival by oral capecitabine.|The secondary end point was to analyze the relationship between preventive effectiveness of capecitabine with thymidine phosphorylase expression level of tumor tissue.	Phase 2|Phase 3	https://ClinicalTrials.gov/show/NCT00561522
NCT00882869	Completed	No Results Available	Drug: AEG35156 antisense IV infusion|Drug: Sorafenib	To determine the recommended dose of AEG35156 in combination with sorafenib patients with advanced HCC|To evaluate the efficacy of AEG35156 in combination with sorafenib based on PFS(PII) using sorafenib alone for comparison|To determine the safety profile of AEG35156 in combination with sorafenib in advanced HCC|To determine the response rate of AEG35156 in combination with sorafenib in advanced HCC	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT00882869
NCT01438450	Unknown status	No Results Available	Drug: Oral|Other: Supportive	Survival|Tumour response|Number of patients with side effects|Quality of life|Change from baseline in Child status at 1 year	Phase 2|Phase 3	https://ClinicalTrials.gov/show/NCT01438450
NCT01406574	Completed	Has Results	Drug: OPB-31121|Drug: OPB-31121 phase2	Subjects With Treatment Emergent Adverse Events|Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)|Best Overall Response	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT01406574
NCT00495846	Completed	No Results Available	Drug: Octreotide-LAR, Lanreotide Autogel|Other: Locoregional treatments	Prolongation of the survival curve (>6 months)|Improvement of liver function, Reduction of biological markers of disease (if elevated before starting the treatment)|Improvement of quality of life according with SF36 questionnaire	Phase 2|Phase 3	https://ClinicalTrials.gov/show/NCT00495846
NCT02465060	Recruiting	No Results Available	Drug: Adavosertib|Drug: Afatinib|Drug: Binimetinib|Drug: Capivasertib|Drug: Crizotinib|Other: Cytology Specimen Collection Procedure|Drug: Dabrafenib|Drug: Dasatinib|Drug: Defactinib|Drug: FGFR Inhibitor AZD4547|Other: Laboratory Biomarker Analysis|Drug: Larotrectinib|Biological: Nivolumab|Drug: Osimertinib|Drug: Palbociclib|Biological: Pertuzumab|Drug: PI3K-beta Inhibitor GSK2636771|Drug: Sapanisertib|Drug: Sunitinib Malate|Drug: Taselisib|Drug: Trametinib|Biological: Trastuzumab|Biological: Trastuzumab Emtansine|Drug: Vismodegib	Objective response rate, defined as the percentage of patients whose tumors have a complete or partial response to treatment|Overall survival, evaluated specifically for each drug (or step)|Progression free survival|Time to progression	Phase 2	
NCT01116635	Completed	No Results Available	Drug: doxorubicin, superabsorbent polymer microspheres, embolotherapy	Histopathological correlation with surgically resected tumor|Dose limiting toxicities|serum doxorubicin release patter|maximum tolerated dose	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT01116635
NCT00946153	Completed	No Results Available	Drug: E7080	Dose-Escalation Component: To determine the MTD defined by dose-limiting toxicity (DLT) of E7080. Safety assessments based on adverse events, physical exams, and selected lab values.|Expansion Component: Time to progression.|Dose-Escalation Component: To evaluate the anti-tumor effect of E7080 using Response Evaluation Criteria in Solid Tumors (RECIST).|Expansion Component: Progression-free survival.|Expansion Component: Objective response rate.|Expansion Component: Disease control rate.|Expansion Component: Overall survival.	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT00946153
NCT02129322	Not yet recruiting	No Results Available	Drug: Sorafenib|Drug: S-1|Drug: Oxaliplatin	Time to Recurrence (TTR)|Overall survival (OS)	Phase 2	https://ClinicalTrials.gov/show/NCT02129322
NCT03289533	Recruiting	No Results Available	Drug: Avelumab (MSB0010718C)|Drug: Axitinib (AG-013736)	Adverse events (AEs) and laboratory abnormalities as graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v. 4.03.|Time to Progression (TTP)|Overall Survival (OS)|Maximum plasma concentration (Cmax) of avelumab|Maximum plasma concentration (Cmax) of axitinib|Tumor tissue biomarker status (ie, positive or negative based on, for example, PD-L1 expression and/or quantitation of tumor infiltrating CD8+ T lymphocytes as assessed by immunohistochemistry [IHC]).|Anti drug antibodies (ADAs, neutralizing antibodies [nAbs]) for avelumab when in combination with axitinib.|Progression Free Survival (PFS)|Objective Response (OR)|Time to Tumor Response (TTR)|Duration of Response (DR)|Trough plasma concentration (Ctrough) of avelumab|Trough plasma concentration (Ctrough) of axitinib|Disease Control (DC)	Phase 1	https://ClinicalTrials.gov/show/NCT03289533
NCT03482102	Recruiting	No Results Available	Drug: Tremelimumab|Drug: Durvalumab|Radiation: Radiation	Best Overall Response rate|Number of Participants With Treatment Related Adverse Events|Overall Survival|Disease Control Rate|Progression Free Survival|Duration of Response|Time to Disease Progression	Phase 2	https://ClinicalTrials.gov/show/NCT03482102
NCT01251458	Completed	No Results Available	Drug: Torisel	• To establish the maximum tolerated dose (MTD) and a suitable dose for Phase II evaluation of Torisel® given as a weekly dose in patients with advanced hepatocellular carcinoma (HCC)|• To determine and establish the safety and toxicity profile of Torisel® and to identify any dose limiting toxicities (DLTs) in advanced HCC|• To determine progression-free survival (PFS) in patients with advanced hepatocellular carcinoma (HCC) treated with Torisel®|• To correlate stathmin expression in pre-treatment HCC tumour biopsies and clinical response to Torisel®|• To determine the response rate (CR and PR) based on RECIST criteria|• To determine clinical benefit rate (CBR, percent of patients experiencing CR, PR or SD ≥ 12 weeks)|• To determine duration of response (DR)|• To determine overall survival (OS)	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT01251458
NCT00843934	Unknown status	No Results Available	Drug: epirubicin|Drug: Cisplatin	response rate	Phase 2|Phase 3	https://ClinicalTrials.gov/show/NCT00843934
NCT00784290	Completed	No Results Available	Drug: Orantinib (TSU-68)	Step 1(Phase I) Safety|Step 2(Phase II) Response rate(RR)|Step 1(Phase I) Response rate(RR)|Step 2(Phase II) Safety	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT00784290
NCT00731445	Completed	No Results Available	Drug: Z-208	Phase I: Determine the maximum tolerated dose (MTD) of Z-208 in patients with advanced hepatocellular carcinoma|Phase II : Assess the objective tumor response rate in patients according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria|Phase I : Assess the objective tumor response rate in patients according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria|Phase I : Determine the pharmacokinetics of this drug in these patients|Phase I : Determine the adverse effects profile of this drug in these patients|Phase II: Determine the PFS	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT00731445
NCT00712790	Completed	No Results Available	Drug: Sorafenib|Radiation: SIR-Spheres	Toxicity and safety|Tumour response rate (liver ± any site).|Progression free survival at any site.|Progression free survival in the liver.|Survival|Hepatic and extra-hepatic recurrence rate.|Quality of life.|Rate of downstaging to surgical resection or ablative therapy.	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT00712790
NCT00933816	Completed	No Results Available	Drug: sorafenib, cisplatin, fluorouracil	Dose limiting toxicity in phase I and Time to progression in Phase II|Phase I and II: Overall survival (OS)|Phase I and II: Progression free survival (PFS)|Phase I: Time to progression (TTP)|Phase I and II: Response Rate (RR)|Phase I and II: Adverse effect (AE)	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT00933816
NCT00819650	Completed	No Results Available	Drug: Licartin (generic name,[131I]metuximab injection)	Overall survival|Time to recurrence	Phase 2	https://ClinicalTrials.gov/show/NCT00819650
NCT00820053	Completed	No Results Available	Drug: epirubicin and lipiodol	Overall survival|Time to recurrence	Phase 2	https://ClinicalTrials.gov/show/NCT00820053
NCT00390195	Unknown status	No Results Available	Drug: RAD001 (everolimus)	Maximum tolerated dose in Phase I|Disease control rate in Phase II|Angiogenic factors|Pharmacokinetics|Pharmacogenetics|Pharmacodynamics|Overall survival|Time to tumor progression|Tumor marker	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT00390195
NCT03044587	Recruiting	No Results Available	Drug: Arm NaI-IRI + 5-FU + Leucovorin (Arm A)|Drug: Arm Cisplatin + Gemcitabine (Arm B)	Progression-free survival [PFS]|Overall progression free survival according to RECIST 1.1|3-years overall survival|Disease control rate according to RECIST 1.1|Objective tumor response rate (ORR) according to RECIST 1.1|Toxicity/Safety according to CTC-AE-criteria|Health related quality of life|Retrospective correlation of resectability in accordance with a central surgical board compared to local surgical review|Retrospective central radiological review	Phase 2	https://ClinicalTrials.gov/show/NCT03044587
NCT00155272	Unknown status	No Results Available	Drug: Thalidomide	The primary endpoint is the feasibility and tolerability of thalidomide plus radiotherapy.|The secondary end point is correlation of parameters of tumor perfusion assessed by DCEMRI and serum cytokine levels with objective tumor response.	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT00155272
NCT03511222	Not yet recruiting	No Results Available	Drug: Vorolanib|Drug: Nivolumab|Drug: Pembrolizumab|Procedure: Peripheral blood draw	Recommended phase II dose (RP2D) of vorolanib plus pembrolizumab|Recommended phase II dose (RP2D) of vorolanib plus nivolumab|Safety and toxicity of vorolanib plus pembrolizumab as measured by the number and type of adverse events experienced by participant|Safety and toxicity of vorolanib plus nivolumab as measured by the number and type of adverse events experienced by participant|Objective response rate (ORR)|Optimal duration of treatment regimen|Overall survival (OS)|Progression-free survival (PFS)|Immune-related progression-free survival (irPFS)	Phase 1	https://ClinicalTrials.gov/show/NCT03511222
NCT03515369	Not yet recruiting	No Results Available	Drug: Babaodan oral capsule|Drug: Placebo oral capsule	3-year disease free survival|disease free survival|overall survival|EORTC QLQ-C30	Phase 4	https://ClinicalTrials.gov/show/NCT03515369
NCT03539822	Not yet recruiting	No Results Available	Drug: Cabozantinib|Drug: Durvalumab	Maximum Tolerated Dose (MTD)|Proportion of participants with adverse events (AEs).|Overall Response Rate (ORR)|Overall Benefit Rate (OBR)|Progression Free Survival (PFS)|Overall Survival (OS)	Phase 1	https://ClinicalTrials.gov/show/NCT03539822
NCT03507998	Recruiting	No Results Available	Drug: CGX1321	Number of participants with adverse events and/or abnormal laboratory values that are related to treatment|CGX1321 maximum or peak concentration|CGX1321 minimum or trough concentration|CGX1321 time to maximum concentration|CGX1321 half life	Phase 1	https://ClinicalTrials.gov/show/NCT03507998
NCT00273247	Completed	No Results Available	Drug: Interferon alpha-2b	Recurrence Free Survival|Disease Specific Survival|Overall Patient Survival	Phase 3	https://ClinicalTrials.gov/show/NCT00273247
NCT03144661	Recruiting	No Results Available	Drug: INCB062079	Safety and tolerability of INCB062079 as measured by assessment of adverse events (AEs)|Tumor response rates in subjects with measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST)|Cmax of INCB062079|Tmax of INCB062079|Cmin of INCB062079|AUC0-t of INCB062079|t½ of INCB062079|Cl/F of INCB062079|Analysis of biomarkers	Phase 1	https://ClinicalTrials.gov/show/NCT03144661
NCT02423239	Unknown status	No Results Available	Drug: Dexanabinol|Drug: Sorafenib|Drug: Nab-paclitaxel|Drug: Gemcitabine	Maximum Tolerated Dose (MTD) of dexanabinol given in combination with standard chemotherapies|Number of adverse events (AEs) in patients receiving dexanabinol monotherapy|Number of adverse events (AEs) in patients receiving dexanabinol in combination with standard chemotherapies|Area under curve (AUC) of dexanabinol and (where applicable) combination chemotherapy|Maximum concentration (Cmax) of dexanabinol and (where applicable) combination chemotherapy|Minimum concentration (Cmin) of dexanabinol and (where applicable) combination chemotherapy|Tumour response ( RECIST 1.1, assessment by CT or MRI)	Phase 1	https://ClinicalTrials.gov/show/NCT02423239
NCT03101488	Recruiting	No Results Available	Drug: KN035	Incidence of dose limiting toxicities (DLTs) in dose escalation study|Percentage of participants with adverse events (AEs), serious adverse events and AEs of special interest|ORR of HCC patients in dose expansion study|Peak Plasma Concentration (Cmax) of KN035 in Chinese patients|Peak Time (Tmax) of KN035 in Chinese patients|Area under the plasma concentration versus time curve (AUC) of KN035 in Chinese patients|t1/2 of KN035 in Chinese patients|Trough concentration of KN035 in Chinese patients|Plasma clearance (CL) of KN035 in Chinese patients|Apparent volume of distribution of KN035 in Chinese patients|Accumulation rate of KN035 in Chinese patients|Anti-Drug Antibody of KN035 in Chinese patients|Changes of lymphocyte Subtyping|Changes of cytokine|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Progression-Free survival (PFS)|Duration of Response (DOR)|Correlation of tumor response with the PD-L1 expression|Correlation of the tumor response with the expression of specific gene mutation	Phase 1	https://ClinicalTrials.gov/show/NCT03101488
NCT03222076	Recruiting	No Results Available	Drug: Nivolumab|Drug: Ipilimumab	Safety of Nivolumab Alone or Nivolumab plus Ipilimumab in Participants with Hepatocellular Carcinoma (HCC) Determined by Adverse Events|Objective Response Rate (ORR)|Progression-free survival (PFS)|Conversion Rate to Surgery for Potentially Resectable Participants.	Phase 2	https://ClinicalTrials.gov/show/NCT03222076
NCT02354898	Recruiting	No Results Available	Drug: BBI503|Drug: Sorafenib	Determine of the Maximum Tolerated Dose (MTD) of BBI503 monotherapy and in combination with Sorafenib by assessing dose-limiting toxicities (DLTs)|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Pharmacokinetic profile of BBI503|Assessment of the preliminary anti-tumor activity by performing tumor assessments approximately every 8 weeks|Progression Free Survival|Overall Survival	Phase 1	https://ClinicalTrials.gov/show/NCT02354898
NCT03319459	Recruiting	No Results Available	Drug: FATE-NK100|Drug: Cetuximab|Drug: Trastuzumab	Incidence of dose-limiting toxicity (DLT)|Objective-response rate (ORR)|FATE-NK100 persistence	Phase 1	https://ClinicalTrials.gov/show/NCT03319459
NCT02572687	Active, not recruiting	No Results Available	Drug: Ramucirumab|Drug: MEDI4736	Number of Participants with Dose Limiting Toxicities (DLTs)|Percentage of Participants with a Best Response of Complete Response (CR) or Partial Response (PR): Objective Response Rate (ORR)|Proportion of Participants with a Best Overall Response of CR, PR, or Stable Disease (SD): Disease Control Rate (DCR)|Duration of Response (DoR)|Time to First Response (TTR)|Progression Free Survival (PFS)|Overall Survival (OS)|Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ramucirumab and MEDI4736|PK: Minimum Concentration (Cmin) of Ramucirumab and MEDI4736|Number of Participants with Treatment Emergent Anti Ramucirumab Antibodies|Number of Participants with Treatment Emergent Anti MEDI4736 Antibodies	Phase 1	https://ClinicalTrials.gov/show/NCT02572687
NCT03095781	Recruiting	No Results Available	Drug: XL888|Biological: Pembrolizumab	Recommended phase II dose of the combination of XL888 and pembrolizumab as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Overall response rate as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1|Overall survival|Progression free survival|Response duration as assessed by RECIST 1.1	Phase 1	https://ClinicalTrials.gov/show/NCT03095781
NCT02262455	Completed	No Results Available	Drug: STM 434|Drug: Liposomal doxorubicin	Maximum Tolerated Dose (MTD)|Recommended Phase 2 dose (RP2D)|Radiographic response rate|Muscle function and body composition	Phase 1	https://ClinicalTrials.gov/show/NCT02262455
NCT01546519	Completed	Has Results	Drug: Vismodegib	Maximum Observed Plasma Concentration and Concentration at Steady-state Following Multiple Doses of Vismodegib|The Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUC[0-24hours]) Following Multiple Doses of Vismodegib|The Percentage of Dose of Vismodegib in 24-hour Total Urine|Renal Clearance of Vismodegib|Amount of Vismodegib Excreted Into Urine in 24 Hours (Ae0-24hr)|Time to Maximum Plasma Concentration (Tmax) of Vismodegib|Minimum Plasma Concentration (Cmin) of Vismodegib|Apparent Clearance (CL/F) of Vismodegib|Apparent Non-renal Clearance (CLNR/F) of Vismodegib	Phase 1	https://ClinicalTrials.gov/show/NCT01546519
NCT03407001	Recruiting	No Results Available	Procedure: Ultrasound|Drug: Lumason	Accuracy of contrast enhanced ultrasound (CEUS) utilizing contrast agent compared to B-mode non-contrast enhanced ultrasound for liver lesion detection, including hepatocellular carcinoma (HCC), in cirrhotic US patients	Early Phase 1	https://ClinicalTrials.gov/show/NCT03407001
NCT03009461	Recruiting	No Results Available	Procedure: HAIC|Drug: Sorafenib	Overall survival	Phase 2	https://ClinicalTrials.gov/show/NCT03009461
NCT03192644	Recruiting	No Results Available	Procedure: TAI|Procedure: TACE|Drug: epidoxorubicin and cisplatin and lipiodol|Drug: mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)	recurrence-free survival (RFS)|recurrence rate|Overall survival (OS)	Phase 3	https://ClinicalTrials.gov/show/NCT03192644
NCT03219372	Recruiting	No Results Available	Drug: Pravastatin Pill|Drug: Placebo Oral Tablet	Time to Recurrence|Recurrence Free Survival|Overall Survival|Waitlist drop-off|Change in liver stiffness|Change in liver fat fraction|Change in Inflammatory Biomarkers	Phase 2	https://ClinicalTrials.gov/show/NCT03219372
NCT03313596	Recruiting	No Results Available	Drug: ADV-Tk|Procedure: LT	Progression-free survival, PFS|Overall survival, OS|Time of the tumor progression,TTP|Median overall survival time	Phase 3	https://ClinicalTrials.gov/show/NCT03313596
NCT02387307	Unknown status	No Results Available	Drug: rSIFN-co	To determine the safety and tolerability of rSIFN-co|To determine the RD of rSIFN-co for solid tumors|To evaluate extended safety and antitumor efficacy (Disease Control Rate) of rSIFN-co at the RD|To determine the objective response rate (ORR), progression-free survival (PFS), and time to progression (TTP) on rSIFN-co|To determine the FDG-PET response before and after administration of rSIFN-co	Phase 1	https://ClinicalTrials.gov/show/NCT02387307
NCT02029690	Active, not recruiting	No Results Available	Drug: ADI-PEG 20	Define initial estimates of efficacy, measured by RECIST 1.1 criteria for non-squamous NSCLC, advanced peritoneal mesothelioma, metastatic uveal melanoma, HCC, glioma and sarcomatoid cancers for ADI-PEG 20 in combination with pemetrexed and cisplatin.|Define initial estimates of efficacy, measured by modified RECIST criteria for advanced MPM|Determine the MTD of ADI-PEG 20 in combination with pemetrexed and cisplatin	Phase 1	https://ClinicalTrials.gov/show/NCT02029690
NCT01174121	Recruiting	No Results Available	Biological: Young TIL|Drug: Aldesleukin|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Pembrolizumab	Rate of tumor regression|Frequency of treatment related to adverse events|Safety and efficacy of pembrolizumab following TIL therapy	Phase 2	https://ClinicalTrials.gov/show/NCT01174121
NCT02315066	Recruiting	No Results Available	Drug: PF-04518600|Drug: PF-04518600 plus PF-05082566	Number of participants with Dose-limiting toxicities (DLT) [Dose Escalation]|Overall safety profile [Dose Expansion]|Incidence of anti-drug antibodies and neutralization assays|Number of participants with objective response|Unbound (free) cell surface OX40 in peripheral blood|Maximum Observed Plasma Concentration (Cmax)|Area under the concentration versus time curve (AUCt)	Phase 1	https://ClinicalTrials.gov/show/NCT02315066
NCT02755311	Unknown status	No Results Available	Procedure: liver resection|Procedure: transarterial chemoembolization|Drug: carboplatin|Drug: lipiodol|Drug: epirubicin , pirarubicin , hydroxycamptothecin and fluorouracil|Other: absorbable gelatin sponge particles	Overall survival|Mortality	Phase 3	https://ClinicalTrials.gov/show/NCT02755311
NCT03017326	Recruiting	No Results Available	Drug: Cisplatin|Drug: Doxorubicin|Drug: Carboplatin|Drug: 5Fluorouracil|Drug: Vincristine|Drug: Etoposide|Drug: Irinotecan|Drug: Gemcitabine|Drug: Oxaliplatin|Drug: Sorafenib	Event-free survival (EFS)|Response in HCC is defined as complete (CR) or partial (PR) response according to RECIST version 1.1 criteria|Failure-free survival (FFS)|Overall survival (OS)|Toxicity categorized and graded using Common Terminology Criteria for Adverse Events (CTCAE)|Chemotherapy-related cardiac, nephro- and oto-toxicity using Common Terminology Criteria for Adverse Events (CTCAE)|Hearing loss according to the SIOP Boston Scale|Best Response|Surgical resectability defined as complete resection, partial resection or transplant|Adherence to surgical guidelines	Phase 3	https://ClinicalTrials.gov/show/NCT03017326
NCT02232633	Active, not recruiting	No Results Available	Drug: BBI503	Disease Control Rate (DCR)|Objective response rate (ORR)|Progression free survival (PFS)|Overall survival (OS)|Pharmacodynamics (biomarkers) of BBI503 when tumor biopsy is possible|Number of Patients with Adverse Events	Phase 2	https://ClinicalTrials.gov/show/NCT02232633
NCT02973516	Recruiting	No Results Available	Drug: P03277	Diagnosis value	Phase 2	https://ClinicalTrials.gov/show/NCT02973516
NCT00849264	Completed	No Results Available	Drug: chemotherapy with endostar|Drug: treatment with CBP and 5-FU|Drug: treatment with endostar, CBP and 5-FU	overall survival|disease-free survival	Phase 2	https://ClinicalTrials.gov/show/NCT00849264
NCT03468231	Recruiting	No Results Available	Drug: Sorafenib|Drug: HAIC of FOLFOX|Drug: HAIC of OXA	Overall survival|Progress free survival|Adverse Events|Number of of Patients developed Adverse Events|Tumor response	Phase 3	https://ClinicalTrials.gov/show/NCT03468231
NCT01953926	Recruiting	No Results Available	Drug: Neratinib|Drug: Paclitaxel|Drug: Fulvestrant|Drug: Trastuzumab	Objective Response Rate (ORR first)|Objective Response Rate (ORR)|Progression-free survival (PFS)|Clinical Benefit Rate (CBR)|Duration of Response (DOR)|Overall Survival (OS)|Safety (Adverse Events [AEs] and Serious Adverse Events [SAEs])	Phase 2	https://ClinicalTrials.gov/show/NCT01953926
NCT02074202	Unknown status	No Results Available	Drug: 18F- fluorocholine|Drug: 18F- fluorodeoxyglucose	The pathological diagnosis of the liver tumor will be compared with the test result of the PET/CT scan findings.	Phase 3	https://ClinicalTrials.gov/show/NCT02074202
NCT02650427	Recruiting	No Results Available	Drug: Sitagliptin	Safety (Number of adverse events. Toxicity grade > 3)|DPPIV Activity|CXCL10 truncation|Immune cells trafficking|Infiltration of leucocytes in tumor tissue	Phase 1	https://ClinicalTrials.gov/show/NCT02650427
NCT00923481	Completed	Has Results	Drug: Fostamatinib disodium	Response Rate|Number of Participants With Adverse Events	Phase 2	https://ClinicalTrials.gov/show/NCT00923481
NCT01522820	Completed	No Results Available	Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Sirolimus	Incidence of adverse events in patients receiving the DEC-205/NY-ESO-1 fusion protein CDX-1401 with and without sirolimus, as evaluated according to the NCI CTCAE scale version 4.0|NY-ESO-1 specific cellular immunity|NY-ESO-1 specific humoral immunity	Phase 1	https://ClinicalTrials.gov/show/NCT01522820
NCT01482442	Completed	No Results Available	Drug: sorafenib|Drug: SIR-Sphere	Median overall survival time|Common Terminology Criteria for Adverse Events|Progression-free survival|Response rate|General and hepatic specific quality of life scores|Health care costs	Phase 3	https://ClinicalTrials.gov/show/NCT01482442
NCT01575574	Completed	No Results Available	Drug: GADOXETIC ACID	hepatocellular carcinoma diagnosed|magnetic resonance imaging sensitivity	Phase 4	https://ClinicalTrials.gov/show/NCT01575574
NCT01733004	Completed	No Results Available	Drug: MM-141	Severity and number of adverse events related to escalating doses of MM-141	Phase 1	https://ClinicalTrials.gov/show/NCT01733004
NCT02586285	Unknown status	No Results Available	Drug: S-Adenosyl Methionine	Time to tumor recurrence|Overall survival	Phase 1	https://ClinicalTrials.gov/show/NCT02586285
NCT00630084	Completed	No Results Available	Drug: pegylated interferon alpha 2a and plus ribavirin	Efficacy - Sustained virological response (SVR), HCV RNA seronegative by PCR throughout 24-week off-treatment period.|Rapid virologic response (RVR), HCV RNA seronegative by PCR at week 4.|Early virological response (EVR), by PCR-negative or at least 2 logs decline from baseline of serum HCV RNA at 12 weeks of treatment.|Safety - adverse event rate and profile	Phase 4	https://ClinicalTrials.gov/show/NCT00630084
NCT02452853	Unknown status	No Results Available	Procedure: HR|Drug: FOLFOX4	Recurrence rate|Number of Complications reported using the National Cancer Institute Common Toxicity Criteria grading version 4.0|Recurrence-free survival|Overall survival	Phase 2	https://ClinicalTrials.gov/show/NCT02452853
NCT02182687	Recruiting	No Results Available	Radiation: Stereotactic Body Radiation Therapy (SBRT)|Procedure: Trans-Arterial Chemoembolization (TACE)|Drug: Doxorubin	Time to first additional intervention to the treated lesions|Toxicity|Number of further interventions|Pathologic response of treated lesion(s)|Radiologic response of treat lesion(s)|Quality of Life	Phase 2	https://ClinicalTrials.gov/show/NCT02182687
NCT03116984	Recruiting	No Results Available	Procedure: Transcatheter arterial chemoembolization|Radiation: external- beam radiotherapy|Drug: Adriamycin|Drug: Lipiodol	3-year overall survival(OS)	Phase 3	https://ClinicalTrials.gov/show/NCT03116984
NCT00375245	Completed	No Results Available	Drug: Rapamycin (sirolimus)|Other: Grapefruit Juice	Pharmacokinetic interaction	Phase 1	https://ClinicalTrials.gov/show/NCT00375245
NCT01272557	Unknown status	No Results Available	Drug: Doxorubicin|Drug: Sorafenib	Time to progression (TTP) according to RECIST 1.1 criteria|• Assessment of overall survival (OS) of disease control rate (CR, PR, SD) to RECIST 1.1 criteria and to EASL criteria • Assessment of safety and quality of life (FACT-Hep) and potential of biomarkers to predict the tumor response	Phase 2	https://ClinicalTrials.gov/show/NCT01272557
NCT00526617	Completed	No Results Available	Drug: ABT-888|Drug: Temozolomide	Maximum Tolerated Dose|Safety and Tolerability|Pharmacokinetic Profile	Phase 1	https://ClinicalTrials.gov/show/NCT00526617
NCT02301091	Recruiting	No Results Available	Procedure: TACE|Procedure: RFA|Drug: pirarubicin,mitomycin and lobaplatin	Overall survival rates|Progression-free survival rates|Response rate of PVTT|Number of participants with adverse events	Phase 3	https://ClinicalTrials.gov/show/NCT02301091
NCT03591965	Not yet recruiting	No Results Available	Drug: ATG-008	Cmax|AUC|The incidence of treatment emergent adverse events (TEAEs) & SAE assessed by CTCAE v4.03|ORR|OS|TTP|PFS|DCR|DOR|TTR|6, 9 and 12 month of survival rate	Phase 2	https://ClinicalTrials.gov/show/NCT03591965
NCT03586973	Recruiting	No Results Available	Drug: Cabozantinib	24-Week Progression-Free Survival Rate (PFSR)|Progression-Free Survival (PFS)|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Overall Survival (OS)	Phase 2	https://ClinicalTrials.gov/show/NCT03586973
NCT03578874	Recruiting	No Results Available	Drug: Sorafenib|Drug: Capecitabine|Drug: Oxaliplatin	Resectability|Objective response rate|Progression-free survival|Overall survival	Phase 2	https://ClinicalTrials.gov/show/NCT03578874
NCT01374750	Completed	No Results Available	Drug: Sirolimus|Drug: m-TOR inhibitor free	To evaluate recurrence-free survival|To evaluate the survival rate|To evaluate the renal function|To evaluate the safety with sirolimus	Phase 2	https://ClinicalTrials.gov/show/NCT01374750
NCT02774187	Active, not recruiting	No Results Available	Drug: Sorafenib|Procedure: Hepatic arterial infusion chemotherapy|Drug: Folfox Protocol	Overall survival|Time to progression|Adverse Events|Number of of Patients developed Adverse Events	Phase 3	https://ClinicalTrials.gov/show/NCT02774187
NCT01533324	Unknown status	No Results Available	Drug: S-1 combined with Leucovorin	DCR|TTP ( time to progression)|OS ( overall survival)|safety	Phase 2	https://ClinicalTrials.gov/show/NCT01533324
NCT03519997	Recruiting	No Results Available	Drug: Pembrolizumab|Drug: Bavituximab	Overall Response Rate|Overall Survival|Safety and Tolerability: rates of adverse events according to the CTCAE	Phase 2	https://ClinicalTrials.gov/show/NCT03519997
NCT03516071	Recruiting	No Results Available	Drug: Brivanib 800 mg, QD|Drug: Brivanib 400 mg, BID	Disease control rate (DCR) at 3 months from randomization|Time to Progress (TTP)|Disease control rate (DCR) at 6 months from randomization|Progression-free survival (PFS)|Objective response rate (ORR)|Overall survival (OS)	Phase 2	https://ClinicalTrials.gov/show/NCT03516071
NCT03511703	Not yet recruiting	No Results Available	Drug: Apatinib|Drug: Chemotherapy drugs+Iodized oil	overall survival	Phase 2	https://ClinicalTrials.gov/show/NCT03511703
NCT03510871	Not yet recruiting	No Results Available	Drug: nivolumab, ipilimumab	the percentage of subjects with tumor shrinkage after study drug treatment	Phase 2	https://ClinicalTrials.gov/show/NCT03510871
NCT03510416	Not yet recruiting	No Results Available	Drug: Apatinib|Radiation: TACE	Time To Progression|Overall Survival	Phase 2	https://ClinicalTrials.gov/show/NCT03510416
NCT03469479	Recruiting	No Results Available	Drug: FOLFOX|Procedure: Hepatic resection	Overall survival|Disease-free survival|Adverse Events	Phase 3	https://ClinicalTrials.gov/show/NCT03469479
NCT03518502	Recruiting	No Results Available	Procedure: transarterial chemoembolization (TACE)|Drug: Sorafenib	Overall survival|Time to progression (TTP)|Progression free survival (PFS)|Median survival time (MST)	Phase 4	https://ClinicalTrials.gov/show/NCT03518502
NCT03447951	Not yet recruiting	No Results Available	Drug: Para-Toluenesulfonamide	Objective Response Rate (ORR)|Local disease control rate (LDCR)|Time to treated tumor progression (TTTTP)|Three-year overall survival (OS)|Time to tumor stage progression (TSP)|Difference in ORR between group 1 and group 2|Difference in LDCR between group 1 and group 2|Difference in TTTTP between group 1 and group 2|Incidence of Treatment-Emergent Adverse Events|FACT-Hep quality of life score|EQ-5D-5L quality of life score	Phase 2	https://ClinicalTrials.gov/show/NCT03447951
NCT03434379	Recruiting	No Results Available	Drug: Atezolizumab|Drug: Bevacizumab|Drug: Sorafenib	Overall Survival (OS)|Objective Response (OR) defined as complete response or partial response as determined by the Investigator according to RECIST V1.1|Progression Free Survival (PFS) as Determined by the Investigator According to RECIST v1.1|Time to Progression (TTP) as Determined by the Investigator According to RECIST v1.1|Duration of Response (DOR) as Determined by the Investigator According to RECIST v1.1|OR as Determined by an Independent Review Facility (IRF) According to Response Evaluation Criteria in Solid Tumors, v1.1 (RECIST v1.1)|PFS as Determined by an IRF According to RECIST v1.1|TTP as Determined by an IRF According to RECIST v1.1|DOR as Determined by an IRF According to RECIST v1.1|OR as Determined by an IRF According to Hepatocellular Carcinoma Modified RECIST (HCC mRECIST)|PFS Determined by an IRF According to HCC mRECIST|TTP as Determined by an IRF According to HCC mRECIST|DOR as Determined by an IRF According to HCC mRECIST|Time to Deterioration (TTD) in Patient-Reported HRQoL/GHS, physical functioning, and role functioning, as determined by European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Score|OR as determined by the investigator according to RECIST v1.1|Serum Concentration of Atezolizumab|Change from Baseline in Anti-Drug Antibodies (ADAs) to Atezolizumab|Percentage of Participants with Adverse Events|OR as Determined by an IRF According to RECIST v1.1|OS	Phase 3	https://ClinicalTrials.gov/show/NCT03434379
NCT03433703	Recruiting	No Results Available	Drug: Lenvatinib	Number of Participants with Treatment-emergent Adverse Events|Number of Participants with Treatment-emergent Serious Adverse Events|Overall Survival (OS)|Progression-free Survival (PFS)|Time to Progression (TTP)	Phase 2	https://ClinicalTrials.gov/show/NCT03433703
NCT03418922	Recruiting	No Results Available	Drug: Lenvatinib|Drug: Nivolumab	Part 1: Number of Participants with Dose-Limiting Toxicities (DLTs)|Part 1 and Part 2: Number of Participants with Any Serious and/or Non-serious Adverse Event|Part 1 and Part 2: Overall Response Rate (ORR)|Part 1 and Part 2: Clinical Benefit Rate (CBR)|Part 1 and Part 2: Disease Control Rate (DCR)|Part 2: Duration of Response (DOR)|Part 2: Progression Free Survival (PFS)|Part 2: Time to Progression (TTP)|Part 2: Time to Response (TTR)|Part 2: Overall Survival (OS)	Phase 1	https://ClinicalTrials.gov/show/NCT03418922
NCT03407495	Not yet recruiting	No Results Available	Drug: IOP Injection	The Sensitivity and specificity of IOP-enhanced MRI|Optimal time to perform a MRI scan after injection of IOP|The Number of lesions detected in liver|The size of lesions detected in liver	Phase 2	https://ClinicalTrials.gov/show/NCT03407495
NCT03389126	Recruiting	No Results Available	Drug: Avelumab	response rate	Phase 2	https://ClinicalTrials.gov/show/NCT03389126
NCT03382886	Recruiting	No Results Available	Drug: Nivolumab|Drug: Bevacizumab	Adverse Events that occur|Determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D)|Progression Free Survival (PFS)|Overall Survival	Phase 1	https://ClinicalTrials.gov/show/NCT03382886
NCT03338647	Recruiting	No Results Available	Drug: DEB|Radiation: SBRT	Progression (total of local, intra- and extrahepatic)|Response|Local control of treated tumor|Intrahepatic failure|Extrahepatic failure|Overall survival|Toxicity|Cost-benefit	Phase 3	https://ClinicalTrials.gov/show/NCT03338647
NCT03337841	Not yet recruiting	No Results Available	Drug: Pembrolizumab	One-year recurrence-free survival rate|Recurrence free survival|Overall survival|Objective response rate after neoadjuvant phase|Tumor markers|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]	Phase 2	https://ClinicalTrials.gov/show/NCT03337841
NCT03303469	Recruiting	No Results Available	Drug: FMISO	Quantitate HCC tumor hypoxia at baseline using FMISO PET.|Measure changes in HCC tumor hypoxia and blood flow after TACE, prior to radiotherapy.|Measure changes in treated HCC tumor hypoxia following TACE and radiotherapy	Phase 2	https://ClinicalTrials.gov/show/NCT03303469
NCT03298451	Recruiting	No Results Available	Drug: Durvalumab|Drug: Tremelimumab (Regimen 1)|Drug: Tremelimumab (Regimen 2)|Drug: Sorafenib|Drug: Durvalumab (Regimen 1)|Drug: Durvalumab (Regimen 2)	Overall Survival (OS)|Time to Progression (TTP)|Progression-free survival (PFS)|Objective response rate (ORR)|Disease control rate (DCR)|Duration of response (DoR)|Health status/quality of life measured by European Organization for Research and Treatment of Cancer (EORTC) 30-item core quality of life questionnaire (QLQ-C30)|Presence of ADA for durvalumab and tremelimumab|The pharmacokinetics (PK) of durvalumab and tremelimumab as determined by trough concentration|Disease-related symptoms measured by EORTC 18-item hepatocellular cancer health-related quality of life questionnaire (QLQ-HCC18)|The pharmacokinetics (PK) of durvalumab and tremelimumab as determined by peak concentration	Phase 3	https://ClinicalTrials.gov/show/NCT03298451
NCT03268499	Recruiting	No Results Available	Drug: Cisplatin	Time to progression (TTP)	Phase 2	https://ClinicalTrials.gov/show/NCT03268499
NCT03261791	Recruiting	No Results Available	Drug: Apatinib	recurrence-free survival|overall survival|safety: the potential side effects	Phase 2	https://ClinicalTrials.gov/show/NCT03261791
NCT03245190	Recruiting	No Results Available	Drug: Chiauranib	16 weeks progression-free rate (16W-PFR)|Rate of Treatment-Related Adverse Events in Study Participants|Time to progression(TTP)|Objective response rate (ORR)|Disease-control rate (DCR)|Duration of response (DOR)|Progression-free survival (PFS)|Overall survival (OS)|6 months progression-free rate|6 months overall survival rate|12 months overall survival rate	Phase 1	https://ClinicalTrials.gov/show/NCT03245190
NCT03236649	Not yet recruiting	No Results Available	Drug: Icaritin|Drug: Sorafenib Tosylate Tablets	Overall survival (OS)|Progression-free survival (PFS)|Time to progress（TTP）|Overall response rate (ORR)|Overall disease control rate (DCR)|Assessment on Quality of life 1|Assessment on Quality of life 2	Phase 3	https://ClinicalTrials.gov/show/NCT03236649
NCT03236636	Not yet recruiting	No Results Available	Drug: Icaritin|Drug: HUACHANSU PIAN	Overall survival (OS)|Progression-free survival (PFS)|Time to progress（TTP）|Overall response rate (ORR)|Overall disease control rate (DCR)|Assessment on Quality of life 1|Assessment on Quality of life 2	Phase 3	https://ClinicalTrials.gov/show/NCT03236636
NCT03235167	Not yet recruiting	No Results Available	Drug: CpG DNA|Procedure: transcatheter arterial chemoembolization|Drug: Placebo - Concentrate	survival time|metastasis free survival time	Phase 1	https://ClinicalTrials.gov/show/NCT03235167
NCT03212625	Recruiting	No Results Available	Drug: Urea Cream 20%|Drug: Placebos	Hand-Foot Skin Reaction(HFSR) prevalence rate on each group|Event free survival of HFSR|Severe HFSR prevalence rate|Prevalence of discontinuation or reduction of sorafenib|Assessment of Quality Of Life (QOL)|Overall survival|Tumor response|Other side effect	Phase 4	https://ClinicalTrials.gov/show/NCT03212625
NCT03208335	Recruiting	No Results Available	Drug: recombinant human endostatin	progress-free survival(PFS)|response rate(RR)|clinical benefit rate(CBR)|overall survival(OS)|adverse event(AE)|Quality of life (QOL)	Phase 2	https://ClinicalTrials.gov/show/NCT03208335
NCT03192618	Recruiting	No Results Available	Procedure: adjuvant transarterial chemoinfusion (TAI)|Drug: mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)	Disease-free survival (DFS)|recurrence rate|Overall survival (OS)	Phase 3	https://ClinicalTrials.gov/show/NCT03192618
NCT03175705	Recruiting	No Results Available	Biological: HCC antigens-specific CD8+ T lymphocytes|Drug: IL-2|Drug: Tegafur	Incidence of Treatment-Emergent Adverse Events [Safety]|Biological activity of infused T cells	Phase 1	https://ClinicalTrials.gov/show/NCT03175705
NCT03175679	Recruiting	No Results Available	Biological: iNKT cells|Drug: IL-2|Drug: Tegafur	Incidence of Treatment-Emergent Adverse Events [Safety]|Biological activity of infused iNKT cells	Phase 1	https://ClinicalTrials.gov/show/NCT03175679
NCT03163992	Recruiting	No Results Available	Drug: Pembrolizumab	overall response rate|overall response	Phase 2	https://ClinicalTrials.gov/show/NCT03163992
NCT03145558	Recruiting	No Results Available	Drug: Tirapazamine|Drug: Doxorubicin	Progression Free Survival|Overall survival|Complete Response rate|Time to Embolization Failure|Duration of CR	Phase 2	https://ClinicalTrials.gov/show/NCT03145558
NCT00475956	Completed	No Results Available	Drug: AZD2171|Drug: AZD0530	Determine the safety and tolerability of ascending daily oral doses of AZD2171 when co-administered with AZD0530 to patients with advanced solid tumours by assessment of AEs, vital signs, HRCT Scans, clin chem, haematology, urinalysis, ECG and phys exam|Pharmacokinetics (PK) of AZD2171 alone and in combination with AZD0530|Safety and efficacy|Genetic variation of pathways targeted by AZD2171 and AZD0530	Phase 1	https://ClinicalTrials.gov/show/NCT00475956
NCT03116945	Recruiting	No Results Available	Drug: 68Gallium Citrate	Uptake of positron emitting radiotracer, 68Gallium Citrate will be measured in the lesions of hepatocellular carcinoma.	Phase 2	https://ClinicalTrials.gov/show/NCT03116945
NCT03114085	Not yet recruiting	No Results Available	Drug: Capecitabine|Drug: Apatinib	time to progression	Phase 2	https://ClinicalTrials.gov/show/NCT03114085
NCT03109886	Recruiting	No Results Available	Drug: Milciclib maleate	Overall Safety Profile|Objective Response Rate (ORR)|Progression-Free Survival (PFS)|Time to Progression (TPP)|TPP-3 months|Duration of overall Response (DoR)	Phase 2	https://ClinicalTrials.gov/show/NCT03109886
NCT01839604	Completed	Has Results	Drug: AZD9150	Number of Participants With Dose Limiting Toxicities During Cycle 1|Evaluation of Pharmacokinetics (PK) of AZD9150 (Following Single Administrations in Patients With HCC) by Determining Cmax, Using the Plasma Concentration Data.|Preliminary Assessment of the Anti-tumour Activity of AZD9150 by Evaluation of Tumour Response.|Evaluation of Pharmacokinetics (PK) of AZD9150 (Following Single Administrations in Patients With HCC) by Determining Tmax, Using the Plasma Concentration Data.	Phase 1	https://ClinicalTrials.gov/show/NCT01839604
NCT03062358	Recruiting	No Results Available	Biological: pembrolizumab|Drug: placebo|Other: best supportive care (BSC)	Overall Survival (OS)|Progression Free Survival (PFS)|Objective Response Rate (ORR)|Duration Of Response (DOR)|Disease Control Rate (DCR)|Time To Progression (TTP)|Incidence of Adverse Events (AEs)|Incidence of Discontinuations	Phase 3	https://ClinicalTrials.gov/show/NCT03062358
NCT03059147	Recruiting	No Results Available	Drug: SF1126	Rate of dose limiting toxicities|Treatment-emergent adverse events|Peak plasma concentration (Cmax)|Area under the plasma concentration versus time curve (AUC)|Progression-free survival	Phase 1	https://ClinicalTrials.gov/show/NCT03059147
NCT01834963	Recruiting	No Results Available	Drug: Interferon Alfa、Fluorouracil|Drug: Cisplatin、Fluorouracil	Two-year overall survival rate|Progression free survival time|Overall survival time|toxicity	Phase 2	https://ClinicalTrials.gov/show/NCT01834963
NCT03048123	Completed	No Results Available	Procedure: Hepatic arterial infusion|Procedure: Transarterial chemoembolization|Drug: Folfox Protocol|Drug: TACE Drug Protocol	Disease control rate|Time to progression|Adverse Events	Phase 2	https://ClinicalTrials.gov/show/NCT03048123
NCT03046979	Recruiting	No Results Available	Drug: Apatinib	Objective Response Rate(ORR)|Disease Control Rate (DCR)|Progression free survival (PFS)|Overall survival (OS)|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0[Quality of life]|Incidence of Treatment-Emergent Adverse Events [Safety]	Phase 2	https://ClinicalTrials.gov/show/NCT03046979
NCT03033446	Recruiting	No Results Available	Radiation: Y-90 Radioembolization|Drug: Nivolumab	Response Rate|Time to Response|Duration of Response|Time to Progression|Progression Free Survival|Overall Survival|Quality of Life using the FACT-HEP score|Quality of Life using EORTC QLQ-C30|Adverse events from the combination of RE and nivolumab assessed by NCI CTCAE v4.0	Phase 2	https://ClinicalTrials.gov/show/NCT03033446
NCT03024684	Recruiting	No Results Available	Drug: Atorvastatin|Drug: Placebo Oral Tablet	3-year cumulative incidence of recurrent HCC between the intervention group and control counterpart|occurrence of clinical complications related to hepatic decompensation	Phase 4	https://ClinicalTrials.gov/show/NCT03024684
NCT03006926	Recruiting	No Results Available	Drug: lenvatinib|Drug: pembrolizumab (200 mg)	Number of participants with any serious adverse event and number of participants with any non-serious adverse event.|Dose-limiting toxicity (DLT) of lenvatinib and pembrolizumab during Cycle 1|Objective response rate (ORR) based on modified Response Evaluation Criteria In Solid Tumors (mRECIST)|Duration of response (DOR) based on mRECIST|Mean maximum concentration (Cmax) of lenvatinib|Mean time to reach maximum concentration (Tmax) of lenvatinib|Mean terminal half-life (t1/2) of lenvatinib|Mean area under the drug concentration-time curve (AUC) of lenvatinib|Mean apparent total clearance (CL/F) of lenvatinib|Mean apparent volume of distribution (Vz/F) of lenvatinib|Mean measured concentration at the end of a dosing interval (Ctrough) of pembrolizumab|Mean clearance (CL) of pembrolizumab|Number of participants with anti-drug antibodies (ADA) for pembrolizumab	Phase 1	https://ClinicalTrials.gov/show/NCT03006926
NCT02987907	Recruiting	No Results Available	Drug: Dexamethasone|Drug: Normal Saline	response rate (RR)|proportions of participants with severe adverse events according to CTCAE v4.03|overall survival (OS)|progression-free survival (PFS)|time to progression (TTP)	Phase 3	https://ClinicalTrials.gov/show/NCT02987907
NCT02472249	Recruiting	No Results Available	Radiation: CT perfusion|Drug: Norepinephrine intra-arteriel/hepatic	Liver blood flow	Phase 4	https://ClinicalTrials.gov/show/NCT02472249
NCT02981498	Recruiting	No Results Available	Procedure: Hepatic arterial infusion chemotherapy|Drug: Folfox Protocol	progression-free survival rate|Objective response|OS|AE event	Phase 2	https://ClinicalTrials.gov/show/NCT02981498
NCT02973685	Recruiting	No Results Available	Procedure: Hepatic arterial infusion chemotherapy|Procedure: Transarterial chemoembolization|Drug: Folfox Protocol|Drug: TACE Drug Protocol	Overall survival|Time to progression|Adverse Events|Number of of Patients developed Adverse Events	Phase 3	https://ClinicalTrials.gov/show/NCT02973685
NCT02967887	Recruiting	No Results Available	Drug: cisplatin and 5-fluorouracil	Objective tumor response|Time-to-Progression|Progression-free-survival	Phase 2	https://ClinicalTrials.gov/show/NCT02967887
NCT00168987	Completed	No Results Available	Drug: oral nutritional supplement rich in eicosapentanoic acid	improvement of muscle function (hand grip strength, respiratory muscle function) at two months|improvement of cognitive function at two months|improvement of quality of life at two months|tolerance of the oral nutritional supplement|improvement of nutritional state (body weight, muscle mass, body cell mass, phase angle, serum albumin)	Phase 4	https://ClinicalTrials.gov/show/NCT00168987
NCT02956772	Not yet recruiting	No Results Available	Drug: TACE|Drug: Arsenic trioxide	Progression free survival|Objective response rate|Overall Survival|Incidence of adverse events	Phase 2	https://ClinicalTrials.gov/show/NCT02956772
NCT02953743	Active, not recruiting	No Results Available	Drug: Lenvatinib	Mean maximum observed concentration (Cmax)|Mean time at which the highest drug concentration occurs (tmax)|Mean area under the concentration-time curve from zero time to time of last quantifiable concentration (AUC(0-t))|Mean maximum observed concentration at steady-state (Css,max )|Mean minimum observed concentration at steady-state (Css,min)|Average steady-state concentration (Css,av)|Mean time at which the highest drug concentration occurs at steady-state (tss,max)|Mean area under the concentration-time curve over the dosing interval on multiple dosing (AUC(0-τ))|Number of participants with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)	Phase 1	https://ClinicalTrials.gov/show/NCT02953743
NCT02927626	Recruiting	No Results Available	Drug: Yang Yin Fu Zheng therapy|Drug: Routine medical care	Survival rate|Objective response rate|quality of life(QOL)	Early Phase 1	https://ClinicalTrials.gov/show/NCT02927626
NCT02906397	Recruiting	No Results Available	Drug: Galunisertib 150mg by mouth twice a day|Radiation: Stereotactic Body Radiotherapy (SBRT)	Safety based upon standard laboratory and clinical adverse event monitoring|Progression free survival (PFS) who are receiving the combination of galunisertib plus SBRT as compared to the PFS of Galunisertib alone in historical controls.|Response rate|Overall survival (OS)|Inhibition of TGF-β signaling by intervention as evidenced by downstream changes in this pathway|Promotion of anti-tumor immunity with addition of intervention to SBRT	Phase 1	https://ClinicalTrials.gov/show/NCT02906397
NCT02905188	Not yet recruiting	No Results Available	Genetic: GLYCAR T cells|Drug: Cytoxan|Drug: Fludarabine	Number of Patients with Dose Limiting Toxicity|Percent of Patients with best response as either complete remission or partial remission|Median T cell persistence	Phase 1	https://ClinicalTrials.gov/show/NCT02905188
NCT02631499	Not yet recruiting	No Results Available	Procedure: TACE|Drug: Epirubicin|Drug: lipiodol	Early recurrence rates|Overall Survival	Phase 4	https://ClinicalTrials.gov/show/NCT02631499
NCT02867280	Recruiting	No Results Available	Drug: Sorafenib	Recurrence free survival|Time To Recurrence|Recurrence rate|Overall survival|Incidence of Treatment-related Adverse Events measures using CTCAE v4.0|Incidence of dose modification of sorafenib due to adverse events.	Phase 3	https://ClinicalTrials.gov/show/NCT02867280
NCT02856126	Recruiting	No Results Available	Procedure: Hepatic arterial infusion chemotherapy|Procedure: Transarterial chemoembolization|Drug: TACE regimen|Drug: HAIC Regimen|Drug: Oral Sorafenib	Overall survival|Progress free survival|Adverse Events|Number of of Patients developed Adverse Events	Phase 3	https://ClinicalTrials.gov/show/NCT02856126
NCT02834780	Recruiting	No Results Available	Drug: H3B-6527	Number of Dose-limiting Toxicities (DLTs) as a function of the dose of H3B-6527 for determination of the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D)|Number of Participants with Treatment Emergent Adverse Event (TEAE) and Serious Adverse Event (SAE)|Mean Area under the Plasma Concentration-time Curve from Time 0 Through the Last Measurable Point (AUC0-t) of H3B-6527|Mean Area under the Plasma Concentration-time Curve Extrapolated to Infinity (AUC0-inf) of H3B-6527|Mean Maximum Observed Plasma Concentration (Cmax) of H3B-6527|Mean Time of Maximum Observed Plasma Concentration (tmax) of H3B-6527|Mean Accumulation Ratio (Racc) of H3B-6527|Preliminary antitumor activity will be determined by using mRECIST/Response Evaluation Criteria in Solid Tumors, (RECIST) 1.1.|Objective Response Rate (ORR)|Duration of Response (DOR)|Progression-free Survival (PFS)|Overall Survival (OS)|Time to Response	Phase 1	https://ClinicalTrials.gov/show/NCT02834780
NCT02814461	Recruiting	No Results Available	Drug: Axitinib|Radiation: Radiation	The maximal tolerated dose (MTD)	Phase 1	https://ClinicalTrials.gov/show/NCT02814461
NCT02809534	Recruiting	No Results Available	Drug: Anlotinib	12-week Progression-free survival rate(PFR 12w)|Time to Progression(TTP)|24-week Progression-free survival rate(PFR 24w)|Serum Alpha-Fetoprotein level (AFP)|Overall Survival (OS)|Objective Response Rate (ORR)|Disease Control Rate (DCR)	Phase 2	https://ClinicalTrials.gov/show/NCT02809534
NCT02799212	Recruiting	No Results Available	Drug: somatostatin infusion|Drug: placebo infusion	presence of postoperative ascites during the postoperative course|Duration of ascites|Volume of ascites|postoperative morbidity|Postoperative morbidity on Liver failure|Postoperative morbidity on Renal failure	Phase 3	https://ClinicalTrials.gov/show/NCT02799212
NCT03463876	Recruiting	No Results Available	Drug: SHR 1210+apatinib	Objective Response Rate (ORR)|Duration of Response (DoR)|Disease Control Rate (DCR)|Time to objective response(TTR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).|9-month survival rate|12-month survival rate|Overall survival(OS)|Progression-free survival(PFS)|Safety as measured by the rate of AEs, SAEs and laboratory abnormalities	Phase 2	https://ClinicalTrials.gov/show/NCT03463876
NCT02562755	Recruiting	No Results Available	Biological: Pexastimogene Devacirepvec (Pexa Vec)|Drug: Sorafenib	Overall Survival|Time to Progression (TTP)|Progression Free Survival (PFS)|Overall Response Rate (ORR)|Disease Control Rate (DCR)|Incidence of Adverse Events (AE) and Serious Adverse Events (SAE)|Time to Symptomatic Progression (TSP)	Phase 3	https://ClinicalTrials.gov/show/NCT02562755
NCT02733809	Recruiting	No Results Available	Drug: Sorafenib	Overall and disease-free survival genes.|The predictors of survival ( response to Sorafenib )|Potential genetic targets for resistance.	Phase 4	https://ClinicalTrials.gov/show/NCT02733809
NCT02716766	Recruiting	No Results Available	Drug: Sorafenib|Drug: Capecitabine|Drug: Oxaliplatin	Time to progression (TTP)|Objective Response Rate (ORR)|Progression-free survival (PFS)|Overall survival (OS)|Frequency and severity of adverse events and laboratory abnormalities	Phase 2	https://ClinicalTrials.gov/show/NCT02716766
NCT03419481	Recruiting	No Results Available	Drug: pembrolizumab	Response rate (RR) according to RECIST1.1|1-year survival rate|Response rate according to irRECIST|Assessment of response duration|Progression-free survival (PFS)|Time-to-progression (TTP)|Overall survival (OS)	Phase 2	https://ClinicalTrials.gov/show/NCT03419481
NCT02702401	Active, not recruiting	No Results Available	Biological: Pembrolizumab|Drug: Placebo|Other: Best Supportive Care	Progression-Free Survival (PFS)|Overall Survival (OS)|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Time to Progression (TTP)|Duration of Response (DOR)	Phase 3	https://ClinicalTrials.gov/show/NCT02702401
NCT02672488	Recruiting	No Results Available	Drug: Sorafenib|Drug: Metformin	Overall Survival|Time To Progression|Progression Free Survival|Objective Response Rate	Phase 2	https://ClinicalTrials.gov/show/NCT02672488
NCT02658019	Active, not recruiting	No Results Available	Drug: Pembrolizumab|Procedure: Peripheral Blood Sample (optional)|Genetic: Tumor Tissue Collection (optional)	Disease Control Rate (DCR) in Study Participants|Rate of Treatment-Related Adverse Events in Study Participants|Progression-Free Survival (PFS)|Overall Survival (OS)|Objective Response Rate (ORR)|Duration of Response (DoR)	Phase 2	https://ClinicalTrials.gov/show/NCT02658019
NCT01761266	Active, not recruiting	No Results Available	Drug: Lenvatinib|Drug: Sorafenib	Overall survival (OS)|Progression-free survival (PFS)|Time to progression (TTP)|Objective Response Rate (ORR)|Health Related Quality of Life (HRQoL)|Plasma PK lenvatinib exposure parameters	Phase 3	https://ClinicalTrials.gov/show/NCT01761266
NCT02630108	Recruiting	No Results Available	Procedure: Thermal Ablation|Drug: EADM|Drug: Ultra-fluid lipiodol|Other: Gelatin sponge articles	Overall Survival|Time-to-Disease Progression|Objective response rate (ORR)|Progression free survival(PFS)|Numbers of TACE and TACE combined with ablation cycles|Number of participants with adverse events and severe adverse events in TACE alone and TACE combined with ablation groups	Phase 3	https://ClinicalTrials.gov/show/NCT02630108
NCT03278444	Recruiting	No Results Available	Other: Basic drugs therapy of HCC|Drug: Arginine hydrochloride|Drug: Trimetazidine hydrochloride	Overall Survival|Progression-free Survival|Disease Control Rate (DCR)|Objective Response Rate(ORR)|biomarker|Chinese Quality of Life Questionnaire - EORTC QLQ-C30 score	Phase 3	https://ClinicalTrials.gov/show/NCT03278444
NCT03275376	Recruiting	No Results Available	Drug: Atorvastatin 10mg|Drug: Placebo Oral Tablet	Overall survival|Best tumor response|Progression free survival	Phase 2	https://ClinicalTrials.gov/show/NCT03275376
NCT02576509	Active, not recruiting	No Results Available	Drug: Nivolumab|Drug: Sorafenib	Overall Survival (OS)|Progression-Free Survival (PFS)|Programmed death (PD)-L1 expression|Overall Response Rate (ORR)	Phase 3	https://ClinicalTrials.gov/show/NCT02576509
NCT02564614	Completed	No Results Available	Drug: RO7070179	Change From Baseline to Week 6 in HIF1A mRNA Level in Tumor Tissue|Change From Baseline to Week 6 in hypoxia-inducible factor 1a (HIF1A) Tumor Concentrations|Change From Baseline to Week 6 in HIF2 Tumor Concentrations|Change From Baseline to Week 6 in Vascular Endothelial Growth Factor (VEGF) Tumor Concentrations|Change From Baseline to Week 6 in Erythropoietin (EPO) Tumor Concentrations|Change From Baseline to Week 6 in Prolyl 4 Hydroxylase Tumor Concentrations|Change From Baseline to Week 6 in CD34/von Willebrand factor (VWF) Tumor Concentrations|Change in Blood Alpha-fetoprotein (AFP) Concentrations from Baseline|Time to Progression (TTP) According to Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST (mRECIST)|Percentage of Participants With Complete Response (CR) and Partial Response (PR) According to RECIST and mRECIST|Duration of Response (DOR) According to RECIST and mRECIST|Progression Free Survival (PFS) According to RECIST and mRECIST|Overall Survival (OS) According to RECIST and mRECIST|Percentage of Participants With Tumor Growth According to RECIST and mRECIST|Maximum Observed Plasma Concentration (Cmax)|Time to Reach Maximum Observed Plasma Concentration (Tmax)|Area under the Concentration-Time Curve From Zero to 168 Hours [AUC (0-168 hours)]|Plasma Decay Half-Life (t1/2)	Phase 1	https://ClinicalTrials.gov/show/NCT02564614
NCT02028949	Completed	No Results Available	Drug: Zavedos®|Other: Blood samples	tolerance: toxicity will be evaluated according to the NCI CTC AE version 4.03 scale to determine the limiting dose|Study the pharmacokinetics of idarubicin in this delivery method|Evaluate overall survival|Evaluate progression-free survival|Evaluate time to progression|Evaluate the rate of objective response	Phase 1	https://ClinicalTrials.gov/show/NCT02028949
NCT03551444	Recruiting	No Results Available	Drug: Administration of DAA-based treatment	Recurrence rate|effect of timing of administration of DAAs after achieving rCR as regard recurrence rate|Identifications of predictive factors of HCC recurrence	Phase 3	https://ClinicalTrials.gov/show/NCT03551444
NCT02534961	Unknown status	No Results Available	Drug: Cefazolin	Infection after radiofrequency ablation	Phase 4	https://ClinicalTrials.gov/show/NCT02534961
NCT02528643	Active, not recruiting	No Results Available	Drug: enzalutamide|Drug: placebo	Overall Survival (OS)|Safety profile of enzalutamide as assessed by adverse events, serious adverse events, laboratory tests, vital signs, electrocardiograms (ECG) and physical exams|Pharmacokinetics of enzalutamide and N-desmethyl enzalutamide in plasma: Cmin|Progression Free Survival (PFS)	Phase 2	https://ClinicalTrials.gov/show/NCT02528643
NCT02524119	Recruiting	No Results Available	Drug: LEE011|Procedure: Chemoembolization	Progression Free Survival|Survival|Safety measured by adverse events|Tolerability measured by adverse events|Treatment Response (Tumor assessments)	Phase 2	https://ClinicalTrials.gov/show/NCT02524119
NCT02513199	Recruiting	No Results Available	Radiation: SBRT|Drug: TACE	Response rate|Performance status|Time to progression (TTP)|Overall survival (OS)|Progression free survival (PFS)	Phase 2	https://ClinicalTrials.gov/show/NCT02513199
NCT02509169	Unknown status	No Results Available	Drug: TAE plus P53 gene|Other: TAE	overall survival|immuno-reaction (lymphocyte counts and subgroup ratios)|progression free survival	Phase 2	https://ClinicalTrials.gov/show/NCT02509169
NCT02504983	Unknown status	No Results Available	Drug: sorafenib|Procedure: TACE	Complete remission|Time to partial (including complete) response|Time-to-tumor-progression (TTP)|Progression free survival (PFS).|Overall survival (OS)|Safety and tolerability of TACE plus sorafenib therapy recorded and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0.	Phase 4	https://ClinicalTrials.gov/show/NCT02504983
NCT02447679	Completed	No Results Available	Drug: thalidomine|Drug: tegafur-uracil	tumor recurrence	Phase 2	https://ClinicalTrials.gov/show/NCT02447679
NCT02436902	Recruiting	No Results Available	Procedure: TACE|Drug: Sorafenib|Drug: TACE plus sorafenib|Procedure: transarterial chemotherapy plus embolization	Overall survivals|Hospital mortality|Recurrence rates	Phase 3	https://ClinicalTrials.gov/show/NCT02436902
NCT02425605	Unknown status	No Results Available	Radiation: CCRT|Drug: sorafenib	Overall survival|PFSL defined as dynamic CT scan|PFSO defined as definitive imaging technique|tumor response defined as modified RECIST|toxicity defined as NCI-CTC(version 4.02)	Phase 2	https://ClinicalTrials.gov/show/NCT02425605
NCT02421185	Recruiting	No Results Available	Drug: JNJ-42756493 (erdafitinib)	Part 1:Recommended Phase 2 Dose (RP2D)|Number of participants with Objective Response|Number of Participants With Adverse Events|Time to Progression (TTP)|Disease Control Rate (DCR)|Progression-free Survival|Maximum Observed Plasma Concentration of JNJ-42756493 (erdafitinib)|Time of Maximum Observed Plasma Concentration of JNJ-42756493 (erdafitinib)|Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)|Half life of JNJ-42756493 (erdafitinib)|Apparent Volume of Distribution at Steady-State of JNJ-42756493 (erdafitinib)|Total Clearance of JNJ-42756493 (erdafitinib)|Accumulation Index of JNJ-42756493 (erdafitinib)|Duration of Objective Response (DOR)	Phase 1	https://ClinicalTrials.gov/show/NCT02421185
NCT02418988	Unknown status	No Results Available	Drug: TACE plus rAd-p53 artery injection|Drug: TACE	overall survival|safety as assessed by adverse events, vital sign, lab tests, ECG and physical examination|progression-free survival	Phase 2	https://ClinicalTrials.gov/show/NCT02418988
NCT02403544	Unknown status	No Results Available	Radiation: IGRT|Drug: Capecitabine|Drug: Oxaliplatin	Maximum Tolerated Dose (MTD) for capecitabine and oxaliplatin|Dose Limiting Toxicity (DLT)|In field recurrence rate (LR) or local failure free survival (LFFS)|Intrahepatic failure rate or intrahepatic failure free survival (IHFFS)|Extrahepatic failure rate or extrahepatic failure free survival (EHFFS)|Overall survival|Tumor response rate including complete response and partial response rates	Phase 1	https://ClinicalTrials.gov/show/NCT02403544
NCT02399033	Recruiting	No Results Available	Drug: Xihuang Capsules	Hepatocellular carcinoma recurrence rate in the three years after hepatectomy|Hepatocellular carcinoma recurrence rate in a year after hepatectomy|Relapse free survival (RFS)|Hepatocellular carcinoma survival rate in a year or three years after hepatectomy|Overall survival(OS)|Improvement in quality of life in a year or three years after hepatectomy|number of participants with improvement of clinical symptoms, Such as flank pain, bloating, fatigue, anorexia and other syndromes of traditional Chinese Medicine.|The incidence of adverse reaction.	Phase 4	https://ClinicalTrials.gov/show/NCT02399033
NCT03007225	Completed	No Results Available	Drug: Trans-arterial chemoembolization (TACE)|Drug: TACE with Drug Eluting Beads procedure	Radiological response (CT/ MRI) after procedure (efficacy)	Phase 4	https://ClinicalTrials.gov/show/NCT03007225
NCT02987699	Recruiting	No Results Available	Drug: 5-Fu, oxaliplatin , leucovorin	Tumor response|Adverse Events|Number of of Patients developed Adverse Events	Phase 2	https://ClinicalTrials.gov/show/NCT02987699
NCT02358395	Completed	No Results Available	Drug: BBI608|Drug: Sorafenib	Assessment of safety and tolerability of BBI608 given in combination with Sorafenib by reporting of adverse events and serious adverse events.|Assessment of dose-limiting toxicities (DLTs).|Pharmacokinetic profile of BBI608 when administered in combination with Sorafenib.|Assessment of the preliminary anti-tumour activity.|Progression Free Survival|Overall Survival	Phase 1	https://ClinicalTrials.gov/show/NCT02358395
NCT02971696	Completed	No Results Available	Drug: Sorafenib|Drug: Best Supportive care	overall survival (OS)|Event free survival|Detection of changes in quality of life|Sorafenib induced side effects	Phase 3	https://ClinicalTrials.gov/show/NCT02971696
NCT02961998	Completed	No Results Available	Drug: Celecoxib|Drug: Sorafenib	Incidence of participants with clinically definite Sorafenib-related Hand Foot Syndrome|Overall survival	Phase 4	https://ClinicalTrials.gov/show/NCT02961998
NCT02338297	Unknown status	No Results Available	Procedure: TACE|Drug: EGM|Drug: PVA	overall survival|APS improvement|Time To Progression|progression free survival|Response Rate	Phase 3	https://ClinicalTrials.gov/show/NCT02338297
NCT02329860	Active, not recruiting	No Results Available	Drug: Apatinib|Drug: Placebo	Overall Survival|Time to progression（TTP）|Progression free survival (PFS)|Objective tumor response|Disease control RATE	Phase 3	https://ClinicalTrials.gov/show/NCT02329860
NCT02308319	Not yet recruiting	No Results Available	Drug: Tenofovir disoproxil fumarate	Recurrence free survival|Overall survival|New onset ascites, variceal bleeding, hepatic encephalopathy|Child-Pugh score and MELD score at baseline and at final follow-up|Reactivation of hepatitis B	Phase 4	https://ClinicalTrials.gov/show/NCT02308319
NCT02304289	Completed	No Results Available	Drug: Artesunate	Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Maximum tolerated dose (MTD)|Pharmacokinetic analysis of Cmax, Cmin, Tmax, and AUC.|Time to tumor progression (TTP)|Overall survival (OS)|Quality of life based on the "Functional Assessment of Cancer Therapy Hep-30 scale" (FACT-Hep-30)	Phase 1	https://ClinicalTrials.gov/show/NCT02304289
NCT03253250	Recruiting	No Results Available	Drug: ETV；TDF；ADV|Drug: Peginterferon Alfa-2a	Recurrence-free Survival Rate (RFS）|Overall Survival Rate (OS）	Phase 4	https://ClinicalTrials.gov/show/NCT03253250
NCT02267213	Completed	No Results Available	Drug: Lipotecan	Disease Control Rate (DCR)|Objective response rate (ORR; where ORR= CR rate + PR rate)|Duration of Disease control (DDC)|Time to Progression (TTP)|Progression Free Survival (PFS)|Overall Survival (OS)|Change of Tumor markers/Bio-markers|AEs|Vital signs|Resting 12-lead ECGs|Hematology|Clinical chemistry|Urinalysis data|PK parameters, including AUC, Cmax and Tmax of S,S-TLC388, S,R-TLC388, metabolites TLC-U1, TLC-U2, and topotecan	Phase 2	https://ClinicalTrials.gov/show/NCT02267213
NCT02253511	Unknown status	No Results Available	Drug: Cidan capsule	Overall survival|Recurrence-free survival	Phase 4	https://ClinicalTrials.gov/show/NCT02253511
NCT01915589	Completed	No Results Available	Drug: Refametinib (BAY86-9766)	Objective tumor response according to Modified Response Evaluation Criteria in Solid Tumors (mRECIST) assessed by central radiological review|Objective tumor response according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 assessed by central radiological review|Objective tumor response according to RECIST 1.1 and mRECIST assessed by investigators|Disease control (central and investigator's assessment)|Overall survival|Time to radiographic tumor progression (central and investigator's assessment)|Duration of response (central and investigator's assessment)|Time to objective response (central and investigator's assessment)|Change in tumor size (central and investigator's assessment)|Best overall response (central and investigator's assessment)|Progression-free survival (central and investigator's assessment)|Number of participants with adverse events as a measure of safety and tolerability	Phase 2	https://ClinicalTrials.gov/show/NCT01915589
NCT02311205	Active, not recruiting	No Results Available	Procedure: Conventional Transarterial Chemoembolization (TACE)|Drug: sorafenib	Overall survival (OS)|Safety (adverse events and laboratory values)|Liver dysfunction (laboratory values related to liver)|Time to progression (TTP)|Time to TACE failure (TTTF)|Time to sorafenib failure (TTSF)|Tumor response rate (TRR)|Disease control rate (DCR)	Phase 2	https://ClinicalTrials.gov/show/NCT02311205
NCT02234986	Active, not recruiting	No Results Available	Drug: ENMD-2076	Overall Response Rate|Progression Free Survival (PFS6) rate	Phase 2	https://ClinicalTrials.gov/show/NCT02234986
NCT02210182	Completed	No Results Available	Drug: Oral Pentamidine|Other: Placebo	pharmacokinetics|plasma Pharmacokinetics|Adverse events|markers of efficacy|Biomarker	Phase 1	https://ClinicalTrials.gov/show/NCT02210182
NCT01840592	Active, not recruiting	No Results Available	Drug: Sorafenib|Drug: Doxorubicin	overall survival|median time to progression|median progression free survival|median overall survival|toxicity	Phase 2	https://ClinicalTrials.gov/show/NCT01840592
NCT00846131	Completed	No Results Available	Drug: Sorafenib|Drug: Yttrium-90 (Y-90)	To Evaluate sorafenib as an adjunct to Y-90 for control of HCC as a bridge/downstage to transplant|To characterize the toxicity profile of sorafenib and Y90 using NCI CTC toxicity grading scales.|To identify predictive and prognostic markers of how the liver cancer will respond to treatment.	Phase 1	https://ClinicalTrials.gov/show/NCT00846131
NCT02178358	Active, not recruiting	No Results Available	Drug: LY2157299|Drug: Sorafenib|Drug: Placebo	Overall Survival (OS)|Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) of LY2157299 and LY2157299 in Combination with Sorafenib|Time to Tumor Progression|Progression Free Survival|Objective Response Rate|Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Score|Change from Baseline in EORTC QLQ Hepatocellular Carcinoma (HCC-18) Questionnaire Score	Phase 2	https://ClinicalTrials.gov/show/NCT02178358
NCT02738697	Recruiting	No Results Available	Drug: Adjuvant chemotherapy|Procedure: Follow-up	Overall survival|Disease-free survival|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	Phase 3	https://ClinicalTrials.gov/show/NCT02738697
NCT01915602	Completed	No Results Available	Drug: Refametinib (BAY86-9766)|Drug: Sorafenib (BAY43-9006)	Objective tumor response according to Modified Response Evaluation Criteria in Solid Tumors (mRECIST) assessed by central radiological review|Objective tumor response according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 assessed by central radiological review|Objective tumor response according to RECIST 1.1 and mRECIST assessed by investigators|Disease control (central and investigator's assessment)|Overall survival|Time to radiographic tumor progression (central and investigator's assessment)|Duration of response (central and investigator's assessment)|Time to objective response (central and investigator's assessment).|Change in tumor size (central and investigator's assessment)|Best overall response (central and investigator's assessment)|Progression-free survival (central and investigator's assessment)|Number of participants with adverse events as a measure of safety and tolerability	Phase 2	https://ClinicalTrials.gov/show/NCT01915602
NCT02724332	Completed	No Results Available	Drug: Rapamycin	Overall Survival|Time to recurrence	Phase 1	https://ClinicalTrials.gov/show/NCT02724332
NCT02715492	Not yet recruiting	No Results Available	Drug: LMWH|Procedure: TACE	Number of patients with portal vein thrombosis	Phase 3	https://ClinicalTrials.gov/show/NCT02715492
NCT02128958	Recruiting	No Results Available	Drug: CF102|Drug: Placebo	Overall Survival|time to progression|Safety profile|laboratory parameters of hepatic dysfunction and viral hepatitis|adenosine A3 receptor (A3AR) expression|Pharmacokinetics (PK) of CF102 in this population	Phase 2	https://ClinicalTrials.gov/show/NCT02128958
NCT01192971	Completed	No Results Available	Drug: Apatinib	TTP (Time To Progression)|Overall Survival safety|DCR (Disease control rate|ORR (objective response rate)|QoL (quality of life)	Phase 2	https://ClinicalTrials.gov/show/NCT01192971
NCT00355862	Completed	No Results Available	Drug: CNI, MMF, Steroids, Aza etc. (mTOR inhibitor free)|Drug: Sirolimus	Recurrence free survival	Phase 3	https://ClinicalTrials.gov/show/NCT00355862
NCT01997957	Unknown status	No Results Available	Drug: S-1	Time to progression(TTP)|Overall survival(OS)|Response rate (RR)|Disease Control Rate (DCR)|Number of Participants with Serious and Non-Serious Adverse Events	Phase 4	https://ClinicalTrials.gov/show/NCT01997957
NCT01972672	Unknown status	No Results Available	Drug: Icaritin	time to progress（TTP）|Progression-free survival (PFS)|Overall survival (OS)|Overall response rate (ORR) (proportion of patients with confirmed partial and complete responses)|Overall disease control rate (DCR)|Assessment on Quality of life|Type, incidence, severity, seriousness and relationship to study drug of adverse events (AEs) and serious adverse events (SAEs);|Laboratory abnormal findings	Phase 2	https://ClinicalTrials.gov/show/NCT01972672
NCT01970748	Unknown status	No Results Available	Drug: Propranolol|Procedure: Esophageal variceal ligation	Bleeding|Complication survival	Phase 4	https://ClinicalTrials.gov/show/NCT01970748
NCT01966133	Active, not recruiting	No Results Available	Drug: Ethiodized Oil + Doxorubicin	Disease-free survival|Overall Survival|Complications of transarterial chemoembolisation	Phase 3	https://ClinicalTrials.gov/show/NCT01966133
NCT01934829	Completed	No Results Available	Drug: urea-based cream	The incidence of all-grade HFSR|Prophylactic topical application of ointment to reduce the hand-foot skin reactions in patients with hepatocellular carcinoma treated with sorafenib|The percentage of patients requiring sorafenib dose-reduction|The percentage of patients requiring discontinuation of sorafenib therapy|The percentage of patients discontinuing treatment	Phase 2	https://ClinicalTrials.gov/show/NCT01934829
NCT02779465	Not yet recruiting	No Results Available	Drug: Vitamin D3	Change in serum levels of 25-hydroxy vitamin D|Change in serum creatinine|Change in fibrosis score|Number of participants on Vitamin D treatment with adverse events	Phase 4	https://ClinicalTrials.gov/show/NCT02779465
NCT02771405	Recruiting	No Results Available	Drug: Sofosbuvir|Drug: Ribavirin|Drug: Simeprevir|Drug: daclatasvir|Drug: Ledipasvir	Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment|Percentage of participants with virologic failure during treatment or relapse after treatment|Percentage of Participants who will show any radiological or laboratory changes denoting local or denovo recurrence of HCC	Phase 3	https://ClinicalTrials.gov/show/NCT02771405
NCT01903694	Completed	No Results Available	Drug: Sorafenib + Pravastatin|Drug: Sorafenib	determination of the tumor according to the evaluation criteria of Response Evaluation Criteria in Solid Tumors	Phase 3	https://ClinicalTrials.gov/show/NCT01903694
NCT01897610	Completed	No Results Available	Drug: Immuncell-LC	To assess progression-free survival (PFS)|To assess the overall survival (OS)|To evaluate the Disease control rate|To assess the changes of Alpha Feto Protein(AFP)figures from baseline to the last observation date|Number of participants with adverse events	Phase 2	https://ClinicalTrials.gov/show/NCT01897610
NCT01897038	Completed	No Results Available	Drug: Onartuzumab|Drug: Sorafenib	Number of Participants with Dose-limiting Toxicities (DLT)|Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)|Area Under the Concentration-time Curve (AUC) of Onartuzumab|Steady-state Plasma Concentrations of Sorafenib When Administered in Combination With Onartuzumab|Progression-free Survival (PFS)|Percentage of Participants With Objective Response|Duration of Response (DR)|Overall Survival (OS)|Percentage of Participants With Progression-free Survival at 4 Months (PFS4)|Number of Participants With Anti-therapeutic Antibodies (ATAs) Against Onartuzumab	Phase 1	https://ClinicalTrials.gov/show/NCT01897038
NCT01894269	Unknown status	No Results Available	Drug: Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.	overall survival|HBV reactivation	Phase 4	https://ClinicalTrials.gov/show/NCT01894269
NCT01935700	Recruiting	No Results Available	Drug: Colchicine	overall survival|Number of participants with adverse events	Phase 2	https://ClinicalTrials.gov/show/NCT01935700
NCT02426450	Unknown status	No Results Available	Procedure: RFA|Drug: Oxaliplatin|Drug: 5-Fluorouracil/Leucovorin	Recurrence rate|Safety and Tolerability|Recurrence-free survival|Overall survival	Phase 2	https://ClinicalTrials.gov/show/NCT02426450
NCT00884520	Completed	No Results Available	Drug: [F-18] VM4-037	Safety will be the outcome demonstrated in this clinical trial through analyses of adverse events in subjects who receive study drug.	Early Phase 1	https://ClinicalTrials.gov/show/NCT00884520
NCT01774344	Active, not recruiting	Has Results	Drug: Regorafenib (BAY73-4506)|Drug: Placebo	Overall Survival (OS)|Time to Progression (TTP)|Progression Free Survival (PFS)|Objective Tumor Response Rate (ORR)|Disease Control Rate (DCR)	Phase 3	https://ClinicalTrials.gov/show/NCT01774344
NCT02561546	Unknown status	No Results Available	Drug: p53 gene therapy|Drug: Trans-catheter embolization	fasting plasma glucose (FPG)|glycosylated hemoglobin (A1C)|overall survival (OS)|progression free survival (PFS)|postprandial glucose (PPG)	Phase 2	https://ClinicalTrials.gov/show/NCT02561546
NCT01755767	Completed	No Results Available	Drug: Tivantinib|Drug: Placebo	Rate of Overall Survival (OS) within 36 Months|Rate of Progression Free Survival (PFS) within 10 months	Phase 3	https://ClinicalTrials.gov/show/NCT01755767
NCT01752933	Completed	No Results Available	Drug: SGI-110	Assess the disease control rate (DCR) at 16 weeks for patients treated with SGI-110 after failure of sorafenib|Assess safety and tolerability of SGI-110|Determine alpha fetoprotein response as a result of SGI-110 administration|Duration of response|Progression-free survival|Overall survival	Phase 2	https://ClinicalTrials.gov/show/NCT01752933
NCT01737827	Recruiting	No Results Available	Drug: INC280	Time to progression using Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1|Overall Response Rate|Progression free survival|Overall survival|Disease Control Rate|Safety: adverse events, serious adverse events|Safety: hematology and chemistry values, vital signs, electrocardiograms|Tolerability of study drug|Plasma pharmacokinetic parameter: AUC0-t|Alpha-fetoprotein|Soluble c-MET|Soluble Hepatocyte Growth Factor|Plasma pharmacokinetic parameter: CL/F|Plasma pharmacokinetic parameter: Cmax|Plasma pharmacokinetic parameter: Tmax|Plasma pharmacokinetic parameter: T1/2|Plasma pharmacokinetic parameter: Racc	Phase 2	https://ClinicalTrials.gov/show/NCT01737827
NCT01770431	Completed	Has Results	Drug: Huaier Granule	Incidence of Recurrence and Metastasis After Hepatectomy|Postoperative Survival Period	Phase 4	https://ClinicalTrials.gov/show/NCT01770431
NCT01715532	Unknown status	No Results Available	Drug: Huachansu|Other: TACE	Progression free survival|Overall survival	Phase 2	https://ClinicalTrials.gov/show/NCT01715532
NCT01687673	Active, not recruiting	No Results Available	Drug: Temsirolimus|Drug: Sorafenib:	Median time to progression (TTP)|Response rate (RR)|Progression free survival (PFS)|Overall survival (OS)|Time to treatment failure (TTF)|Toxicity & tolerability	Phase 2	https://ClinicalTrials.gov/show/NCT01687673
NCT01681446	Recruiting	No Results Available	Drug: interferon-alpha (IFN-alpha)	disease free survival|overall survival|time to recurrence|Number of Participants with Adverse Events	Phase 3	https://ClinicalTrials.gov/show/NCT01681446
NCT01656265	Completed	No Results Available	Drug: ARQ 197	Number of participants with dose-limiting toxicity (DLT), as a measure of safety and tolerability|Profiles of Pharmacokinetics|Antitumor effects according to RECIST 1.1.	Phase 1	https://ClinicalTrials.gov/show/NCT01656265
NCT01655693	Active, not recruiting	No Results Available	Drug: Doxorubicin|Drug: Best Standard of Care	Overall survival(OS) in each group|Incidence and severity of all Treatment Emergent Adverse Events according to NCI-CTC v4.0 scale in each group	Phase 3	https://ClinicalTrials.gov/show/NCT01655693
NCT01639703	Completed	Has Results	Drug: Xenetix-CT perfusion imaging	Blood Volume (BV) According to Degree of Lesions Differentiation|Blood Flow (BF) According to Degree of Lesions Differentiation|Permeability Surface (PS) According to Degree of Lesions Differentiation|Arterial Liver Perfusion (ALP) According to Degree of Lesions Differentiation|Portal Venous Liver Perfusion (PVP) According to Degree of Lesions Differentiation|Total Liver Perfusion (TLP) According to Degree of Lesions Differentiation|Hepatic Perfusion Index (HPI) According to Degree of Lesions Differentiation|Blood Volume According to Immunohistochemistry Parameter (Glutamine Synthetase)|Blood Volume According to Immunohistochemistry Parameter (CD31)|Blood Flow According to Immunohistochemistry Parameter (Glutamine Synthetase)|Blood Flow According to Immunohistochemistry Parameter (CD31)|Permeability Surface According to Immunohistochemistry Parameter (Glutamine Synthetase)|Permeability Surface According to Immunohistochemistry Parameter (CD31)	Phase 4	https://ClinicalTrials.gov/show/NCT01639703
NCT01605734	Unknown status	No Results Available	Procedure: TACE|Drug: sorafenib combined with TACE	Time to Progression|FACT-Hep|Disease control rate|Safety|PFS and OS|Number of TACE sessions and the interval time between two TACE sessions|AFP	Phase 2	https://ClinicalTrials.gov/show/NCT01605734
NCT01594125	Completed	Has Results	Drug: Nintedanib high dose|Drug: Nintedanib low dose|Drug: Nintedanib medium dose	Number of Participants With Dose Limiting Toxicities to Determine Maximum Tolerated Dose (MTD) of Nintedanib|Number of Participants With Objective Tumour Response According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.0|Progression Free Survival (PFS)|Time to Progression (TTP)|Number of Participants With Response by Alpha Fetoprotein (AFP)	Phase 1	https://ClinicalTrials.gov/show/NCT01594125
NCT01567930	Unknown status	No Results Available	Drug: Temsirolimus	Disease Progression|Response rate|Safety and tolerability|Biochemical response|Pharmacokinetics|Circulating tumor cells levels	Phase 2	https://ClinicalTrials.gov/show/NCT01567930
NCT02281266	Not yet recruiting	No Results Available	Procedure: curative resection|Drug: thymalfasin|Drug: nucleoside analog (suggest to use entecavir)	Recurrence-free Survival|Recurrence-free Survival (RFS)|Overall survival (OS)|Mean recurrence time|Tumor sample immune cell counts|incidence and types of Adverse Events (AE) and serious adverse event (SAE)|number of patients with abnormal laboratory value, vital signs and ECG result	Phase 4	https://ClinicalTrials.gov/show/NCT02281266
NCT01507168	Completed	No Results Available	Drug: Placebo|Drug: RO5137382	Progression-free survival (tumor assessments according to RECIST criteria)|Overall survival|Time to progression (TTP): Time from randomization to first documented disease progression|Disease control rate (DCR): Complete response, partial response or stable disease lasting at least 6 weeks|Safety: Incidence of adverse events|Pharmacokinetics: Serum concentrations (Cmax,Cmin)|GPC-3 expression in tumor tissue (biopsy) by immunohistochemistry (IHC) assay	Phase 2	https://ClinicalTrials.gov/show/NCT01507168
NCT01507064	Completed	No Results Available	Drug: Sorafenib|Procedure: laser ablation (LA)	Effectiveness of sorafenib in increasing the effectiveness of laser ablation (LA)|Safety of sorafenib treatment prior to LA.|Survival in the two treatment groups	Phase 2	https://ClinicalTrials.gov/show/NCT01507064
NCT01377220	Unknown status	No Results Available	Drug: 11C-Choline		Phase 2	https://ClinicalTrials.gov/show/NCT01377220
NCT01489566	Unknown status	No Results Available	Drug: Tyroserleutide for injection ,chemotherapy(mitomycin, and Fluorouracil )|Drug: the placebo ,chemotherapy(mitomycin, and Fluorouracil )	RFS(Recurrence Free Survival)|OS （Overall Survival）|QOL score	Phase 3	https://ClinicalTrials.gov/show/NCT01489566
NCT01451658	Unknown status	No Results Available	Drug: propranolol	Rebleeding|complication survival	Phase 4	https://ClinicalTrials.gov/show/NCT01451658
NCT01429961	Unknown status	No Results Available	Drug: SOX	Time to progression (TTP)|overall survival|response rate|toxicity	Phase 2	https://ClinicalTrials.gov/show/NCT01429961
NCT00080236	Completed	No Results Available	Drug: IDN-6556|Drug: Placebo	Peak absolute change in alanine aminotransferase (ALT) values measured from baseline to up to 3 days post-transplantation|Peak absolute change in aspartate transaminase (AST) values measured from baseline to up to 3 days post-transplantation	Phase 2	https://ClinicalTrials.gov/show/NCT00080236
NCT01409499	Unknown status	No Results Available	Procedure: hepatic resection|Procedure: transcatheter hepatic arterial chemoembolization|Drug: sorafenib	Overall survival (OS)|Progression Free Survival (PFS)|AEs and SAEs|cost of treatments	Phase 4	https://ClinicalTrials.gov/show/NCT01409499
NCT01381211	Unknown status	No Results Available	Drug: TACE-DEB|Drug: 90Y-RE	Time to Progression (TTP).|Time to Local Progression (TLP).|Survival of patients dedicated to either treatment arm.|Quality of life|Tumor response to therapy according to mRECIST criteria|Treatment-related costs.|Toxicities and adverse events (recorded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE version 3.0)	Phase 2	https://ClinicalTrials.gov/show/NCT01381211
NCT01357486	Completed	No Results Available	Drug: sorafenib|Drug: Pravastatin|Drug: Sorafenib + Pravastatin|Other: patients receiving best supportive care	Time to radiologic progression|Overall survival|Survival without progression|Time to treatment failure|Objective response rate at four months|Number and description of AE for toxicity and SAE|Quality of life	Phase 2	https://ClinicalTrials.gov/show/NCT01357486
NCT01806740	Active, not recruiting	No Results Available	Drug: Meglumine Gadoterate	correlation between % change of DCE-MRI perfusion parameters|correlation between DCE-MRI perfusion parameters and other data	Phase 4	https://ClinicalTrials.gov/show/NCT01806740
NCT01352728	Completed	No Results Available	Drug: Axitinib	Two-year survival rate|Overall confirmed objective response rate (ORR) as determined according to modified RECIST.|Disease Control Rate (DCR)|Duration of Response (DR)|Time to Progression (TTP)|Progression-Free Survival (PFS)|Overall survival (OS)|Type, incidence, severity, timing, seriousness, and relatedness of adverse events and laboratory abnormalities|Quality of Life|Tissue and Serum Biomarkers	Phase 2	https://ClinicalTrials.gov/show/NCT01352728
NCT01308723	Completed	No Results Available	Drug: RO5323441|Drug: sorafenib	Part I : Safety/dose-limiting toxicity: Incidence of adverse events|Part I: Determination of recommended Part II dose|Part II: Safety/tolerability: Incidence of adverse events|Pharmacokinetics of RO5323441 in combination with sorafenib|Pharmacokinetics of sorafenib in combination with RO5323441|Pharmacodynamic biomarkers (DCE-Magnetic Resonance Imaging evaluations, Placental Growth Factor, Vascular Endothelial Growth Factor Receptors)|Efficacy: tumor assessments by Magnetic Resonance Imaging or Computed Tomography according to RECIST criteria|Impact on wound healing (skin biopsies)|Safety: additional anti-drug antibodies sampling after termination of study drug treatment	Phase 1	https://ClinicalTrials.gov/show/NCT01308723
NCT01308645	Unknown status	No Results Available	Drug: SB injection	Evaluating Tumor Response Rate|Pain Scores on the Visual Analog Scale|Number of Participants with Adverse Events as a Measure of Safety and Tolerability scale|Determine duration of response rate by measuring time to progression	Phase 2	https://ClinicalTrials.gov/show/NCT01308645
NCT01287585	Completed	No Results Available	Drug: ADI-PEG 20 (arginine deiminase formulated with polyethylene glycol)|Drug: Placebo	Overall survival|Safety and tolerability - number of participants with adverse events.	Phase 3	https://ClinicalTrials.gov/show/NCT01287585
NCT01273662	Completed	No Results Available	Drug: AG-013736	disease stabilization|time-to-tumor progression	Phase 2	https://ClinicalTrials.gov/show/NCT01273662
NCT01258608	Completed	No Results Available	Drug: Mapatumumab|Drug: Placebo|Drug: Sorafenib	Time to progression (TTP)|Overall survival (OS)|Progression-free survival (PFS)|Overall response|Disease control|Time to response|Duration of response|Frequency and severity of adverse events (AEs)|Clinical laboratory tests|Vital signs|Anti-mapatumumab antibody response|Serum mapatumumab concentration	Phase 2	https://ClinicalTrials.gov/show/NCT01258608
NCT01246986	Active, not recruiting	No Results Available	Drug: LY2157299|Drug: Sorafenib|Drug: Ramucirumab	Relationship of change in response biomarker to clinical benefit|Time to progression|Population pharmacokinetics|Recommended dose for phase 3 HCC trials|Overall survival|Progression free survival|Proportion of participants achieving an objective response (response rate)|Duration of tumor response|Time to treatment failure|Change from baseline in Functional Assessment of Cancer Therapy, Hepatobiliary (FACT-Hep) sub-scores and total score|Time to worsening of symptoms (FACT-Hep)	Phase 2	https://ClinicalTrials.gov/show/NCT01246986
NCT01170104	Unknown status	No Results Available	Drug: Sorafenib|Procedure: TACE (Transcatheter arterial chemoembolization)	Time to progression|To evaluate the toxicity profiles	Phase 2	https://ClinicalTrials.gov/show/NCT01170104
NCT01131689	Completed	No Results Available	Drug: sorafenib, TS-1	MTD	Phase 1	https://ClinicalTrials.gov/show/NCT01131689
NCT01129570	Completed	No Results Available	Drug: Silybin	The maximum tolerated dose of siliphos in patients with advanced hepatocellular carcinoma|Mean intra-patient percent change in AST, ALT and total serum bilirubin levels|Quality of life as measured by the FACT-hepatobiliary questionnaire|Plasma concentrations of silybinin, silybinin B, silibinin glucoronide, and silibinin sulfate|Mean intra-patient percent change in serum concentrations of CRP, IGF-1, and IGFBP-3|Tumor response as measured by RECIST criteria and AFP concentrations	Phase 1	https://ClinicalTrials.gov/show/NCT01129570
NCT01126463	Recruiting	No Results Available	Drug: 188Re-SSS Lipiodol	Maximal tolerated dose|Bio-availability	Phase 1	https://ClinicalTrials.gov/show/NCT01126463
NCT01098760	Completed	No Results Available	Drug: Sorafenib (Nexavar, BAY43-9006) Sorafenib (Nexavar, BAY43-9006) + Nerison Fatty Ointment Sorafenib (Nexavar, BAY43-9006)+Neribas Fatty Ointment	Time to progression|Progression-free survival|Overall survival|Adverse event and serious adverse event (SAE) profiles|Child-Pugh status progression|Plasma Sorafenib exposure (AUC0-12)|For subjects randomized into HFSR study subgroup: overall HFSR incidence in the first 3 weeks of Sorafenib treatment|For HFSR study subgroup: a mean HFSR grade determined at the end of the first 3 weeks of sorafenib treatment.	Phase 4	https://ClinicalTrials.gov/show/NCT01098760
NCT01088581	Completed	No Results Available	Drug: Adjuvant group	2-year recurrence rate and adverse events|overall survival	Phase 3	https://ClinicalTrials.gov/show/NCT01088581
NCT01055743	Unknown status	No Results Available	Procedure: Radical resection|Drug: Fluorouracil Implants	To assess the clinical benefit of fluorouracil implants regional chemotherapy during the radical resection in early stage hepatocellular carcinoma patients. The primary endpoint is disease-free survival (DFS).|Quality of Life|Incidence Rate of Complications|Adverse Events	Phase 2	https://ClinicalTrials.gov/show/NCT01055743
NCT01040559	Completed	No Results Available	Drug: idarubicin	Dose-limiting toxicity assessed according NCI CTC AE v3.0|Objective responses according criteria of the European Association for the Study of the Liver and according RECIST criteria.|Quality of life (EORTC QLQ-C30)|Pharmacokinetics parameters of idarubicin and idarubicinol	Phase 1	https://ClinicalTrials.gov/show/NCT01040559
NCT01035229	Completed	Has Results	Drug: Everolimus|Drug: Everolimus Placebo|Other: Best Supportive Care (BSC)	Overall Survival (OS)|Time to Tumor Progression (TTP)|Percentage of Participants With Disease Control Rate (DCR)|Time to Definitive Deterioration of ECOG Performance Score (PS) Score|Time to Definitive Deterioration of EORTC QLQ-C30 Scores|Pharmacokinetics Assessments - Cmin|Pharmacokinetics Assessments - Cmax	Phase 3	https://ClinicalTrials.gov/show/NCT01035229
NCT01418729	Completed	No Results Available	Drug: Pravastatin	Overall survival|Time to progression|time to symptomatic progression (TTSP).	Phase 2	https://ClinicalTrials.gov/show/NCT01418729
NCT01004003	Completed	Has Results	Drug: Sorafenib|Drug: BIBF 1120	Maximum Tolerated Dose in Phase I|Time to Progression (TTP) in Phase II|Incidence of Dose Limiting Toxicity in Phase I|Objective Tumour Response by RECIST|Progression Free Survival (PFS)|Overall Survival	Phase 2	https://ClinicalTrials.gov/show/NCT01004003
NCT01003015	Completed	No Results Available	Drug: BAY73-4506	Adverse Event Collection|Time to progression|Objective response rate|Disease control rate|Overall survival|Trough concentration of Regorafenib and metabolites (for Europe only)|Full Pharmacokinetics profile of BAY73-4506 and metabolites (for Korea only)	Phase 2	https://ClinicalTrials.gov/show/NCT01003015
NCT00990860	Unknown status	No Results Available	Drug: doxorubicin|Procedure: TACE (Transcatheter arterial chemoembolization)	Safety and tolerability (such as adverse events and laboratory changes (haematology, clinical chemistry))|Time to Progression|Overall survival|Progression Free Survival|No. of TACE cycles	Phase 2	https://ClinicalTrials.gov/show/NCT00990860
NCT00988741	Completed	No Results Available	Drug: ARQ 197|Drug: Placebo	Evaluate time to progression among all patients treated with ARQ 197 compared to placebo|Evaluate progression-free survival, overall survival, objective response rate and disease control rate among all patients treated with ARQ 197 compared to placebo.|Evaluate objective response rate in crossover population following radiographic disease progression on placebo.|Further characterize the safety of ARQ 197 in patients with unresectable HCC|Further evaluate pharmacokinetics of ARQ 197.	Phase 2	https://ClinicalTrials.gov/show/NCT00988741
NCT00987935	Completed	Has Results	Drug: Sorafenib|Drug: BIBF 1120	Maximum Tolerated Dose in Phase I|Time to Progression (TTP) in Phase II|Time to Progression (TTP) in Phase II (Follow-up Analyses)|Incidence and Intensity of Adverse Events (AEs) Reported as the Number of Patients With AEs According to Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 Throughout the Treatment Period.|Incidence of Dose Limiting Toxicity in Phase I|Objective Tumour Response by RECIST|Progression Free Survival (PFS)|Overall Survival|AUC0-12,ss,Norm (Area Under the Plasma Concentration-time Curve Between 0 and 12 Hours at Steady State, Normalised Values) of Nintedanib|AUC0-12,ss,Norm (Area Under the Plasma Concentration-time Curve Between 0 and 12 Hours at Steady State, Normalised Values) of BIBF 1202 (Metabolite of Nintedanib)|AUC0-12,ss,Norm (Area Under the Plasma Concentration-time Curve Between 0 and 12 Hours at Steady State, Normalised Values) of BIBF 1202 Glucuronide (Metabolite of Nintedanib)|Cmax,ss,Norm (Maximum Concentration of the Nintedanib in Plasma at Steady State, Normalised Values)|Cmax,ss,Norm (Maximum Concentration of the BIBF 1202 in Plasma at Steady State, Normalised Values)|Cmax,ss,Norm (Maximum Concentration of the BIBF 1202 Glucuronide in Plasma at Steady State, Normalised Values)|fe0-12,ss (Fraction Excreted in Urine Between 0 and 12 Hours at Steady State) for Nintedanib	Phase 2	https://ClinicalTrials.gov/show/NCT00987935
NCT00508001	Completed	Has Results	Drug: Vandetanib|Drug: Best Supportive Care	Tumour Stabilisation Rate|Objective Response Rate|Progression-free Survival|Overall Survival	Phase 2	https://ClinicalTrials.gov/show/NCT00508001
NCT00149565	Completed	No Results Available	Drug: IFN-α2b	134 patients for each of the two treatment arms are needed.	Phase 3	https://ClinicalTrials.gov/show/NCT00149565
NCT01559844	Completed	Has Results	Drug: Sofosbuvir|Drug: Ribavirin	Percentage of Participants With Posttransplant Virologic Response (pTVR) at Posttransplant Week 12|Percentage of Participants Experiencing Any Adverse Event Leading to Permanent Discontinuation of Sofosbuvir Prior to Receiving Transplant|Percentage of Participants With Graft Loss Following Transplant|Number of Participants Who Died|Percentage of Participants With Posttransplant Virologic Response (pTVR) Through Posttransplant Week 48|Percentage of Participants With HCV RNA < LLOQ (ie, 25 mL/IU) During Treatment Through Week 48|HCV RNA and Change From Baseline in HCV RNA Through Week 8|Proportion of Participants With Virologic Failure Prior to Transplant	Phase 2	https://ClinicalTrials.gov/show/NCT01559844
NCT00943449	Completed	No Results Available	Drug: 4SC-201|Drug: Sorafenib	Progression Free Survival Rate (PFSR) of repeated oral doses of 4SC-201 and of the treatment combination of Sorafenib plus 4SC-201|To establish the MTD of 4SC-201 in combination with Sorafenib|To investigate the safety and tolerability of repeated oral doses of 4SC-201 and of the treatment combination of ascending repeated oral doses of 4SC-201 and Sorafenib|To investigate biomarkers	Phase 2	https://ClinicalTrials.gov/show/NCT00943449
NCT00921531	Unknown status	No Results Available	Drug: Thalidomide|Drug: TACE	Overall survival|time to progression	Phase 3	https://ClinicalTrials.gov/show/NCT00921531
NCT00908752	Completed	No Results Available	Drug: Brivanib|Other: Brivanib Placebo|Procedure: TACE Therapy	To compare the Overall Survival (OS) of HCC patients who receive brivanib as adjuvant treatments to TACE therapy, with the OS of HCC patients who receive matched placebo with TACE therapy|To compare the Time-To-Disease Progression (TTDP) of patients receiving brivanib with TACE therapy to that of patients receiving placebo with TACE therapy|To compare the time to extrahepatic spread or vascular invasion in the brivanib and placebo arms|To determine the total number of TACE sessions in the brivanib and placebo arms and to compare the rate of TACE sessions in the brivanib and placebo arms|To evaluate the safety of brivanib in combination with TACE	Phase 3	https://ClinicalTrials.gov/show/NCT00908752
NCT00901901	Completed	Has Results	Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Erlotinib (Tarceva)|Drug: Placebo	Overall Survival|Time to Radiological Tumor Progression (TTP)|Disease Control|Health-related Quality of Life and Utility Values as Measured by EQ-5D - Index|Health-related Quality of Life and Utility Values as Measured by EQ-5D - VAS	Phase 3	https://ClinicalTrials.gov/show/NCT00901901
NCT00892658	Active, not recruiting	No Results Available	Drug: Sorafenib	Determine the MTD of sorafenib and RT in patients with hepatocellular carcinoma using an iso-toxicity radiation dose allocation scheme. Determine the acute toxicity (< 3 months) of sorafenib when combined with RT.|Determine late toxicities, in-field local control at 3 months, overall survival, progression time, and progression free survival. Quantify alteration in perfusion parameters.Assess serum and tissue biomarkers. Assess quality of life in these patients.	Phase 1	https://ClinicalTrials.gov/show/NCT00892658
NCT01265576	Unknown status	No Results Available	Drug: Sorafenib|Drug: VT-122 (propranolol plus etodolac)|Drug: Placebo	failure free survival|clinical benefit response	Phase 2	https://ClinicalTrials.gov/show/NCT01265576
NCT00858871	Completed	No Results Available	Drug: Brivanib|Drug: Placebo|Drug: Sorafenib	To compare the overall survival of brivanib versus sorafenib in subjects with advanced HCC who have not received prior systemic treatment|To compare the time to progression (TTP) (investigator assessed using modified RECIST criteria for HCC|To compare the investigator assessed objective response rate (ORR) and disease control rate (DCR) using modified RECIST criteria for HCC|To determine duration of response, duration of disease control, and time to response (TTR)|To assess the safety profile of brivanib and sorafenib|To explore PK and exposure-response in the study population|To compare time to symptomatic progression|To compare health-related quality of life	Phase 3	https://ClinicalTrials.gov/show/NCT00858871
NCT00855218	Completed	Has Results	Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Placebo	Time to Progression (TTP) - Independent Radiological Review (Primary Analysis)|Overall Survival (OS)|Time to Untreatable Progression (TTUP)|Time to Vascular Invasion/Extrahepatic Spread (TTVI/ES)|Tumor Response - Independent Radiological Review|Tumor Response - Investigator Assessment	Phase 2	https://ClinicalTrials.gov/show/NCT00855218
NCT01259193	Unknown status	No Results Available	Drug: Sorafenib and Zoledronic Acid	numbers of adverse events|Overall survival (OS), time to progression (TTP)	Phase 2	https://ClinicalTrials.gov/show/NCT01259193
NCT00844688	Unknown status	No Results Available	Drug: sorafenib|Drug: Gemcitabine	RECIST criteria for response evaluation by CT sacan abdomen in Target lesion of HCC|Toxicity evaluation in accordance with CTCAE v3.0	Phase 2	https://ClinicalTrials.gov/show/NCT00844688
NCT00829465	Completed	No Results Available	Drug: Licartin|Procedure: Transcatheter arterial chemoembolization	OS of 1 years; TTP	Phase 4	https://ClinicalTrials.gov/show/NCT00829465
NCT00823290	Unknown status	No Results Available	Drug: Sorafenib + LBH589	Maximum tolerated dose of LBH589|Safety, tolerability and adverse events (based on CTCAE 3.0)|Reduction of lesion size (radiologically assessed according to RECIST)|Laboratory abnormalities (CTC grade 3 or grade 4 toxicities)	Phase 1	https://ClinicalTrials.gov/show/NCT00823290
NCT00805896	Unknown status	No Results Available	Drug: Songyou|Drug: placebo	Time to tumor progression(TTP)|Overall survival (OS)	Phase 2	https://ClinicalTrials.gov/show/NCT00805896
NCT00802555	Completed	No Results Available	Drug: ARQ 197	To evaluate the safety of ARQ 197 when administered in cirrhotic patients diagnosed with HCC|To evaluate time to disease progression (TTP), objective response rate (ORR), and disease control rate (DCR) in patients with HCC|To evaluate dynamic changes of hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), and soluble c-Met in patients' peripheral blood that are associated with ARQ 197 treatment	Phase 1	https://ClinicalTrials.gov/show/NCT00802555
NCT00752063	Unknown status	No Results Available	Drug: Sorafenib with Capecitabine and Oxaliplatin	Progression-free survival|Tumor response rate, overall survival and safety of the regimen in HCC patients	Phase 2	https://ClinicalTrials.gov/show/NCT00752063
NCT00703365	Completed	No Results Available	Drug: Sorafenib and Gemcitabine	To evaluate the efficacy (progression free survival (PFS)) of sorafenib in patients with advanced/unresectable HCC.|To evaluate overall, survival, overall response rate (RECIST), time to progression (TTP), disease control rate (DCR) and side-effect profile of sorafenib in combination with gemcitabine in patients suffering from HCC.	Phase 2	https://ClinicalTrials.gov/show/NCT00703365
NCT01263002	Completed	No Results Available	Drug: clevudine, Adefovir	Proportion of patients with HBV DNA levels ＜ 60 IU/mL	Phase 4	https://ClinicalTrials.gov/show/NCT01263002
NCT00554125	Unknown status	No Results Available	Drug: sirolimus	Disease-free survival|overall survival	Phase 3	https://ClinicalTrials.gov/show/NCT00554125
NCT00635323	Completed	No Results Available	Drug: Irinotecan plus capecitabine	Overall response rate|Time to progression|Duration of overall response|Overall tumour growth control rate|Overall survival|Adverse events|Physical exam|Laboratory tests	Phase 2	https://ClinicalTrials.gov/show/NCT00635323
NCT00619541	Completed	No Results Available	Drug: Infusional 5-Fluorouracil|Drug: Sorafenib (Bay 43-9006)	N° of non progressive disease (complete and partial responses, stable disease)|Toxicity of the combination,ORR,Duration of responses, TTP and OS.PK, PD,Baseline pERK concentration, phospho VEGF-R2 concentration, plasma proteomics and gene expression profiling on blood cells and tumor biopsy	Phase 2	https://ClinicalTrials.gov/show/NCT00619541
NCT00559455	Completed	No Results Available	Drug: Oxaliplatin|Drug: Fluorouracil|Drug: Leucovorin	Tumor Response Rate evaluated using RECIST (Response Evaluation Criteria in Solid Tumors) by physical examination, chest X-ray, abdomen-pelvis CT (Computed tomography) scan|Time to Progression (TTP), 6 month survival, overall survival, AFP	Phase 2	https://ClinicalTrials.gov/show/NCT00559455
NCT00524498	Completed	No Results Available	Drug: OPC-18|Drug: cisplatin	Antitumor effect (tumor size reduction)|Disease control rate Overall survival Progression-free survival	Phase 2	https://ClinicalTrials.gov/show/NCT00524498
NCT00519688	Completed	No Results Available	Drug: Thalidomide|Drug: Tegafur/Uracil	To evaluate the overall response rate of UFUR and thalidomide in the treatment of advanced HCC by RECIST criteria|To determine the disease stabilization rate.|To assess the progression- free survival and overall survival.|To establish the safety profile.	Phase 2	https://ClinicalTrials.gov/show/NCT00519688
NCT00517920	Completed	No Results Available	Drug: ABT-869	Progression-Free Rate|Objective Response Rate	Phase 2	https://ClinicalTrials.gov/show/NCT00517920
NCT00492752	Completed	Has Results	Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Placebo	Overall Survival|Time to Symptomatic Progression (TTSP)|Time to Progression (TTP)|Disease Control|Change in Functional Assessment of Cancer Therapy (FACT) Hepatobiliary Symptom Index-8 (FHSI-8) Score From Baseline to Cycle 1 and Cycle 3|Change in Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) Score From Baseline to Cycle 3 and End of Treatment|Number of Participants With Different Tumor Response|Duration of Response|Time to Response|Area Under the Curve From Time 0 to 12 Hours Post-dose (AUC 0-12) After 21 Days of Sorafenib Treatment|Normalized Area Under the Curve (AUC Norm) After 21 Days of Sorafenib Treatment|Maximum Concentration (Cmax) After 21 Days of Sorafenib Treatment|Normalized Maximum Concentration (Cmaxnorm) After 21 Days of Sorafenib Treatment|Time of Maximum Concentration (Tmax) After 21 Days of Sorafenib Treatment	Phase 3	https://ClinicalTrials.gov/show/NCT00492752
NCT00490685	Completed	No Results Available	Drug: Sorafenib (BAY-43-9006)		Phase 2	https://ClinicalTrials.gov/show/NCT00490685
NCT00484211	Completed	No Results Available	Drug: NGR-hTNF	Antitumour activity defined as progression free survival (PFS)|Tumor growth control rate (TGCR) according to WHO criteria|Pharmacokinetics in patients treated with weekly schedule|Safety|Overall survival (OS)|Experimental imaging study (DCE-MRI)	Phase 2	https://ClinicalTrials.gov/show/NCT00484211
NCT00478374	Completed	No Results Available	Drug: Sorafenib|Procedure: Transarterial chemoembolisation with doxorubicin	To assess the safety and tolerability of the administration of sorafenib in patients with hepatocellular carcinoma treated with TACE by determining the MTD.|tumor volumetry|changes in the blood concentration of tumor marker AFP	Phase 1	https://ClinicalTrials.gov/show/NCT00478374
NCT00834860	Unknown status	No Results Available	Drug: peginterferon alpha-2a and ribavirin	Efficacy: sustained virological response (SVR), HCV RNA seronegative by PCR throughout 24-week off-treatment period.|Rapid virologic response (RVR), HCV RNA seronegative by PCR at week 4.|Early virological response (EVR), by PCR-negative or at least 2 logs decline from baseline of serum HCV RNA at 12 weeks of treatment.|Safety: adverse event rate and profile.	Phase 4	https://ClinicalTrials.gov/show/NCT00834860
NCT00471965	Completed	No Results Available	Drug: Oxaliplatin + 5-Fluorouracil/Leucovorin|Drug: Doxorubicin	Overall survival|Time to progression|Response rate, secondary resection rate, quality of life	Phase 3	https://ClinicalTrials.gov/show/NCT00471965
NCT00464919	Completed	No Results Available	Drug: Sorafenib|Drug: tegafur/uracil (UFUR®)	To determine the progression- free survival of sorafenib plus tegafur/uracil (UFUR®) for the treatment of advanced or metastatic HCC.|The 6-month progression-free survival rate.|The objective tumor response rate.|The disease stabilization rate (complete response + partial response + stable disease for at least 2 months).|The overall survival.|The safety profile.|To evaluate the changes of circulating biomarkers indicating the angiogenesis activity and their correlation with objective tumor response.	Phase 2	https://ClinicalTrials.gov/show/NCT00464919
NCT00464295	Completed	No Results Available	Drug: Capecitabine in HCC	To evaluate response rate and overall survival after completing minimum of three cycles of Capecitabine in Advance HCC|To evaluate the time to progression, toxicity and quality of life for patients on chemotherapy	Phase 2	https://ClinicalTrials.gov/show/NCT00464295
NCT00460681	Unknown status	No Results Available	Drug: Thymopentin	disease-free survival|overall survival	Phase 3	https://ClinicalTrials.gov/show/NCT00460681
NCT00423306	Unknown status	No Results Available	Drug: Darinaparsin	Response Rate|Survival (overall and progression free)|toxicities	Phase 2	https://ClinicalTrials.gov/show/NCT00423306
NCT00960518	Unknown status	No Results Available	Drug: adefovir|Procedure: TACE	the progression free survival (PFS)|the rate of overall survival	Phase 2	https://ClinicalTrials.gov/show/NCT00960518
NCT00386984	Completed	No Results Available	Drug: Somatostatin (octreotide)	Overall survival time|Costs of the treatment measured by days of in-patient treatment|Side effects|Patient compliance|Quality of life|Somatostatin receptors in the tumor tissue|Prognostic relevance of the Somatostatin receptors	Phase 3	https://ClinicalTrials.gov/show/NCT00386984
NCT00384800	Unknown status	No Results Available	Drug: Thalidomide(THADO), Tegafur/Uracil(UFUR)	Primary Objective|To assess the overall response rate of tegafur/uracil (UFUR®) and thalidomide in the treatment of advanced or metastatic hepatocellular carcinoma.|Secondary Objectives|To determine the disease stabilization rate (CR+PR+SD).|To assess the progression-free survival and overall survival.|To establish the safety profile.|To evaluate the changes of circulating factors indicating the angiogenesis activity and their correlation with objective tumor response.	Phase 2	https://ClinicalTrials.gov/show/NCT00384800
NCT00287222	Completed	Has Results	Drug: Bevacizumab|Drug: Erlotinib	Number of Participants Who Remained Free of Progression at the 27th Week.	Phase 2	https://ClinicalTrials.gov/show/NCT00287222
NCT00768157	Unknown status	No Results Available	Drug: antiviral treatment (lamivudine or entecavir)|Procedure: radical resection of HBV-related HCC	Overall survivals|Recurrence rate	Phase 4	https://ClinicalTrials.gov/show/NCT00768157
NCT00280618	Completed	No Results Available	Drug: Oxaliplatin	Time to Tumor Progression (TTP) and Response Rate: evaluated by RECIST|Adverse Events collections and evaluation	Phase 2	https://ClinicalTrials.gov/show/NCT00280618
NCT00241020	Completed	No Results Available	Drug: Octreotide	Overall Survival|Objective response|Survival without progression|Digestive bleeding|Renal insufficiency|Quality of life|· Safety	Phase 3	https://ClinicalTrials.gov/show/NCT00241020
NCT00162669	Unknown status	No Results Available	Drug: bevacizumab	The main response parameter will be the disease control rate, defined by the objective response and stable disease rate (Response Evaluation Criteria in Solid Tumors [RECIST criteria]) after two consecutive tumor evaluations during treatment.|Overall survival, progression-free survival, toxicity (National Cancer Institute-Common Toxicity Criteria Version 3 [NCI-CTC V3])|Evaluation of vascular changes will be performed using Doppler ultrasound with injection of sonographic contrast agent	Phase 2	https://ClinicalTrials.gov/show/NCT00162669
NCT00142467	Completed	No Results Available	Drug: Gemcitabine|Drug: Oxaliplatin|Drug: Bevacizumab	Time to disease progression of gemcitabine, oxaliplatin and bevacizumab regimen in patients with hepatocellular carcinoma.|Number of participants with adverse events|Objective response rate|Overall survival	Phase 2	https://ClinicalTrials.gov/show/NCT00142467
NCT00142428	Completed	No Results Available	Drug: Cetuximab	Progression free survival in patients treated with cetuximab for unresectable or metastatic hepatocellular carcinoma|Number of patients with adverse events|Overall Survival|Objective Response Rate	Phase 2	https://ClinicalTrials.gov/show/NCT00142428
NCT00082082	Completed	No Results Available	Drug: Thymalfasin (thymosin alpha-1)|Procedure: Trans arterial chemoembolization (TACE)		Phase 2	https://ClinicalTrials.gov/show/NCT00082082
NCT00375661	Completed	No Results Available	Drug: interferon-alfa-2b and ribavirin	Incidence of adverse effect of interferon	Phase 4	https://ClinicalTrials.gov/show/NCT00375661
NCT00056992	Completed	No Results Available	Drug: ADI-PEG 20		Phase 2	https://ClinicalTrials.gov/show/NCT00056992
NCT00116454	Completed	No Results Available	Drug: 131 I-lipiodol	to determine if the Lipiocis treatment decreases the % of tumoral recurrence after 24 months, judged on the rise of alpha-fetoprotein and the reappearance of one or more tumours on the hepatic CT scan|overall survival|recurrence-free survival|treatment toxicity|Deterioration of the hepatocellular function	Phase 3	https://ClinicalTrials.gov/show/NCT00116454
NCT00043433	Unknown status	No Results Available	Drug: intravenous T900607-sodium		Phase 2	https://ClinicalTrials.gov/show/NCT00043433
NCT00006332	Completed	No Results Available	Drug: Tetrathiomolybdate		Phase 2	https://ClinicalTrials.gov/show/NCT00006332
NCT00003597	Completed	No Results Available	Biological: recombinant human thrombopoietin|Drug: carboplatin|Drug: etoposide|Drug: ifosfamide|Biological: G-CSF	Determine the pharmacokinetics and toxicities associated with the administration of recombinant human thrombopoietin (rhTPO)|Evaluate the time for patients to demonstrate platelet recovery	Phase 1	https://ClinicalTrials.gov/show/NCT00003597
NCT00637637	Unknown status	No Results Available	Drug: indinavir sulfate|Drug: ritonavir|Radiation: radiation therapy	Time to treatment failure in the brain (TTF) as determined by the radiological response rate|Overall survival (OS)|Radiological volumetric response to treatment|Local intracranial disease progression at 4 months|Progression-free survival at 6 months|Improvement of symptoms|Time to symptom relapse or symptom progression|Duration of use of steroids|Duration of use of anticonvulsive drugs	Phase 2	https://ClinicalTrials.gov/show/NCT00637637
NCT00073944	Completed	No Results Available	Drug: forodesine hydrochloride		Phase 1	https://ClinicalTrials.gov/show/NCT00073944
NCT02301104	Completed	No Results Available	Drug: TAS-102	PK parameters of FTD, FTY, and TPI in plasma after a single dose of TAS-102|Safety monitoring including adverse events, vital signs, and laboratory assessments	Phase 1	https://ClinicalTrials.gov/show/NCT02301104
NCT02162563	Recruiting	No Results Available	Drug: FOLFOX/ FOLFIRI with bevacizumab|Drug: FOLFOXIRI with bevacizumab|Drug: FOLFOX/ FOLFIRI with panitumumab	Progression-free survival (PFS)|R0/1 secondary resection rate|Median overall survival|Response rate|Toxicity (AE)|Pathological complete response rate (pCR)|Postoperative morbidity|Correlation of evaluation by the panel with outcome	Phase 3	https://ClinicalTrials.gov/show/NCT02162563
NCT00941655	Completed	Has Results	Drug: Oxaliplatin|Drug: Irinotecan|Drug: 5-Fluorouracil|Drug: Leucovorin|Procedure: Gastrectomy and/or metastasectomy	Overall Survival in Patients With Limited Metastatic Gastric Carcinoma: Arm I|Overall Survival in Patients With Limited Metastatic Gastric Carcinoma: Arm II|Count of Participants With Adverse Events|12 Months Disease Free Survival (DFS)|Gillys Stage Before and After Surgery|Completeness of Cytoreduction (CCR) Score|Median Blood Loss During Surgery|Median Hospital Stay After Initial Surgery|Median Duration of Cytoreduction Surgery and Heated Intraperitoneal Chemotherapy (HIPEC)|Quality of Life (QOL) Parameters Between the Two Study Groups|Patterns of Disease Recurrence Between the Two Therapeutic Approaches and Their Clinical Implications	Phase 3	https://ClinicalTrials.gov/show/NCT00941655
NCT03296839	Not yet recruiting	No Results Available	Radiation: SBRT|Drug: Chemotherapy	progression-free survival (PFS) at 2 years|local control rates|liver PFS|overall survival|cancer-specific survival|Incidence of SBRT toxicities|Quality of life|salvage hepatic therapy|ceramide and its sphingolipid metabolites	Phase 3	https://ClinicalTrials.gov/show/NCT03296839
NCT01453283	Completed	No Results Available	Drug: Trabectedin (ecteinascidin-743, ET-743, YONDELIS [R])		Phase 1	https://ClinicalTrials.gov/show/NCT01453283
NCT01167049	Unknown status	No Results Available	Drug: CAPECITABINE	Tumor response will be evaluated using RECIST criteria. Survival data will be analyzed by Kaplan Meier method. 95% CI will be provided	Phase 2	https://ClinicalTrials.gov/show/NCT01167049
NCT02693067	Recruiting	No Results Available	Drug: Rose bengal disodium	Number of Participants with Adverse Events|Objective Response Rate (ORR)|Target Lesion Somatostatin Receptor (SSTR) Expression|Change in Neuroendocrine Tumor Biomarkers|Reduction in Major Symptoms|Reduction in Other Symptoms|Change in Peripheral Blood Mononuclear Cells (PBMC)	Phase 1	https://ClinicalTrials.gov/show/NCT02693067
NCT01836653	Completed	No Results Available	Drug: Bevacizumab|Drug: Cetuximab|Drug: L-OHP|Drug: l-LV|Drug: 5-FU	Progression-free survival|Response rate	Phase 2	https://ClinicalTrials.gov/show/NCT01836653
NCT01632722	Completed	No Results Available	Drug: Bevacizumab, mFOLFOX, FOLFIRI	2 years recurrence-free survival (2Y-RFS)	Phase 2	https://ClinicalTrials.gov/show/NCT01632722
NCT03519074	Recruiting	No Results Available	Drug: TS-1 combined with cisplatin	Efficacy evaluations: Disease status|Efficacy Evaluation: Timing	Phase 2	https://ClinicalTrials.gov/show/NCT03519074
NCT03398291	Not yet recruiting	No Results Available	Procedure: Synchronous resection of primary pancreatic cancer and liver oligometastasis|Drug: Standard chemotherapy	Real overall survival|Overall survival|Quality of life|Postoperative morbidity|Postoperative mortality	Phase 3	https://ClinicalTrials.gov/show/NCT03398291
NCT03223779	Recruiting	No Results Available	Drug: TAS-102|Radiation: Photon SBRT	Maximum Tolerated Dose (MTD)|The Duration of Local Control|Toxicity associated with TAS-102 combined with SBRT|Progression Free Survival|Overall Survival|Association between KRAS or BRAF mutation status with local control|Serial ctDNA	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT03223779
NCT00874406	Unknown status	No Results Available	Drug: tac + folfox4|Drug: folfox4	progression free survival|overall survival	Phase 4	https://ClinicalTrials.gov/show/NCT00874406
NCT02912052	Not yet recruiting	No Results Available	Drug: Peri-operative chemotherapy|Drug: postoperative chemotherapy	Disease free survival，DFS|Overall survival	Phase 3	https://ClinicalTrials.gov/show/NCT02912052
NCT00540982	Completed	No Results Available	Drug: indocyanine green|Drug: lidocaine|Drug: vinorelbine ditartrate|Other: high performance liquid chromatography|Other: intracellular fluorescence polarization analysis|Other: liquid chromatography|Other: mass spectrometry|Other: pharmacological study	Correlation of indocyanine green and lidocaine metabolism with vinorelbine ditartrate pharmacokinetics|Pharmacokinetics of vinorelbine ditartrate as measured by high performance liquid chromatography (15) or by liquid chromatography/tandem mass spectrometry assay|Test of dose adjustment of vinorelbine ditartrate	Phase 1|Phase 2	https://ClinicalTrials.gov/show/NCT00540982
NCT00408551	Unknown status	No Results Available	Drug: floxuridine|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Drug: oxaliplatin	Tumor response as measured by carcinoembryonic antigen (CEA) level, RECIST criteria, and positron emission tomography (PET) scan|Hepatic toxicity|Therapeutic efficacy based on time from selective internal radiation therapy (SIRT) to in-liver disease progression|Therapeutic efficacy based on the proportion of patients who achieve down-staging among all chemo-SIRT treated patients	Phase 2	https://ClinicalTrials.gov/show/NCT00408551
NCT00004142	Completed	No Results Available	Drug: Floxuridine|Drug: Fluorouracil (5-FU)|Procedure: Conventional surgery|Procedure: Radiofrequency ablation	Patient Tumor Response Rate	Phase 2	https://ClinicalTrials.gov/show/NCT00004142
NCT00438737	Unknown status	No Results Available	Biological: bevacizumab|Biological: cetuximab|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy	Response rate (preoperative response rate)|Safety (rate of perioperative safety findings)|Progression-free survival|Pathological resection rate|Overall survival	Phase 2	https://ClinicalTrials.gov/show/NCT00438737
NCT01912222	Completed	Has Results	Drug: IXAZOMIB	Unbound AUC(0-last): Unbound Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Ixazomib|Unbound Cmax: Unbound Maximum Observed Plasma Concentration for Ixazomib|Tmax- Time to Reach the Maximum Plasma Concentration (Cmax) for Ixazomib|Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAE) and Serious Adverse Events (SAE)|Number of Participants Reporting Clinically Significant Change From Baseline in Laboratory Values|Number of Participants Reporting Clinically Significant Change From Baseline in Vital Signs	Phase 1	https://ClinicalTrials.gov/show/NCT01912222
NCT01070355	Completed	No Results Available	Drug: Eicosapentaenoic acid free fatty acid|Drug: Placebo	Histological Ki67 cancer cell proliferation index|Histological neo-CK18 cancer cell apoptosis index|Histological tumour CD31-positive cell microvessel density|Safety and tolerability of EPA treatment|Metastatic tissue and healthy liver tissue fatty acid composition and prostaglandin levels|Plasma markers of prostaglandin metabolism|Platelet aggregation|Urinary markers of prostaglandin metabolism	Phase 2	https://ClinicalTrials.gov/show/NCT01070355
NCT02063529	Recruiting	No Results Available	Drug: FOLFOXIRI + Cetuximab|Drug: FOLFOXIRI	the percentage of patients who had a curative liver treatment following protocol treatment, i.e., liver metastases that can be completely resected and/or ablated with no evidence of residual malignant disease.|Reported adverse events.|Response rate|Progression free survival|Time to recurrence|Quality of life (QLQ C30)	Phase 2	https://ClinicalTrials.gov/show/NCT02063529
NCT00508326	Completed	No Results Available	Drug: Paclitaxel	Maximum Tolerated Dose of Monthly Cytotoxic Intraarterial Hepatic Paclitaxel	Phase 1	https://ClinicalTrials.gov/show/NCT00508326
NCT01226719	Completed	Has Results	Drug: Panitumumab|Drug: Oxaliplatin|Drug: Irinotecan|Drug: Leucovorin|Drug: 5-Fluorouracil	Overall Response Rate (ORR)|R0 Resection Rate|Progression-free Survival (PFS)|To Determine the Acute Toxicity Produced by This Regimen.|Overall Survival (OS)	Phase 2	https://ClinicalTrials.gov/show/NCT01226719
NCT00742911	Completed	No Results Available	Drug: Disulfiram|Drug: Copper Gluconate	Determine the safety and toxicity profile of co-administration of disulfiram and copper gluconate for the treatment of refractory malignancies that have metastasized to the liver|Determine if disulfiram and copper gluconate induce measurable responses for the treatment of hepatic metastases from solid tumors|Qualitative assessment of the induction of S-glutathionylation in proteins of circulating leukocytes in patients treated with disulfiram and copper gluconate	Phase 1	https://ClinicalTrials.gov/show/NCT00742911
NCT01839877	Active, not recruiting	No Results Available	Drug: HIA DEBIRI + systemic FOLFOX	Progression-free survival rate at 9 months|safety of the study treatment|Overall survival	Phase 2	https://ClinicalTrials.gov/show/NCT01839877
NCT00803647	Completed	Has Results	Biological: cetuximab|Drug: 5-FU|Drug: oxaliplatin|Drug: leucovorin	The Percentage of Patients Who Had a Curative (R0) Liver Metastasectomy Following Protocol Treatment, i.e., Metastatic Disease That Can be Completely Resected and/or Ablated With no Postoperative Evidence of Residual Malignant Disease (R0 Resection).|Reported Adverse Events.|Overall Survival (OS). Time From Study Entry Until Death From Any Cause.|Objective Clinical Response Rate (cRR). Measureable Lesions That Can be Accurately Measured in at Least One Dimension With Conventional Radiologic Techniques or Spiral CT.|Recurrence-free Survival (RFS). Time From Study Entry Until First Recurrence.	Phase 2	https://ClinicalTrials.gov/show/NCT00803647
NCT00005077	Completed	No Results Available	Drug: oxaliplatin		Phase 1	https://ClinicalTrials.gov/show/NCT00005077
NCT00507962	Completed	No Results Available	Drug: Cisplatin|Drug: Liposomal Doxorubicin	Maximum tolerated dose (MTD)	Phase 1	https://ClinicalTrials.gov/show/NCT00507962
NCT00885885	Completed	No Results Available	Drug: Panitumumab+FOLFOX-4|Drug: Panitumumab+FOLFIRI	Objective response rate|% of patients whose disease becomes resectable|Time to resection|Duration of response|Progression-free survival|Time to treatment failure|Time to disease relapse following surgery.|Adverse Events|Evaluation of molecular predictive markers for response.	Phase 2	https://ClinicalTrials.gov/show/NCT00885885
NCT00882180	Completed	No Results Available	Drug: ALN-VSP02	Safety and Tolerability of intravenous ALN-VSP02|Plasma and urine PK of ALN-VSP02|Assess preliminary evidence of antitumor/antiangiogenic activity	Phase 1	https://ClinicalTrials.gov/show/NCT00882180
NCT02718430	Active, not recruiting	No Results Available	Drug: VXM01	Safety and tolerability taking into account treatment-limiting toxicities (TLTs)|Immune Response by Enzme Linked Immuno Spot (ELISpot)|Immune biomarker by tumor tissue immunohistochemistry staining|Tumor vasculature by tumor tissue immunohistochemistry staining|Serum biomarker Response by Enzyme Linked Immuno Sorbent Assay (ELISA)|Clinical Response including tumor staging according to the response criteria in solid tumors (RECIST)|Biodistribution and shedding of VXM01	Phase 1	https://ClinicalTrials.gov/show/NCT02718430
NCT03022734	Recruiting	No Results Available	Drug: chemotherapy|Radiation: radiotherapy	complete resection (R0) rate for rectal and liver lesions|Response rate (RECIST V1.1)	Phase 2	https://ClinicalTrials.gov/show/NCT03022734
NCT03340558	Not yet recruiting	No Results Available	Biological: Atezolizumab|Drug: Cobimetinib	Change in CD4 T cell immune infiltrates|Change in CD8 T cell immune infiltrates|Disease-free survival|Overall Survival	Phase 2	https://ClinicalTrials.gov/show/NCT03340558
NCT01269229	Completed	No Results Available	Drug: folfox|Radiation: short course Radiotherapy	complete resection (R0) rate for rectal and liver lesions.|Response rate (RECIST V1.0)|Overall survival rate|Progression free survival time|Toxicity profile	Phase 2	https://ClinicalTrials.gov/show/NCT01269229
NCT00091117	Completed	No Results Available	Drug: bortezomib|Other: pharmacological study	DLT|MTD	Phase 1	https://ClinicalTrials.gov/show/NCT00091117
NCT01695772	Completed	Has Results	Drug: 5-FU based doublet chemotherapy|Drug: bevacizumab	Percentage of Participants Achieving Complete Resection (R0 Resection)|Percentage of Participants Achieving Incomplete Tumor Resection (R1 Resection)|Percentage of Participants Achieving Objective Response|Number of Participants With Disease Progression or Relapse or Death|Progression Free Survival (PFS)|Percent Probability (PP) of Being Alive and Progression Free at Months 3, 6, 9, 12, 15, and 18|Number of Participants With Disease Relapse or Death|Disease Free Survival (DFS)|Percent Probability Of Being Alive and Disease Free at Months 3, 6, 9, and 12	Phase 4	https://ClinicalTrials.gov/show/NCT01695772
NCT02837263	Recruiting	No Results Available	Radiation: Stereotactic body radiotherapy (SBRT)|Drug: Pembrolizumab	Recurrence rate at 1 year|Time to recurrence estimated using the Kaplan-Meier method|Disease-free survival estimated using the Kaplan-Meier method|Overall survival estimated using the Kaplan-Meier method	Phase 1	https://ClinicalTrials.gov/show/NCT02837263
NCT00002793	Unknown status	No Results Available	Drug: fluorouracil|Drug: leucovorin calcium		Phase 3	https://ClinicalTrials.gov/show/NCT00002793
NCT00006479	Unknown status	No Results Available	Drug: FOLFOX regimen|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy		Phase 3	https://ClinicalTrials.gov/show/NCT00006479
NCT02738606	Recruiting	No Results Available	Procedure: Liver Resection Surgery|Drug: Chemotherapy|Behavioral: Survey	Overall Survival	Phase 2	https://ClinicalTrials.gov/show/NCT02738606
NCT01022541	Completed	No Results Available	Drug: Capecitabine|Drug: Oxaliplatin|Drug: Bevacizumab|Procedure: Liver metastasectomy	Overall response rates|Complete resection (R0) rate|Safety and feasibility of adding bevacizumab to neoadjuvant capecitabine and oxaliplatin in patients undergoing liver metastasectomy|Other parameters of efficacy (response and survival) in patients with unresectable liver-only metastases treated with this neoadjuvant combination	Phase 2	https://ClinicalTrials.gov/show/NCT01022541
NCT02885753	Recruiting	No Results Available	Drug: Oxaliplatin intravenous|Drug: 5 Fu|Drug: Folinic Acid|Drug: Oxaliplatin intra-arteriel|Drug: Panitumumab|Drug: Bevacizumab	hepatic progression-free survival	Phase 3	https://ClinicalTrials.gov/show/NCT02885753
NCT03403634	Recruiting	No Results Available	Drug: Celecoxib|Other: Laboratory Biomarker Analysis|Biological: Recombinant Interferon Alfa-2b|Drug: Rintatolimod	Change in tumor-infiltrating lymphocytes (TILs) in the colorectal cancer lesions|Incidence of adverse events according to Common Terminology Criteria for Adverse Events version 4.0|Objective response rate (ORR) assessed by Response Evaluation Criteria in Solid Tumors version (RECIST) 1.1|Overall survival|Progression free survival	Early Phase 1	https://ClinicalTrials.gov/show/NCT03403634
NCT00028626	Completed	No Results Available	Drug: embolization therapy		Phase 2	https://ClinicalTrials.gov/show/NCT00028626
NCT00002692	Unknown status	No Results Available	Drug: fluorouracil|Drug: isolated perfusion|Drug: leucovorin calcium		Phase 3	https://ClinicalTrials.gov/show/NCT00002692
NCT00482222	Unknown status	No Results Available	Biological: cetuximab|Drug: capecitabine|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin|Other: study of socioeconomic and demographic variables|Procedure: adjuvant therapy|Procedure: neoadjuvant therapy|Procedure: quality-of-life assessment	Progression-free survival|Response rate before surgery as assessed by RECIST criteria|Pathological resection status|Overall survival|Toxicity|Quality of life as assessed by the EQ-5D, EORTC QLQ-C30, and EORTC QLQ-LMC21|Cost effectiveness|Safety	Phase 3	https://ClinicalTrials.gov/show/NCT00482222
NCT02350530	Recruiting	No Results Available	Drug: FOLFOXIRI + Bevacizumab|Drug: FOLFOXIRI	The conversion rate of liver metastases|Toxicity assessed using the NCI common toxicity criteria, version 4.0.|Response rate|Overall survival time|Progression free survival|Quality of life (QLQ C30)	Phase 2	https://ClinicalTrials.gov/show/NCT02350530
NCT00049400	Completed	No Results Available	Drug: BMS-247550	dose defining|Progression|Symptomatic deterioration	Phase 1	https://ClinicalTrials.gov/show/NCT00049400
NCT00513266	Unknown status	No Results Available	Biological: bevacizumab|Biological: cetuximab|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Drug: oxaliplatin|Other: laboratory biomarker analysis|Procedure: adjuvant therapy|Procedure: biopsy|Procedure: conventional surgery|Procedure: neoadjuvant therapy	Pathological complete response rate of lesions of less than or equal to 30 mm in size assessed by pathologic examination in resected specimens|Response as assessed by NCIC criteria|Toxicity as assessed by NCIC criteria	Phase 2	https://ClinicalTrials.gov/show/NCT00513266
NCT00003834	Completed	No Results Available	Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin	response rate|overall survival	Phase 2	https://ClinicalTrials.gov/show/NCT00003834
NCT03487939	Not yet recruiting	No Results Available	Drug: FOLFOXIRI	The ratio of tumor downstaging to stage 0 and stage I|Tumor regression grade (TRG)|Disease free survival|Overall survival time|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|ctDNA assessment and relation to clinical outcome|SUVmax assessment and relation to clinical outcome|Quality of life (QLQ C30)	Phase 2	https://ClinicalTrials.gov/show/NCT03487939
NCT00023868	Completed	No Results Available	Drug: FOLFIRI regimen|Drug: cisplatin|Drug: doxorubicin hydrochloride|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Drug: mitomycin C		Phase 3	https://ClinicalTrials.gov/show/NCT00023868
NCT03069950	Recruiting	No Results Available	Drug: Floxuridine (FUDR)|Drug: Irinotecan (CPT-11)|Drug: FLUOROURACIL|Drug: PANITUMUMAB|Drug: DEXAMETHASONE|Drug: Leucovorin	Resection rate assessed using RECIST (version 1.1)	Phase 2	https://ClinicalTrials.gov/show/NCT03069950
NCT00006062	Completed	No Results Available	Drug: oxaliplatin		Phase 1	https://ClinicalTrials.gov/show/NCT00006062
NCT00436267	Unknown status	No Results Available	Drug: fluorouracil|Radiation: selective external radiation therapy|Radiation: tomotherapy|Radiation: yttrium Y 90 glass microspheres|Radiation: yttrium Y 90 resin microspheres	Tumor response|Hepatic and systemic toxicity|Time to progression|Survival	Phase 2	https://ClinicalTrials.gov/show/NCT00436267
NCT00764595	Completed	No Results Available	Drug: imatinib mesylate	Progression-free survival|Tumor response|Overall survival|Types and severities of adverse events	Phase 2	https://ClinicalTrials.gov/show/NCT00764595
NCT00002901	Completed	No Results Available	Drug: docetaxel		Phase 1	https://ClinicalTrials.gov/show/NCT00002901
NCT02494973	Recruiting	No Results Available	Drug: Oxaliplatin HAI|Drug: Oxaliplatin IV|Drug: mFOLFOX6|Drug: LV5FU2	18-month hepatic RFS rate|3-year RFS rate	Phase 2|Phase 3	https://ClinicalTrials.gov/show/NCT02494973
NCT03401294	Not yet recruiting	No Results Available	Drug: FOLFOXIRI and Bevacizumab	Rate of liver metastasectomy|Response rate|Toxicity|The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30)|The European Organization for Research and Treatment of Cancer (EORTC) Colorectal Cancer Module (QLQ-CR29)|The European Organization for Research and Treatment of Cancer (EORTC) Colorectal Liver Metastases Module (LMC21)|Early-PET scan response|Progression-free survival|Overall survival	Phase 2	https://ClinicalTrials.gov/show/NCT03401294
NCT00674024	Completed	No Results Available	Drug: Pazopanib|Drug: Pazopanib (GW786034)(GW786034)	To establish the MTD and DLT of pazopanib in groups of patients with varying degrees of hepatic dysfunction (mild, moderate, and severe) to provide appropriate dosing recommendations for panzopanib in such patients.|To characterize the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of pazopanib and metabolites (GSK1071306, GSK1268992, GSK1268997, and GW700201) in patients with varying degrees of hepatic dysfunction.	Phase 1	https://ClinicalTrials.gov/show/NCT00674024
NCT00006050	Unknown status	No Results Available	Drug: FOLFOX regimen|Drug: fluorouracil|Drug: isolated perfusion|Drug: leucovorin calcium|Drug: oxaliplatin		Phase 2	https://ClinicalTrials.gov/show/NCT00006050
NCT01802645	Recruiting	No Results Available	Drug: Cetuximab|Drug: Bevacizumab|Drug: Irinotecan|Drug: Oxaliplatin|Drug: 5-FU|Drug: Folinic Acid	Response rate|Rate of resected patients without early relaps	Phase 2	https://ClinicalTrials.gov/show/NCT01802645
NCT00656123	Unknown status	No Results Available	Biological: GM-K562 cell vaccine|Biological: allogeneic tumor cell vaccine|Drug: cyclophosphamide|Genetic: gene expression analysis|Genetic: protein analysis|Other: immunoenzyme technique|Other: immunologic technique|Other: laboratory biomarker analysis	Safety and toxicity after course 2|Cellular vaccine response	Phase 1	https://ClinicalTrials.gov/show/NCT00656123
NCT00544349	Completed	No Results Available	Biological: cetuximab|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin	Efficacy: objective tumor response rate (RECIST criteria)|Toxicity as assessed by NCI CTCAE v3.0|Duration of response|Duration and rate of tumor control|Secondary resectability of hepatic metastases|Progression-free survival|Overall survival|Tumor progression rate	Phase 2	https://ClinicalTrials.gov/show/NCT00544349
NCT00063960	Completed	No Results Available	Drug: floxuridine|Drug: irinotecan hydrochloride	overall survival|time to hepatic recurrence or progression	Phase 2	https://ClinicalTrials.gov/show/NCT00063960
NCT02634502	Recruiting	No Results Available	Procedure: radiofrequency ablation|Drug: S-1	Overall survival|Progression free survival	Phase 2	https://ClinicalTrials.gov/show/NCT02634502
NCT00496509	Completed	No Results Available	Drug: ZD6474 (Zactima) 100mg|Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MR)|Procedure: Biomarker Draws|Drug: ZD6474 (Zactima) 300mg	Assess by dynamic contrast-enhanced magnetic resonance imaging the effect of once daily dosing with ZD6474 on tumour perfusion and vascular permeability in patients with advanced colorectal cancer and liver metastases.|Assessment of appropriate Pharmacokinetic parameters|Determine the population PK of ZD6474 and assess the relationship between both free and total plasma PK and measures of Pharmacological activity|Assessment of the effectiveness of ZD6474 as measured by objective response rate and progression free survival based on RECIST.	Phase 1	https://ClinicalTrials.gov/show/NCT00496509
NCT00002716	Completed	No Results Available	Drug: dexamethasone|Drug: floxuridine|Drug: fluorouracil|Drug: leucovorin calcium|Procedure: laparotomy|Procedure: conventional surgery	Overall survival|Time to progression	Phase 3	https://ClinicalTrials.gov/show/NCT00002716
NCT00557102	Completed	No Results Available	Biological: cetuximab|Biological: filgrastim|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium	Tumor response rate|Rate of resectability|Overall and disease-free survival|Tolerability	Phase 2	https://ClinicalTrials.gov/show/NCT00557102
NCT00003368	Completed	No Results Available	Drug: irinotecan hydrochloride		Phase 1	https://ClinicalTrials.gov/show/NCT00003368
NCT00008294	Completed	No Results Available	Drug: FOLFOX regimen|Drug: dexamethasone|Drug: floxuridine|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin		Phase 1	https://ClinicalTrials.gov/show/NCT00008294
NCT03031444	Recruiting	No Results Available	Drug: Cetuximab plus FOLFIRI/FOLFOX|Drug: FOLFIRI/FOLFOX/CapeOX	disease free survival|overall survival|objective response rate	Phase 2|Phase 3	https://ClinicalTrials.gov/show/NCT03031444
NCT03164655	Not yet recruiting	No Results Available	Drug: Oxaliplatin, Cetuximab, Bevacizumab, Panitumumab, Irinotecan, Leucovorin, 5Fluorouracil	Curative-intent (R0-R1) resection (and/or ablation) rate (CRR) of CRLM	Phase 2	https://ClinicalTrials.gov/show/NCT03164655
NCT00003753	Completed	No Results Available	Drug: dexamethasone|Drug: floxuridine|Drug: irinotecan hydrochloride|Procedure: adjuvant therapy|Procedure: conventional surgery		Phase 2	https://ClinicalTrials.gov/show/NCT00003753
NCT00492999	Active, not recruiting	No Results Available	Drug: dexamethasone|Drug: floxuridine|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Drug: oxaliplatin	Resectability rate|Antitumor activity|Response rate|Median time to progression|Survival	Phase 2	https://ClinicalTrials.gov/show/NCT00492999
NCT00280410	Completed	No Results Available	Drug: E7337	Contrast enhancement effect on tumor-like lesions in the liver.|Contrast enhancement effect (amount of change in CT value) on the portal venous phase (portal vein, left and right lobes of the liver parenchyma). Contrast enhancement effect on the arterial phase (hepatic artery).	Phase 2|Phase 3	https://ClinicalTrials.gov/show/NCT00280410
NCT02102789	Recruiting	No Results Available	Drug: mFOLFOX6|Drug: HAI	Complete resection rates (R0 resection rates) (defined as no macroscopic or microscopic residual tumor) of both arms|Overall response rates (ORR) of both arms|R1 resection rates (with microscopic residual tumor) of both arms|Specific R0/R1 resection plus radiofrequency ablation rates of both arms|Recurrence-free survival (RFS) of both arms|5 year cancer specific survival rate of the whole population|Progression free survival(PFS) of both arms|Overall survival (OS) of both arms|Number of participants with surgical complications, AES and SAEs as a measure of safety	Phase 3	https://ClinicalTrials.gov/show/NCT02102789
NCT00037804	Completed	No Results Available	Drug: Irinotecan		Phase 1	https://ClinicalTrials.gov/show/NCT00037804
NCT01923987	Recruiting	No Results Available	Radiation: Short Course Radiotherapy|Drug: Chemotherapy|Procedure: Delayed Surgery	R0 resection rate|Overall survival rate|Progression free survival rate|Tumor regression grade|Toxicity	Phase 2	https://ClinicalTrials.gov/show/NCT01923987
NCT00002842	Completed	Has Results	Drug: floxuridine|Drug: fluorouracil|Drug: leucovorin calcium|Procedure: adjuvant therapy|Procedure: conventional surgery	2 Year Disease-free Survival .	Phase 2	https://ClinicalTrials.gov/show/NCT00002842
NCT00025415	Completed	No Results Available	Drug: imatinib mesylate|Other: pharmacological study	MTD defined based on the toxicities observed during the first cycle of treatment|Toxicity evaluation graded according to the NCI common toxicity criteria and relationship to the study drug|Pharmacokinetic data|Responses|Child-Pugh Classification	Phase 1	https://ClinicalTrials.gov/show/NCT00025415
NCT00026234	Completed	No Results Available	Drug: floxuridine|Drug: dexamethasone|Drug: oxaliplatin|Drug: capecitabine	Toxicity of oxaliplatin as assessed by the National Cancer Institute (NCI) Common Terminology Criteria (CTC) version 2.0|Survival rate|Survival time|Time to recurrence|Time to treatment failure|Adverse events as assessed by NCI CTC version 2.0	Phase 2	https://ClinicalTrials.gov/show/NCT00026234
NCT01638533	Recruiting	No Results Available	Other: Pharmacological Study|Drug: Romidepsin	Maximum tolerated dose of romidepsin in groups of patients with varying degree of hepatic dysfunction according to the National Cancer Institute Common Toxicity Criteria for Adverse Events version 5.0|Dose-limiting toxicity of romidepsin in groups of patients with varying degree of hepatic dysfunction according to the National Cancer Institute Common Toxicity Criteria for Adverse Events version 5.0|Pharmacokinetic (PK) profile of romidepsin in patients with varying degrees of hepatic dysfunction using liquid chromatography-electrospray ionization tandem mass spectrometric method|Child-Pugh classification of hepatic dysfunction|Antitumor activity assessed using Response Evaluation Criteria in Solid Tumors and the International Workshop Lymphoma Response Criteria	Phase 1	https://ClinicalTrials.gov/show/NCT01638533
NCT02559024	Active, not recruiting	No Results Available	Drug: MEDI6469	Safety (side-effects or complications related to the study drug)|Immune Score	Phase 1	https://ClinicalTrials.gov/show/NCT02559024
NCT00056030	Completed	No Results Available	Biological: cetuximab|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin	Surgical resectability rate as assessed by surgical resection of liver metastases|Response rate as measured by RECIST criteria every 6 weeks|Overall survival|Quality of life as assessed by UNISCALE and Symptom Distress Scale every 6 weeks	Phase 2	https://ClinicalTrials.gov/show/NCT00056030
NCT00030563	Completed	No Results Available	Drug: irinotecan hydrochloride|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: radiofrequency ablation		Phase 2	https://ClinicalTrials.gov/show/NCT00030563
NCT00062348	Completed	No Results Available	Drug: boronophenylalanine-fructose complex|Drug: sodium borocaptate|Procedure: conventional surgery	Boron uptake ratio in tumor vs normal tissue|Toxicity measured by NCI-CTC v2.0 up to 28 days after injections	Phase 1	https://ClinicalTrials.gov/show/NCT00062348
NCT00427310	Completed	No Results Available	Drug: fluorouracil|Other: Observation|Drug: sodium heparin	Disease free interval|Survival	Phase 3	https://ClinicalTrials.gov/show/NCT00427310
NCT00537771	Completed	Has Results	Drug: Anastrozole|Drug: Tamoxifen	Incidence of Fatty Liver Disease|Incidence of Abnormal Liver Function|Time to Treatment Failure	Phase 4	https://ClinicalTrials.gov/show/NCT00537771
